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Abstract  
 
Melanocortin receptors (MC, MC1–MC5) are GPCRs, activated with different affinities 
by the melanocortin peptides (α-, β-, γ-MSH and ACTH). MC3 has well characterised 
roles in both the central regulation of energy metabolism and peripheral inflammatory 
responses. The functions and distribution of MC3 and the other MC in tissues of the 
reproductive system are unclear. Compared to wild type mice (WT), an apparent 
decrease in fertility of MC3 null mice (MC3-/-) has been observed and hence it was the 
aim of this series of studies to characterize MC3 and the other MC in tissues of the 
mouse hypothalamo-pituitary-gonadal (HPG) system.      
The relative mRNA expressions of the MC have been identified at each level of the 
HPG axes in both male and female mice. It appeared that the MC mRNA expression 
may be regulated by the reproductive state of an animal and may change with age. 
Two different forms of POMC mRNA have been confirmed in the reproductive axes of 
both genders implicating local melanocortin production. Localization of MC3 protein was 
unsuccessful due to a lack of specificity of all the antibodies applied. Ablation of MC3 
led to a decrease in the total pituitary hormone content in both male and female mice. 
The histology of testes of MC3-/- mice at different ages were abnormal compared to WT. 
In vitro incubation of hemi-sected testes of Balb/c or C57BL/6 mice in varying 
concentrations of selective MC3 agonist had modulatory, although non-significant, 
effects on testosterone production. However, MC3 activation during an inflammatory-
like state in the testis, inhibited nitrite production but had no effects on the release of 
cytokines. The inhibitory action of MC3 agonist on nitrite release was also apparent in 
the K9 Leydig cell line, which expresses all five isoforms of MC.     
MC3 may be both directly and/or indirectly implicated in the control of the mouse HPG 
system. The anti-inflammatory action of testicular MC3 activation could lead to possible 
clinical applications of MC3 agonists in the treatment of inflammatory situations 
associated with the loss of fertility. 
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1 General Introduction 
 
1.1 The role of inflammation in male idiopathic infertility 
 
Reproduction is a vital requisite for the survival of all living organisms. In 
mammals, reproduction is regulated by the evolutionarily conserved 
hypothalamo-pituitary-gonadal (HPG) system (Figure 1.1). Gonadotrophin 
releasing hormone (GnRH), synthesised primarily in cell bodies located in the 
medial preoptic area and arcuate nucleus of hypothalamus, is a key molecule in 
this control circuit. The production of this decapeptide hormone is modulated by 
other neuronal pathways; including, Kisspeptin (KISS1) neurones as well as 
neurotransmitters (GABA, noradrenaline, opiate peptides, dopamine et cetera) 
and peripheral hormones (for example, leptin). GnRH is released in a pulsatile 
manner, approximately one pulse per hour, into the hypophyseal portal 
circulation from the terminals located in the external zone of the median 
eminence and is delivered to the anterior pituitary lying in the hypophyseal 
fossa of the sphenoid bone. GnRH binds to its receptors located on one subset 
of anterior pituitary cells called gonadotrophs. This activation stimulates the 
secretion of luteinizing- (LH) and follicle-stimulating hormones (FSH). These 
glycoprotein hormones consist of two distinct subunits, an α subunit common to 
both LH and FSH as well as thyroid stimulating hormone (TSH) and human 
chorionic gonadotropin (hCG), and a unique β subunit. The two gonadotrophins 
in turn regulate gonadal functioning, including gametogenesis and 
steroidogenesis, in both sexes. Other anterior pituitary hormones namely 
prolactin and growth hormone released from lactotrophs and somatotrophs, 
respectively, as well as posterior pituitary oxytocin can influence gonadal 
functioning. Prolactin, for example, is particularly important in rodents where it 
17 
 
stimulates the generation of the LH surge and maintains the corpus luteum in 
females as well as potentiates the steroidogenic effect of LH on Leydig cells in 
males (Johnson, 2007). 
In the ovary, FSH stimulates follicle maturation whilst LH promotes ovulation 
and corpus luteum formation. The primordial follicles are the fundamental 
components of the ovary and are derived from clusters of oocytes arrested in 
meiotic prophase I (Rajkovic et al., 2006). Each primordial follicle consists of 
primary oocyte (arrested in the dictyate stage of the first meiotic prophase) 
surrounded by mesenchymal cells (granulosa cells). All follicles are embedded 
in the interstisital tissue of the ovary. During development, each primordial 
follicle becomes first a primary, secondary and preantral follicle, then an antral 
follicle and finally a preovulatory follicle, from which an oocyte will be extruded 
during the process of ovulation. In humans, this entire process of the primordial 
follicle development takes several months whilst in rodent only 3 weeks 
(Rajkovic et al., 2006). Recruitment of primordial follicles into growing follicles 
begins prenatally, however, follicular maturation throughout childhood does not 
proceed beyond the preantral stage and follicles undergo atresia. It is following 
puberty that a preantral follicle may develop into an antral and then into 
preovulatory follicle. The transition from one stage to another of a follicle is 
governed by intra- and extra-ovarian factors. The early stage of follicular 
development, up to the preantral follicle, is facilitated by a number of auto- or 
para-crine factors including insulin-like growth factor 1 (IGF1), stem cell factor 
(SCF) and fibroblast growth factor 2 (FGF2). In the late preantral and early 
antral follicles there appear FSH and LH receptors in the granulosa and theca 
interna cells (differentiated from stroma cells surrounding follicle into theca 
interna and externa), respectively. FSH stimulates initial follicular growth whilst 
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LH assists further antral expansion. The gonadotropins stimulate synthesis of 
follicular inhibins influencing release of the FSH, the ratio of inhibin A to inhibin 
B increases with increasing stage of follicle maturation, with inhibin B 
predominating in the follicular phase and inhibin A in the luteal phase. 
Oestrogen is another product of ovarian LH and FSH stimulation. It is produced 
via two routes: de novo from theca cells following LH stimulation or through 
aromatization from theca-derived androgens in granulosa cells mediated by 
FSH. The balance between the two pathways is species dependent, but the 
latter route seems to be significantly more important. Ovarian oestrogens 
themselves stimulate granulosa cell proliferation, hence exerting positive 
feedback, which leads to increased production of steroids. The increase in 
oestrogens, approximately 200 – 400 % above normal concentrations, in the 
late stage of antral expansion in turn exerts positive effects on both the release 
of pituitary LH and locally on the appearance of LH-binding-sites on the outer 
layers of granulosa cells. The increased number of LH receptors in the theca 
and granulosa cells and coinciding short surge of LH lead to the oocyte’s 
expulsion from the follicle during the process of ovulation. The follicle itself 
becomes corpus luteum releasing high concentrations of progestagens, which 
negatively feedback on the release of LH and FSH from pituitary. However, if 
fertilization does not occur the corpus luteum degrades after approximately 14 
days and progestagen concentrations drop. This decrease leads to 
menstruation, which indicates the beginning of a new menstrual cycle. The 
approximate length of the menstrual cycle in human is 28 days. This is in 
contrast to rodents as their reproductive cycle, called the estrous cycle, lasts for 
about 4 to 5 days and resembles a shortened version of that present in large 
farm animals. The length of the estrous cycle in rodent can be altered by 
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mating. The luteal phase of a female mice mating with an infertile male at the 
time of ovulation lasts for 11 to 12 days and is called a pseudopregnancy. 
However, if a female does not mate at the time of ovulation the luteal phase is 
shortened to approximately 2 to 3 days.  The prolonged luteal phase during an 
infertile mating is caused by a regular release of prolactin stimulated by the 
CNS. The stimulus is relayed from the sensory nerves of the cervix activated 
during coitus by the mechanical stimulus of the penis in the cervix (Johnson, 
2007). 
In the testis, similarily to the ovary, FSH promotes spermatogenesis whilst LH 
stimulates release of androgens. The testis displays two major compartments: 
the interstitial and the seminiferous tubule compartment. The interstitial 
compartment contains the blood and the lymphatic vessels. The interstitial islets 
contain mainly Leydig cells and other cells, predominantly macrophages. Leydig 
cells are the major source of androgens, notably testosterone, and variety of 
other steroids or proteins such as oestrogens, oxytocin and insulin-like 3 (Insl3). 
The steroids are synthesized from acetate or cholesterol in reponse to 
stimulation with LH acting through its receptors located on the surface of Leydig 
cells. Additionally, prolactin and inhibin facilitate the stimulatory effects of LH. 
Synthesized testosterone is secreted from the testis via blood and lymphatic 
vessels to enter systemic circulation. It can negatively feedback on pituitary and 
hypothalamus to decrease the release of LH and to a smaller extent FSH. 
Additionally, smaller concentrations of testosterone enter the seminiferous 
tubules, bind to androgen-binding protein and flow into the excurrent ducts. 
Intratesticularly produced testosterone binds to androgen receptor expressing 
cells such as Leydig, myoid and Sertoli cells. In the first cell type it acts in an 
autocrine manner to exert negative feedback. In Sertoli cells testosterone is 
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converted to more active dihydrotestosterone (DHT) by the action of 5α-
reductase. In contrast to the interstitial tissue, the seminiferous tubule has no 
blood and lymphatic vessels and is separated from the interstitial compartment 
by an acellular basal membrane surrounded externally by myoid cells and 
fibrocytes. There is restricted exchange between the two compartments, hence 
they differ in the fluid composition of ions, proteins, charged sugars and 
secreted products. The main components of the seminiferous tubules are germ 
cells at different stage of development. Spermatogonia located in the basal 
compartment are the stem cells from which the A1 spermatogonia emerge after 
a round of mitosis. Each A1 spermatogonia also undergoes a limited number of 
mitotic divisions giving rise to morphologically distinct spermatogonia type A1 to 
A4 at each mitotic division and hence increse the number of cells entering 
spermatogenesis.  After the subsequent fifth division the spermatogonia type B 
are produced, which undergo meiotic division to form spermatocytes. Each 
spermatocyte rapidly enters the second meiotic division to yield haploid 
spermatids. These in turn undergo cytodifferentiation to form mature 
spermatozoa. As germ cells mature they move from the basal toward the 
adluminal compartment between Sertoli cells which provide nutrients for 
developing sperm cells. Sertoli cells are the prime site of FSH receptor (FSH-R) 
expression in the testis, which mediates production of androgen receptors. FSH 
and androgens regulate production of proteins and cytokines by Sertoli cells 
including androgen-binding protein (ABP), transferrin and stem cell factor which 
influence spermatogenesis. Sertoli cells also release sulphated glycoproteins 1 
and 2 (SGP1 and 2) as well as activin A and inhibin B, which inhibits the release 
of FSH from the pituitary. The tight junctional complexes between the adjacent 
Sertoli cells create the blood-testis barrier, which prevents leakage of 
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spermatozoa into the systemic circulation as they are capable of eliciting an 
immune response. This barrier is absent prepubertally, but develops before the 
inititation of spermatogenesis. The process of spermatogenesis is tightly 
coordinated in temporal and spatial manner and is species specific. This 
regulation is probably mediated internally by the Sertoli cells (Russell et al., 
1990).                                                                                                         
 
 
 
Figure 1.1 Neuroendocrine control of the hypothalamo-pituitary-gonadal axis.  
Description in text; KISS1 (kisspeptin); ARC (arcuate nucleus); AVPV (anteroventral 
periventricular nuclei); KISSR1 (kisspeptin receptor); GnRHR (GnRH receptor); FSHR 
(FSH receptor); LHR (LH receptor); hCG (human chorionic gonadotropin); INH (inhibin) 
(Adapted from Matzuk and Lamb, 2008). 
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Disruption at any level of the hypothalamo - pituitary - gonadal axis may lead to 
infertility. Recently, the incidence of infertility has reportedly increased and it 
now affects one in seven couples in the United Kingdom (NICE, 2013).There 
are many definitions of infertility (Ray et al., 2012) but according to the National 
Institute for Health and Clinical Excellence (NICE),  infertility is defined as a 
failure to conceive after a period of 1 year of frequent and unprotected sexual 
intercourse (NICE, 2013). Nearly half of all infertility cases are due to a male 
factor (Forti and Krausz, 1998) and can be associated with different congenital 
or acquired etiologies including Klinefelter syndrome, genetic abnormalities, 
cryptorchidism, varicocele, genital infection, endocrine disturbances or 
immunological factors (Jungwirth et al., 2013). Nevertheless, approximately 44 
% of infertile men are categorized as having idiopathic infertility; that is, no 
demonstratable cause. These men appear normal on physical and endocrine 
examination but have a reduction in spermatozoa number, motility and normal 
morphology (Jungwirth et al., 2013). The exact mechanisms driving these 
abnormalities are unclear but they are thought to be associated with factors 
such as genetic or epigenetic abnormalities, reactive oxygen species or 
environmental pollution (Nieschlag et al., 2010). The contribution of testicular 
inflammatory cells, previously underestimated, has also been recognized and 
may account as an etiological factor in 40 % of idiopathic infertility cases 
(Moghissi et al., 1980; Nieschlag et al., 2010). Both humoral (antibody-
mediated) and cellular immune responses are involved in immunologic infertility, 
although the latter type have received considerably less attention (Turek and 
Lipshultz, 1994). An influx of leukocytes has been detected in many testicular 
pathologies, such as orchitis (Trojian et al., 2009) or torsion associated with 
ischemia-reperfusion injury (Rodriguez et al., 2006; Pellati et al., 2008). It was 
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demonstrated, that pro-inflammatory cytokines released from activated 
inflammatory cells can affect normal testicular steroidogenesis and 
gametogenesis (Hales et al., 1999). Tumor necrosis factor alpha (TNF-α), for 
example, impairs the motility and ability of spermatozoa to penetrate an ovum 
(Perdichizzi et al., 2007). There is little known about the importance of testicular 
immune imbalance in idiopathic infertility (Nieschlag et al., 2010). Treatment for 
this condition is usually conducted empirically with minimal scientific evidence, 
hence it is often ineffective and patients are recommended assisted 
reproduction techniques (ART) to achieve pregnancy in their partner without 
treatment of the underlying causes (Hamada et al., 2011; Jungwirth et al., 
2013). New avenues in understanding testicular inflammation have to be 
explored to help determine possible etiologies of idiopathic infertility in male 
patients and develop novel diagnostic and treatment options. One such avenue 
would be to investigate the anti-inflammatory properties of some of the 
melanocortin receptors in testicular inflammation. 
 
 
1.2  The melanocortin system 
 
The melanocortin system was first identified nearly 90 years ago by the effects 
of what is now known as α-MSH (melanocyte stimulating hormone) on the 
darkening of amphibians’ skin. Later, in the early 1960s these effects were also 
evident in human (Lerner and McGuire, 1961). However, it was not until the 
cloning of the first melanocortin receptor (MC1) (Chhajlani and Wikberg, 1992; 
Mountjoy et al., 1992) and subsequent discovery and cloning of the other four 
melanocortin receptors (Roselli-Rehfuss et al., 1993; Gantz et al., 1993a; 
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Chhajlani, 1996) that an interest in melanocortin signalling in mammalian 
physiology grew. The melanocortin receptors can be activated with different 
affinity by the melanocortin peptides [α-, β-, γ-MSH and adrenocorticotropic 
hormone (ACTH)] or antagonized by endogenous agouti and agouti-related 
protein (AGRP) (Table 1.1). 
 
 
Table 1.1 Summary of melanocortin receptors distribution, functions and ligands  
(rank order of ligands potency based on Fong et al., 2013).  
 
 
1.2.1 Melanocortins 
Melanocortins are derivatives of a larger precursor molecule of approximately 
31 kDa called proopiomelanocortin protein (POMC). This protein is the source 
of ACTH, α- β- and γ-MSH as well as opiate peptides such as β-endorphin, from 
which the name pro-opio-melanocortin was derived. A short sequence of 
pituitary POMC is evolutionary conserved across all vertebrate classes and 
 MC1 MC2 MC3 MC4 MC5 
Expression 
Melanocytes,  
Endothelial 
cells, 
Fibroblasts, 
Monocytes, 
Adrenal cortex, 
Adipocytes 
Brain, Heart, 
Macrophages, 
Gut, Kidney 
Brain, 
Adipose 
tissue 
Lymphocytes, 
Exocrine glands, 
Brain, Adipocytes 
Function 
Pigmentation, 
Anti-
inflammatory 
Anti-pyretic 
Steroido-
genesis, 
 
Lipolysis 
Cardiovascular 
Anti-
inflammatory, 
Energy 
homeostasis 
Energy 
homeostasis, 
Appetite 
regulation,  
Anti-
inflammatory 
Immunoregulatory 
functions,  
Lipolysis, Control 
of sebaceous 
secretion 
Agonist  
α- MSH >      
  β-MSH ≥ 
ACTH               
γ-MSH 
ACTH 
γ-MSH,  
β-MSH ≥ 
 ACTH,  
α-MSH 
β-MSH ≥  
α-MSH, 
ACTH> 
γ-MSH 
β-MSH ≥  
α-MSH≥ 
 ACTH> 
γ-MSH 
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dates back some 450 or more million years ago to common ancestors of both 
teleosts and mammals (Bumaschny et al., 2007).  
Although first identified in the anterior and intermediate lobes of the pituitary, 
POMC mRNA can also be found in the hypothalamus (arcuate nucleus), 
brainstem (solitary tract), hippocampus and cortex of the brain, as well as in 
peripheral organs (including skin, adrenal glands, gastrointestinal tract, immune 
system, ovary, testis and placenta) where its derivatives act as paracrine factors 
(as reviewed by Wikberg et al., 2000; Bicknell, 2008).  
The POMC molecule is composed of three main domains: the N-terminal with γ-
MSH, the central containing ACTH and the C-terminal generating β-lipotrophin 
(as reviewed by Bicknell, 2008) (Figure 1.2). The core amino acid sequence, 
His-Phe-Arg-Trp (HFRW), is common to all melanocortins and is required for 
receptor binding and activation (as reviewed by Getting, 2006a). POMC protein 
is postranslationally processed by prohormone convertases, PC1 and PC2, at 
dibasic cleavage sites (Gantz and Fong, 2003). PC1 leads to cleavage of 
ACTH, whilst PC2 generates smaller POMC peptides such as α-MSH which is 
derived from the first 13 amino acids of ACTH (as reviewed by Wikberg et al., 
2000). The expression of PC1 and PC2 mRNA shows tissue-specific variations 
leading to the formation of different POMC derivatives (Wilkinson, 2006). In the 
mouse pituitary, for example, both PC1 and PC2 are expressed in the 
intermediate lobe melanotrophs generating mainly α-MSH (Marcinkiewicz et al., 
1993). In contrast, the anterior lobe corticotrophs, synthesizing mainly ACTH, 
express principally PC1 and minor levels of PC2 mRNA (Marcinkiewicz et al., 
1993). The majority of circulating melanocortins, primarily α-MSH and ACTH, 
are thought to be of pituitary origin (as reviewed by Bicknell, 2008). 
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Figure 1.2 Processing of proopiomelanocortin (POMC) hormone precursor.       
The specific order of POMC cleavage process is illustrated by the numbers. POMC 
preprohormone is first processed by PC1 into N-POMC1-76, JP, ACTH and β-LPH. 
Further cleavage of N-POMC1-76 generates N-POMC1-49 and γ3-MSH, ACTH, and β-
LPH. PC2 generates α-MSH and CLIP from ACTH, and γ-LPH and β-END from β-LPH. 
ACTH, adrenocorticotrophin; CLIP, corticotrophin-like intermediate peptide; JP, joining 
peptide; LPH, lipotrophin; MSH, melanocyte-stimulating hormone. (Adapted from 
Bicknell, 2008). 
 
 
1.2.2  Melanocortin receptors (MC) 
The melanocortin receptors (MC; MC1-MC5) belong to a class of small 
(rhodopsin) seven-transmembrane (TM) domain receptors coupled to protein G 
(G-protein-coupled receptors; GPCRs). They consist of a single polypeptide that 
is 291 – 361 amino acids long. The intracellular amino- and extracellular 
carboxyl- terminals as well as the second extracellular loop of MC are very short 
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(Figure 3; Yang, 2011). As in other GPCRs, MC contain palmitoylation sites at 
the C-terminus, phosphorylation sites in the 1st and 3rd intracellular 
transmembrane domain and potential sites for N-glycosylation at the N-terminus 
(Yang, 2011). Additionally, they contain a number of cysteine residues in 
various regions of the receptors including extracellular loops, which may lead to 
formation of disulfied bonds and in turn to possible receptor dimerisation 
(Rediger et al., 2012). There is very close, approximately 42-67 % homology in 
the amino acids sequences between the MC (Wikberg, 1999). The majority of 
endogenous melanocortins bind to MC at the orthosteric receptor site but 
reports indicate the presence of a functional allosteric site, which alters receptor 
biological activity and enables increased selectivity across MC subtypes as well 
as selectivity across various signalling pathways (Yang, 2011). This feature of 
MC receptors is particularly important considering the low selectivity of known 
MC agonists and antagonists.  
 
 
Figure 1.3 A model of melanocortin receptors structure indicating the presence 
of extracellular N-terminus, 7-transmembrane domains and intracellular C-
terminus (Adapted from Catania et al., 2004).  
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1.2.2.1 Agonists 
Melanocortins are endogenous agonists for MC and include ACTH, α- β- and γ-
MSH. Both ACTH and α-MSH activate all MC with the exception of MC2 (ACTH 
only receptors). γ-MSH, in contrast, has the highest affinity for MC3, this peptide 
exists in three forms, γ1-MSH, γ2-MSH and γ3-MSH (22-31aa), the latter variant 
occurs most readily in mammals (Eberle, 2000). A number of research groups 
attempted to generate selective MC ligands, however with different degrees of 
success. Available ligands include: MS05 with selectivity for MC1 (Szardenings 
et al., 2000), [D-Trp8]-γ2-MSH for MC3 (Grieco et al., 2000), THIQ for MC4 
(Sebhat et al., 2002) and PG-901for MC5 (Grieco et al., 2002). Nevertheless, 
there is still a need for more selective compounds as independent testing often 
demonstrates low selectivity of proposed ligands (as reviewed by Renquist et 
al., 2011).   
1.2.2.2 Antagonists 
Agouti and agouti-related protein (AgRP) are the two endogenous peptides 
exhibiting antagonistic action on MC. They act as inverse agonists suppressing 
constitutively active MC as opposed to competitive antagonists, which only 
compete for the binding place on the receptors but do not change their 
biological activity (Adan, 2006).  Agouti and AgRP are the only known naturally 
found inverse agonists for GPCRs (as reviewed by Milligan, 2003). Synthetic 
compounds with antagonistic action at MC are also available: HS024 (MC1, 
MC3, MC4, MC5) (Kask et al., 1998), SHU9119 (MC3, MC4) (Adan et al., 1999) 
and HS014 (MC4, MC3) (Schioth et al., 1998), although their selectivity is not 
always satisfactory. 
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1.2.2.3 Melanocortin receptors signalling  
Activation of MC leads to cAMP accumulation through activation of adenyl 
cyclase in the target cell (Wikberg et al., 2000). Other signal transduction 
pathways have also been implicated including activation of inositol triphosphate 
(Konda et al., 1994) and protein kinase C, suggesting that melanocortins may 
modulate a range of signalling pathways, possibly in a tissue-specific manner 
(Wachira et al., 2003).  
1.2.2.4 Melanocortin 1 receptors (MC1) 
MC1 was the first MC to be cloned (Chhajlani and Wikberg, 1992; Mountjoy et 
al., 1992). This receptor subtype is almost exclusively expressed in 
melanocytes (Chhajlani and Wikberg, 1992) and has a well defined role in 
pigmentation (Abdel-Malek, 2001). This 317 amino acid protein can also be 
found in inflammatory cells; including, dendritic cells, neutrophils, B 
lymphocytes and macrophages (Star et al., 1995; Taherzadeh et al., 1999). It is 
believed to mediate anti-inflammatory and immunomodulatory effects in these 
cells (Catania et al., 2004). The most potent MC1 agonist is α-MSH, which also 
activates MC3, MC4 and MC5 (Abdel-Malek, 2001). β-MSH, ACTH and γ-MSH 
also have potency at this receptor (Fong et al., 2013). 
1.2.2.5 Melanocortin 2 receptors (MC2) 
MC2 consists of 297 amino acids and is unique as it is selectively activated by 
ACTH (Catania et al., 2004). It has been identified in the zona glomerulosa and 
fasciculata of the adrenal cortex where it is involved in secretion of 
mineralocorticoids and glucocorticoids, respectively (Mountjoy et al., 1992). 
MC2 has also been shown to stimulate lipolysis in murine adipocytes (Noon et 
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al., 2006). This receptor isoform requires melanocortin 2 receptor accessory 
protein (MRAP) for trafficking to the cell surface (Chung et al., 2008). Mutations 
in this component lead to defective MC2 function and are associated with the 
occurrence of Familial Glucocorticoid Deficiency (FGD) characterised by 
glucocorticoid deficiency.  
1.2.2.6 Melanocortin 3 receptors (MC3) 
The MC3 gene encodes a protein of 361 amino acids. γ-MSH has more than 
100-fold affinity and 45-fold higher potency at MC3 as compared to the other 
MC (as reviewed by Renquist et al., 2011). β-MSH, α-MSH and ACTH can bind 
to it with comparable affinity to each other. The determination of the molecular 
basis of MC3 ligand binding and receptor signalling is incomplete but potential 
amino acid sequences in transmembrane domains have been identified (Chen 
et al., 2006).  
The greatest expression of MC3 is in the brain, where it has been found in more 
than 30 different regions including the hypothalamus (arcuate nucleus, 
dorsomedial part of the ventromedial nucleus and medial preoptic nucleus), 
hippocampus and thalamus (Gantz et al., 1993; Roselli-Rehfuss et al., 1993). 
There are species differences in the pattern of MC3 expression. In the chicken, 
for example, the receptor is absent in the brain but was instead found in the 
adrenal gland (Takeuchi and Takahashi, 1999). The peripheral expression of 
MC3 has been demonstrated in a range of human tissues including gut, 
placenta, kidney, heart, immune cells, ovary and testis (Chhajlani, 1996).  
Although this receptor subtype was identified nearly twenty years ago, its 
physiological functions remain largely enigmatic. Centrally expressed MC3 is 
thought to participate in regulation of food intake as deduced from the knockout 
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model (Butler et al., 2000; Chen et al., 2000). In heart, MC3 plays a protective 
role in myocardial ischemia-reperfusion injury (Getting et al., 2004). 
Furthermore, in kidney, MC3 and its potent agonist γ-MSH have an important 
function in sodium homeostasis as disruption of this system leads to salt-
sensitive hypertension (Ni et al., 2003). Activation of MC3 in B lymphocytes 
(Cooper et al., 2005) and macrophages (Getting et al., 1999) has clear anti-
inflammatory and immunomodulatory effects, which have been applied in 
modulating a range of disease pathologies (as reviewed by Catania et al., 2004; 
Getting, 2006a). 
1.2.2.7 Melanocortin 4 receptors (MC4) 
MC4 consists of 332 amino acids and, similarly to MC3, is primarily expressed in 
the central nervous system (CNS) including the hypothalamus, thalamus and 
hippocampus (Gantz et al., 1993b; Chhajlani, 1996). MC4 mRNA is located in 
paraventricular nucleus (PVN), including both the parvicellular and 
magnocellular neurones of the hypothalamus in the adult rat brain (as reviewed 
by Tao, 2010). Peripheral expression of MC4 is nearly absent and most 
functions are attributed to the centrally expressed receptors. MC4 is involved in 
the regulation of food intake and energy expenditure (Catania et al., 2004). In 
the human, mutations of this receptor subtype lead to severe obesity (Vaisse et 
al., 2000). There are also reports indicating that activation of centrally 
expressed MC4 modulates erectile function and sexual behaviour (Van der 
Ploeg et al., 2004).  
1.2.2.8 Melanocortin 5 receptors (MC5) 
MC5 consists of 325 amino acids and is distributed primarily in the periphery 
although brain expression has also been reported (Fathi et al., 1995). Other 
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sites of expression include: the exocrine glands - sebaceous, preputial, lacrimal 
and Harderian (Chen et al., 1997), rodent adipocytes (Møllera et al., 2011) and 
bovine adrenal gland (Liakos et al., 2000). The key function of this receptor is in 
the regulation of exocrine gland secretions (Chen et al., 1997).    
1.2.3 Anti-inflammatory potential of MC 
Melanocortins comprise an ancient system, with their key role being protection 
and restoration of baseline conditions of the host whenever it is exposed to 
pathogens such as bacterial endotoxins, UV light or affected by overactivity of 
inflammatory mediators (Sarkar et al., 2003). The anti-inflammatory properties 
of melanocortins were first discovered by the effects of α-MSH on suppression 
of inflammation induced by urate crystals (Denko and Gabriel, 1985) and fever 
(Rheins et al., 1989). Further evidence of the anti-inflammatory effects of this 
and other melanocortin peptides has accumulated over years and triggered 
interest as potential therapeutics for the treatment of various forms of 
inflammation (as reviewed by Catania et al., 2004; Getting, 2006a).  
The anti-inflammatory effects of melanocortins are exerted through activation of 
MC on peripheral inflammatory cells leading to reduction in inflammatory 
mediators release and cell migration, as well as indirectly through binding of 
melanocortins within the brain and affecting the neural anti-inflammatory 
pathways (Lipton and Catania, 1997). α-MSH is known to inhibit activation of 
transcription factor NF-ĸB induced by inflammatory stimuli, which leads to 
subsequent suppression of the gene transcription of pro-inflammatory mediators 
(Manna and Aggarwal, 1998). 
MC1 is the prime MC involved in the anti-inflammatory effects of melanocortins. 
This MC subtype has the greatest affinity for α-MSH and is expressed in 
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macrophages (Star et al., 1995; Rajora et al., 1996), neutrophils (Catania et al., 
1996) and mast cells (Artuc et al., 1999). MC1 expression is upregulated in 
response to inflammation (Bhardwaj et al., 1997) and anti-MC1 antibodies can 
attenuate the suppressive effects of α-MSH on TNF-α release from human 
monocytic cell line (Taherzadeh et al., 1999).   
In addition to MC1, evidence exists that activation of MC3 also exerts anti-
inflammatory effects. Its expression was determined in murine (Getting et al., 
1999) and human (Taherzadeh et al., 1999) macrophages. Furthermore, natural 
and synthetic agonists for this receptor subtype had anti-inflammatory effects in 
a model of experimental gout induced by urate crystals (Getting et al., 2001). In 
this model, systemic administration of γ2-MSH and MTII suppressed 
accumulation of KC and IL-1β as well as reduced migration of neutrophils: this 
effect was blocked by SHU9119 (MC3/MC4 antagonist). MC3 activation also 
displays protective effects following ischemia-reperfusion injury characterised 
by influx of leukocytes. In a model of myocardial ischaemia, administration of 
selective and non-selective agonists for MC3 reduced incidence of ventricular 
fibrillation, tachycardia, and death (Mioni et al., 2003) as well as inhibited the 
release of inflammatory markers (Getting et al., 2004). 
Since the expression of MC5 was also detected in human monocytes 
(Taherzadeh et al., 1999), mast cells (Artuc et al., 1999) and in B lymphocytes 
(Buggy, 1998) involvement of this receptor subtype in the immunomodulatory 
effects of MC cannot be excluded.   
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1.3  Expression and role of MC in the HPG system  
 
1.3.1 Hypothalamus 
MC3 and MC4, as aforementioned, are the most abundantly expressed MC in 
the hypothalamic nuclei. They are thought to play a key role in regulating 
appetite and energy balance as deduced from their knockout mice models. The 
MC3 null mice (MC3-/-) exhibited a complex obesity syndrome characterised by 
an increase in adipose mass in parallel with reduced lean mass as well as a 
higher ratio of weight gain to food intake (Butler et al., 2000; Chen et al., 2000). 
It was suggested that the increase in fat mass may be due to abnormalities in 
food partitioning as it was exacerbated in mice placed on a high-fat diet (Ellacott 
et al., 2007). In contrast to other mouse models with similar levels of adiposity, 
MC3-/- mice do not exhibit marked insulin resistance or accumulation of fat in the 
liver, possibly due to reduced inflammatory response to obesity (Ellacott et al., 
2007).     
Conversely, MC4 null (MC4-/-) mice have a phenotype comparative to that of 
diet-induced obese (DIO) mice, characterised by increase in body weight due to 
hypometabolism and hyperphagia (Huszar et al., 1997). These mice develop 
metabolic syndrome with insulin resistance and fatty liver disease (Huszar et al., 
1997) associated with an increase in expression of pro-inflammatory genes 
(Ellacott et al., 2007).  
The obesity phenotype of MC3-/- and MC4-/- mice occur by distinct mechanisms. 
Mutations in MC4 gene in humans led to the phenotype observed in MC4-/- 
mouse, and account for 5 % of all monogenic cases of severe obesity (Vaisse 
et al., 2000). In contrast, nine different mutations in the MC3 gene have been 
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reported to date in human but their relevance to obesity is still unclear (Yang 
and Tao, 2012).  
Although high body growth due to increased intake of nutrients at a young age 
is known to advance sexual maturation, in adulthood overnutrition may inhibit 
reproductive functioning. In men, obesity leads to reduction in circulating 
testosterone (Giagulli et al., 1994) and low spermatozoa concentration 
(Hammoud et al., 2008), whilst in females it is associated with irregular 
menstrual cycles (Douchi et al., 2002). The effects of alterations in food intake, 
under- or over-nutrition, on reproductive function in humans are documented, 
however, the exact mechanism(s) are still being established.  
As described above, MC3 and MC4 regulate energy balance as their absence 
leads to various forms of metabolic abnormalities. The central melanocortin 
system is not only composed of MC3 and/or MC4 expressing neurones but also 
includes neurones expressing MC agonists, POMC (POMC neurones), or MC 
antagonists, agouti gene-related protein (AgRP neurones), originating primarily 
in the arcuate nucleus (Liotta et al., 1984; Haskell-Luevano et al., 1999). The 
posttranslational processing of POMC leads to production of active 
melanocortin peptides in this region including α- and γ-MSH (Liotta et al., 1984). 
The sites of MC3 and MC4 expression in the arcuate nucleus receive projections 
from both the anorexigenic POMC and the orexigenic AgRP neurones (Roselli-
Rehfuss et al., 1993; Mountjoy et al., 1994; Bagnol et al., 1999). Additionally, 
MC3 but not MC4, has been localized in both the POMC and the AgRP 
neurones (Bagnol et al., 1999; Jegou et al., 2000). MC3 expressed in the cell 
bodies of the POMC neurones is thought to serve as an auto-inhibitory receptor 
to decrease the activity of POMC neurones (Jegou et al., 2000; Cowley et al., 
2001). Long-term stimulation of MC3 using [DTrp8]-γ2-MSH by 
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intracerebroventricular (ICV) infusion decreases expression of POMC mRNA 
(Lee et al., 2008). The inhibitory effect of MC3 on the anorexigenic POMC 
neurones becomes even more intriguing considering the complex obesity 
syndrome in MC3-/- mice and the importance of MC3 in adaptations to restricted 
feeding (Sutton et al., 2010; Begriche et al., 2012). 
The prime site of POMC and AgRP neurones expression, the arcuate nucleus, 
is positioned between the median eminence and the 3rd ventricle and hence has 
direct exposure to factors from blood (Liotta et al., 1984; Haskell-Luevano et al., 
1999). This collection of POMC and AgRP neurones receives and integrates a 
number of blood-borne signals; including adipostatic hormones leptin and 
insulin, as well as hunger and satiety signals from ghrelin and peptide YY (PYY) 
(as reviewed by Cone, 2005). The integration of neuronal inputs from other 
brain circuits as well as that of blood-derived factors plays an important role in 
maintaining the energy balance by regulating food intake and energy 
expenditure. An increasing body of evidence indicates that the central 
melanocortin system can convey physiological signals or information from other 
brain regions to GnRH neurones to control the reproductive system. In support 
of this statement, two examples will be described in more detail.  
Oestrogen has a well-described role in the functioning of the reproductive 
system. In females, the hypothalamic action of oestrogen exhibits positive or 
negative feedback depending on the phase of the reproductive cycle (Brawer 
and Naftolin, 1978). The main sites of oestrogen receptor expression, both ERα 
and ERβ, in the hypothalamus include the arcuate and ventromedial nucleus 
(Shupnik, 2002). A direct action of oestrogens on the release of GnRH 
neurones has already been described, however oestrogens also affect 
neurones in close proximity to GnRH cells including POMC and GABAergic 
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neurones (Herbison and Pape, 2001). Oestrogens target POMC neurones 
presynaptically (Blum et al., 1989) and can modulate their G-protein-coupled 
inwardly rectifying potassium channels (GIRKs) (Kelly et al., 2003). This 
modulation of POMC activity by oestrogens is thought to indirectly affect 
reproductive and other systems regulated by the hypothalamic neurones.    
Another extensively researched potential candidate affecting the GnRH 
neurones through the melanocortin system is leptin. It is an adipocyte-derived 
hormone with well-defined anorexigenic effects characterised by inhibition of 
food intake and increase in energy expenditure. Leptin mediates its effects by 
binding to cytokine receptors, which activate the JAK-STAT pathway (as 
reviewed by Huang and Li, 2000). Leptin receptors are expressed in the 
hypothalamus and were localized in the POMC and AgRP neurones (Munzberg 
et al., 2003; Balthasar et al., 2004). Furthermore, administration of leptin 
increases the frequency of POMC action potentials (Cowley et al., 2001) and 
expression of POMC gene, hence reversing the obese and diabetic phenotypes 
of the leptin-deficient mice (Mizuno et al., 2003). In addition to the anorexigenic 
effects, leptin was reported to have important effects on reproductive function. 
Administration of physiological concentrations of leptin recovered preovulatory 
surges of LH and prolactin in food deprived female rats (Watanobe et al., 1999). 
Similarily in starved male rats, infusions of leptin increased prolactin 
concentrations. The exact mechanism of LH regulation by leptin is not clear as 
leptin receptors are absent in the GnRH neurones, suggesting an indirect action 
on GnRH release (Quennell et al., 2009). The involvement of centrally 
expressed MC3 and MC4 have been postulated as administration of MC 
antagonists, SHU9119 and HS014, resulted in inhibition of LH and prolactin 
surges in female rats (Watanobe et al., 1999). In male rats, however, the effects 
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of MC antagonists are controversial as stimulatory (Stanley et al., 1999) or no 
effects (Raposinho et al., 2000) on the basal release of LH, FSH and 
testosterone have been reported. Furthermore, previous experiments using 
non-selective MC agonists, such as α-MSH, in vivo have been performed but 
the effects on GnRH and/or gonadotrophin release are inconsistent: stimulatory 
(Newman et al., 1985), no effect (Khorram and McCann, 1986) or inhibitory 
effects (Scimonelli and Celis, 1990) have been reported. 
Understanding of both the exact downstream mechanisms of the melanocortin 
system on GnRH release and the involvement of MC3 and MC4 receptors are 
still rudimentary. It has been established that POMC and AgRP neurones 
located in the arcuate send their projections to the medial preoptic area (POA) 
and are in close apposition to perikarya and dendrites of GnRH neurones 
(Naftolin et al., 1996). Moreover, studies presented evidence of potential 
synaptic transmission between POMC and GnRH cell bodies (Leshin et al., 
1988; Naftolin et al., 1996). 
Different research groups are actively working to determine the exact MC 
receptor mediating the postsynaptic effects of POMC on GnRH neurones. 
Expression of both MC3 and MC4 were identified in immortalized GnRH-
releasing GT1-1 and GT1-7 neuronal cell lines (Khong et al., 2001; Stanley et 
al., 2003). Both receptors were functional as stimulation with α-MSH dose-
dependently increased GnRH release in GT1-1 (Khong et al., 2001) and GT1-7 
(Stanley et al., 2003) neuronal cell lines. In support of this effect, α-MSH directly 
excited the majority of GnRH neurons of mice through postsynaptic activation of 
both MC3 and MC4 (Roa and Herbison, 2012). This group reported that other 
MC3 or MC4 selective agonists also increased the GnRH neuronal firing. Stanley 
and others (2003) reported that in vivo administration of γ2-MSH, an agonist 
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with the greatest affinity for MC3, into the medial preoptic area of rat resulted in 
significant increases in plasma LH concentrations. Recently, MC4 expression 
was identified in some GnRH neurones located in the preoptic area of the 
hypothalamus and their activation by MTII caused an increase in action 
potential firing of GnRH neurones (Israel et al., 2012). There is, however, 
evidence implying that although MC3 has not yet been found in the GnRH 
neurones, it may work upstream of MC4 in the control of GnRH release. MC3 is 
the dominant receptor expressed in the arcuate and is present on both the 
POMC and the AgRP neurones. This receptor subtype may create a type of 
neuronal circuit between the two populations of neurones and regulate the 
release of melanocortins, thus modulating the activity of MC expressed on the 
GnRH neurones.   
Most of the studies investigating the central effects of melanocortin system 
concentrated on MC3 and MC4 as the prime MC expressed in the brain. 
Evidence exists, however, that the fifth MC named MC5 is also expressed in the 
brain (Chhajlani et al., 1993; Griffon et al., 1994) and its distribution pattern 
corresponds to that of MC3 and MC4 (Fathi et al., 1995). Hypothalamic MC5 is 
mainly expressed in rostral and medial parts of the medial preoptic area (Murray 
et al., 2002). Furthermore, Murray and colleagues (2006) suggested that 
melanocyte concentrating hormone (MCH) stimulates LH release, at least in 
part, by activating MC5 in the preoptic area of rat hypothalamus. MCH is a 
ligand for MCH-1R or MCH-2R receptors but previous work indicated that MC5 
transfected into HEK cells respond to MCH stimulation by releasing IP3 (Murray 
et al., 2000). The hypothalamic MCH fibres are in close vicinity to that of both 
GnRH and POMC neurones (Murray et al., 2006; Ward et al., 2009), thus 
further supporting the postulate that MC5 may mediate some of the effects of 
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MCH on the release of GnRH, although this receptor subtype still has not been 
identified in the GnRH neurones.  
Finally, the melanocortin system may also act on other populations of neurones, 
which have established influence on GnRH release, to modulate reproductive 
function. Backholer and colleagues (2009) suggested that melanocortins exert 
stimulatory effects on LH release during the luteal phase of ewes, possibly via 
kisspeptin cells in the POA and/or orexin cells in the dorsomedial 
hypothalamus, as mRNA expression of these neurones was upregulated 
following treatment.  
The MC3, MC4, MC5 and POMC seem to play a redundant role in the 
modulation of GnRH activity, as none of these knockout models appeared to be 
infertile. Based on presented evidence it is feasible to postulate that the GnRH 
release is controlled by integrated modulation from various neuronal 
populations; including, POMC, AgRP, Kiss1 or MCH expressing neurones, 
which are in very close apposition to each other and most importantly to GnRH 
neurones (Ward et al., 2009; Roa, 2013). The exact role of the melanocortin 
system in this neuronal network is an as-of-yet unresolved but important issue. 
The summary of known effects of the melanocortin system on GnRH release 
and proposed mechanism is presented below (Figure 1.4). 
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Figure 1.4 Proposed model of mechanism(s) through which the melanocortin 
system may affect the GnRH release Description in text (Modified from Israel et al., 
2012).  
 
 
In addition to the effects of the melanocortin system on the GnRH release, 
centrally expressed MC stimulate sexual behaviour in both males and females 
upon activation by endogenous or exogenous ligands. One of the first effects of 
melanocortins on sexual function were reported by Bertolini and co-workers in 
1965, who observed repeated episodes of spontaneous full penile erections in 
male rabbits and dogs after ICV injection of ACTH (Argiolas, 1999; Bertolini et 
al., 2009). Copulatory behaviour was also observed after injections of either α-
MSH or γ-MSH into laboratory animals (Gonzalez et al., 1996). Currently, a 
number of highly selective agonists at MC are being developed for the 
treatment of a range of pathological conditions; including reduced sexual 
arousal and desire in women as well as erectile dysfunction and hypoactive 
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sexual desire disorder (HSDD) (Hadley, 2005). A synthetic analogue of α-MSH, 
PT-141, produced by Palatin Technologies is a novel candidate for the 
treatment of male and female sexual dysfunctions and is currently in Phase 2 of 
development (Rosen et al., 2004; Palatin Technologies, 2014). 
1.3.2 Pituitary 
The melanocortin system may also affect reproductive function at the level of 
the pituitary. There are substantial species differences in pituitary MC 
expression. In the human, three subtypes were detected: MC1, MC4 and MC5 
(Chhajlani, 1996). Expressions of both MC3 and MC5 were identified in the 
anterior and intermediate lobes of the rat pituitary (Lorsignol et al., 1999), 
whereas in mouse only MC3 has been detected (Morooka et al., 1998). The 
expression of MC3 mRNA in the mouse pituitary was localized to the 
intermediate lobe as well as in anterior lobe lactotrophs and some somatotrophs 
(Matsumura et al., 2003). The role of MC3 in the anterior pituitary received 
particularly high attention due to the stimulatory effects on lactotrophs following 
administration of γ3-MSH, an agonist with the highest potency at MC3 
(Roudbaraki et al., 1999; Matsumura et al., 2003), hence this MC subtype will 
be mainly described here.   
Age and gender differences are thought to exist in the expression pattern of 
MC3. In adult life MC3 is mainly present in lactotrophs (Matsumura et al., 2003) 
whilst in immature rats MC3 mRNA was located in pituitary cells expressing 
multiple mRNAs; that is, prolactin, growth hormone, POMC, or thyrotropin 
stimulating hormone-β, in various combinations (Roudbaraki et al., 1999). 
These findings suggest that MC3 may play a role in postnatal development, as it 
is present in a subpopulation of pituitary cells containing more than one 
hormone mRNA, which can be crucial during conditions of higher demand for a 
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specific hormone. Furthermore, Matsumura and colleagues (2003) indicated 
that the number of MC3 mRNA transcripts present in anterior pituitary of adult 
female mice is higher compared to adult males. The reason for this observation 
can be explained by the fact that the proportion of lactotrophs is lower in male 
mice. Lorsignol and colleagues (1999) reported that MC3 was expressed in a 
functional state in anterior pituitary cells of immature rats, as it increased Ca2+ 
concentrations in response to γ-MSH stimulation. This effect was partially 
blocked by administration of SHU9119 (MC3/MC4 antagonist), suggesting 
primary involvement of MC3, since expression of MC4 in the mouse pituitary had 
previously not been reported (Lorsignol et al., 1999). 
The presence of precursor for melanocortin peptides and their generation in the 
pituitary of various species has been well documented (as reviewed by Wikberg 
et al., 2000; Bicknell, 2008). The majority of α-MSH but also small quantities of 
γ-MSH peptides are known to be released in the intermediate lobe of the 
pituitary (as reviewed by Wikberg et al., 2000). In the anterior lobe, both α- and 
γ-MSH release has been reported from corticotrophs and lactotrophs, where 
they act in an auto- or paracrine manner on nearby populations of pituitary cells 
(Marcinkiewicz et al., 1993). The stimulatory effects of α-MSH on in vivo and in 
vitro prolactin release were determined in both mice (Matsumura et al., 2003) 
and rats (Ellerkmann et al., 1992; Hill et al., 1993). Administration of α-MSH 
increased the responsiveness of lactotrophs to other stimuli such as thyrotropin 
releasing hormone (TRH), known to stimulate prolactin secretion (Nunez and 
Frawley, 1998), and directly stimulated the release of prolactin in oestradiol-
primed female rats or mice (Ellerkmann et al., 1992; Morooka et al., 1998). 
Additionally, studies in rats suggested that α-MSH is involved in the regulation 
of suckling-induced prolactin release in lactating females (Hill et al., 1993). 
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Further experiments using an adult male mouse model showed that α-MSH was 
able to stimulate lactotroph proliferation and prolactin release (Matsumura et al., 
2003). The outcomes of these reports suggest that α-MSH may serve as a 
prolactin releasing factor. The receptor mediating the effects of α-MSH in 
lactotrophs is thought to be MC3. There are several lines of evidence supporting 
this statement. First, MC3 is the only MC receptor found to be expressed in both 
rat and mice, which served as a model in the above studies (Morooka et al., 
1998; Lorsingol et al., 1999). The effects of α-MSH can be blocked by SHU9119 
in vitro (Matsumura et al., 2003). Expression of MC3 in anterior pituitary of mice 
increases in response to oestrogen (Matsumura et al., 2004), which is in 
accordance with the α-MSH-mediated increase in prolactin release in 
oestradiol-primed rats and mice (Ellerkmann et al., 1992; Morooka et al., 1998). 
Furthermore, Tilemans and others (1997) demonstrated that γ3-MSH, the 
melanocortin peptide with the highest potency at MC3, induced DNA replication 
in lactotrophs and prolactin release in cell aggregates from immature rats 
pituitaries.  
Some reports, however, suggest that another receptor, different from the classic 
melanocortin receptors, is involved in mediating the effects on lactotrophs.  
Langouche and colleagues (2004) demonstrated that γ3-MSH as well as Ala8- 
γ2-MSH, a very weak agonist at MC3, increased prolactin mRNA expression in 
pituitary cells of immature rats, and this effect was not reduced following 
administration of agouti-related protein (endogenous MC3/4 antagonist). 
Additionally, the rat GH3 cell line (which resembles lactotrophs) responded to 
stimulation with γ2-MSH and Ala8-γ2-MSH by an increase in [S35] GTPγS binding 
however none of the known MC were identified in this cell line (Langouche et 
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al., 2004). No further reports describing the novel receptor have been published 
since then.  
It can be concluded, that the involvement of melanocortin system in regulation 
of reproductive function at the level of pituitary is primarily exerted by regulation 
of prolactin release. The effects of prolactin on reproductive physiology in the 
mammalian female vary according to the reproductive state such as the stage 
of the oestrous/menstrual cycle, mating, pregnancy or lactation. An increase in 
prolactin secretion stimulated by oestradiol during the afternoon of proestrus 
leads to a preovulatory surge coinciding with the LH surge (as reviewed by 
Gregerson, 2006). In contrast, suckling-induced prolactin release during 
lactation inhibits LH secretion by gonadotrophs and thus results in amenorrhea 
(Sortino and Wise, 1989). It is worth mentioning that prolactin is essential in 
maintaining the implantation of corpora lutea during early pregnancy of rodents 
(as reviewed by Gregerson, 2006). Therefore, it can be concluded that episodic 
release of prolactin is crucial for maintaining normal reproductive functions of 
mammalian females. However, chronically elevated levels of prolactin are 
associated with disrupted cyclicity and infertility in females (Voogt et al., 1987). 
In male mice, prolactin exerts stimulatory effects on a number of aspects of 
testicular growth and function, hence lack of prolactin signalling, as deduced 
from prolactin receptor null mice (PRL-R-KO) leads to reduced fertility (as 
reviewed by Bartke, 2004).  
Evidence of a direct role of the melanocortin system on the functioning of 
gonadotrophs exists but has not been fully elucidated. POMC expression was 
identified in 35-80 % of rat gonadotrophs between days 4-11 postnatally (Childs 
et al., 1982). Furthermore, Marcinkiewicz and others (1993) reported the 
presence of prohormone-converting enzyme 1 (PC1) in this population of 
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anterior pituitary cells suggesting the possibility of further POMC cleavage into 
smaller peptides. Gonadotrophs responded to GnRH stimulation by releasing N-
terminal 10 and 12 kDa POMC peptides, which were shown to stimulate 
lactotroph recruitment and prolactin mRNA expression during lactotroph 
development (Van Bael et al., 1996). Thus far, no reports of autocrine actions of 
secreted peptides on gonadotrophs and MC expression in this population of 
cells exist.    
Increased circulating concentrations of α-MSH (possibly of pituitary origin), 
however were reported in the late follicular phase of the menstrual cycle in 
women, when gonadotropin secretion is correspondingly high, suggesting 
possible direct effects on LH and FSH release (Mauri et al., 1990). The direct 
role of melanocortins and their receptors on gonadotrophs and their secretions 
remains to be clearly defined.   
1.3.3 Gonads  
1.3.3.1 Testis 
Expressions of four MC subtypes: MC1, MC2, MC3, MC5, were identified in 
human testes (Chhajlani, 1996). Detectable levels of MC5 mRNA were also 
found in adult mice testes (Fathi et al., 1995). In fetal mice, testicular 
expressions of MC2 and MC5 were reported during embryonic days 13.5 to 18 
(Nimura et al., 2006). Expressions of mRNA for MC2 as well as MC3 and MC4, 
but not MC5 were detected in fetal testes and none of the MC were identified in 
adult mice testes (O'Shaughnessy et al., 2003). The significant age-related 
decrease in this study was further confirmed by real-time PCR for the MC2 
subtype (O’Shaughnessy et al., 2003).  
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POMC derivatives, including α-MSH, γ-MSH and ACTH, were reported in the 
Leydig cells of rodent testes (Bardin et al., 1984; Chen et al., 1984). Both α-
MSH and ACTH were shown to be secreted by Leydig cells into testicular 
interstitial fluid (Bardin et al., 1984). Melanocortins are thought to regulate 
Sertoli cell growth (Bardin et al., 1984) and function in a paracrine fashion by 
increasing Sertoli cell sensitivity to FSH stimulation (Morris et al., 1987). 
Melanocortins have also been reported to affect both aromatase (converts 
androgens to oestrogens) and plasminogen activator (urokinase; local 
fibrinolysis, essential for mammalian spermatogenesis) activities: two 
parameters of Sertoli cell function (Boitani et al., 1989). 
The expression of MC2 and MC5 in the Leydig cells of fetal or neonatal mice 
renders the possibility of an autocrine effect on steroidogenesis (Johnston et al., 
2007). Incubation of fetal, neonatal or adult testes with α- or γ-MSH had no 
effect on testosterone release (O’Shaughnessy et al., 2003). ACTH incubation, 
however, significantly increased androgen production in fetal or neonatal mouse 
testicular tissue but had no effect in adult mouse testicular tissue. The response 
mediated by ACTH was comparable to that of human chorionic gonadotropin 
(hCG; luteinizing hormone analogue) suggesting that both LH and ACTH may 
regulate Leydig cells steroidogenesis in a redundant fashion during postnatal 
life of mice (O’Shaughnessy et al., 2003). This is in agreement with reports 
indicating that steroidogenesis during fetal life can be gonadotropin independent 
(O'Shaughnessy et al., 1998). The fact that ACTH and not α- or γ-MSH 
stimulates androgen production indicates that MC2, the ACTH only receptor, is 
likely to mediate the described ACTH effects in fetal mouse testicular tissue. 
Further experiments determined that testicular MC2 is functional as activation 
with ACTH led to an immediate increase in cAMP release, and similarly to hCG, 
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it increased mRNA expression of the steroidogenic acute regulatory protein 
(StAR) suggesting that both mediators can act on Leydig cells through the same 
signalling pathway (Johnston et al., 2007).  
In contrast to fetal mice, acute administration of pharmacological levels of 
ACTH in adult rabbits and pigs increased testicular testosterone release in vivo 
(Juniewicz et al., 1988). This indicates involvement of the melanocortin system 
in testicular functioning in later life in these species. The discrepancies between 
the two studies may be due to either species differences or possible variation of 
POMC expression influenced by reproductive stage. Bardin and co-workers 
(Bardin et al., 1987a) reported that the amount of POMC peptides as well as 
POMC mRNA changes at different stages of reproductive development in both 
the mouse and the hamster. POMC derivatives were detectable in Leydig cells 
of mice by day 16 of gestation and increased in fetal life, after birth, however, 
their concentrations gradually declined until puberty period at around 40 days of 
life. These results suggest that POMC expression is dependent upon 
gonadotropin secretion and increases during periods of testosterone release in 
fetal life and at puberty (Bardin et al., 1987b). The possibility exists that 
expression of receptors for POMC derivatives may also be influenced by 
gonadotropin secretion and change at certain periods during reproductive 
development.  
In addition to the effects in Leydig cells, Nimura and colleagues (2006) reported 
the presence of MC2 and particularly MC5 in spermatogonia of fetal mice 
suggesting their possible involvement in cell division during the fetal period. 
Gizang-Ginsberg and Wolgemuth (1987) proposed that POMC derivatives may 
serve as a link between germ and Leydig cells. The group reported that POMC 
mRNA expression was particularly high in Leydig cells located in association 
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with seminiferous tubules at spermatogenic stages IX-XII, which contain germ 
cells at later stages. Interestingly, POMC mRNA was undetectable in the testis 
of mutant mice devoid of germ cells, thus emphasizing the importance of 
paracrine interactions between germ and Leydig cells. Although the presence of 
POMC in germ cells is still questionable (Gizang-Ginsberg and Wolgemuth, 
1987), expression of MC in these cells (Nimura et al., 2006) indicates a possible 
paracrine action.  
Testicular expression of mRNAs for the other three subtypes MC1, MC3 and 
MC4, (Chhajlani, 1996; O’Shaughnessy et al., 2003), although still not localized, 
indicates that the melanocortin system may be involved in other activities 
enabling normal testicular functioning. 
1.3.3.2 Ovary 
Similarly to the testis, expression of MC in the ovary has been reported in a 
number of species at different ages. Nimura and colleagues (2006) determined 
the expression of MC2 in the ovaries of fetal mice from embryonic day 13.5 to 
18.5 by immunohistochemistry. MC2 mRNA was also reported to be expressed 
in the ovary of the juvenile nonmammalian vertebrate rainbow trout 
(Oncorhynchus mykiss) (Aluru and Vijayan, 2008), whilst MC5 cDNA was 
determined in human ovaries (Chhajlani, 1996). Amweg and co-workers (2010) 
localized the expression of mRNAs for MC1, MC2 and MC3 in theca cells at 
different stages of follicular development and in corpora lutea of adult cows. 
Interestingly, POMC derivatives such as γ3-MSH were identified in large antral 
follicles and corpora lutea of cycling or pregnant mice but no immunostaining 
was reported in immature animals (Shaha et al., 1984). The mRNA for POMC 
was also absent in ovaries from immature rats but increased markedly during 
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pregnancy or in response to stimulation with gonadotropins (Chen et al., 1986). 
The fact that some MC are co-expressed with POMC suggests an auto- or 
paracrine roles in ovaries, similarly to the male gonads.  
The effects of ovarian MC activation by their agonists vary depending on the 
concentration and frequency of administration. The early studies on the effects 
of exogenous administration of ACTH in laboratory animals, mainly rodents, 
aimed at determining the effects of stress-associated cortisol release on 
reproductive physiology. Christian (1964) reported an increase in follicular 
atresia in immature female rats after chronic administration of ACTH. Similarly, 
repeated administration of synthetic ACTH during the proestrous phase in sows 
disturbed follicular development and prolonged the oestrous cycle (Einarsson et 
al., 2007). McKinney and Pasley (1974) showed that subcutaneous 
administration of exogenous ACTH in vivo reduced uterine and ovarian weights 
in juvenile female rats and delayed sexual maturation, however, histological 
examination of the ovaries did not reveal obvious differences in the number of 
maturing or atretic follicles. The above studies still did not provide an evidence 
of a direct effect of ACTH on the ovary.  
In contrast, acute ACTH administration facilitated ovulation in the presence of 
moderate or high oestrogen concentrations (Baldwin et al., 1974; Putnam et al., 
1991). This effect is supported by the fact that both MC and POMC are 
expressed in antral follicles and corpora lutea (Chen et al., 1986; Amweg et al., 
2010) and that MC4-deficient mice have reduced number of corpora lutea, 
linked to a decrease in ovulation rate (Sandrock et al., 2009). 
ACTH was also reported to exert direct effects on steroidogenesis, as 
pharmacological doses of this peptide stimulated the secretion of 17β-oestradiol 
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and progesterone by ovaries primed with gonadotropins in vivo (Varga et al., 
1986). Likewise, a single administration of ACTH alone or in combination with 
human chorionic gonadotropin increased synthesis of progesterone in rat luteal 
cells in vitro (Horvath et al., 1986). The group suggested that this effect was 
mediated by prostaglandins E, which were released after binding of ACTH to a 
specific receptor located on the membrane of luteal cells.  MC2 is the prime 
candidate mediating the effects of ACTH on ovary, however some groups 
suggested involvement of other MC with lower affinity for ACTH than MC2 
(Horvath et al., 1986). This observation was further supported by work of 
Durando and Celis (1998) who reported significant increases in progesterone 
release from prepubertal rat ovaries in response to α-MSH administration in 
vitro. There have been very few reports using selective MC ligands hence the 
exact receptor(s) mediating the described effects on follicular development, 
steroidogenesis, ovulation and luteal function are yet to be determined.  
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1.4 Aims of the research 
 
The aims of this research were to determine the mRNA and protein distribution 
pattern of MC3 at each level of the hypothalamo-pituitary-gonadal system in 
male and female mice, including the potential co-expression of the other four 
MC when possible. The other aims were to ascertain the role of MC3 in 
reproductive physiology using the MC3-/- mouse model and an in vitro testicular 
culture.  
The above aims were addressed by the following objectives: 
• To determine MC mRNA expression in the reproductive axes of male 
and female mice at different ages and physiological states 
• To establish the exact MC3-expressing cells in mice testes using different 
anti-MC3 antibodies 
• To ascertain the possibility of local melanocortin peptides production by 
determining POMC mRNA expression in the reproductive tissues of male 
and female mice 
• To compare the pituitary hormone content of MC3-/- to wild type mice 
• To compare the morphology of testes from MC3-/- to wild type mice at 
different ages 
• To examine the effects of MC3 activation/inhibition on in vitro 
steroidogenesis and immune responses in testicular tissues from 
C57BL/6 and Balb/c mice 
• To characterise the MC expression and effects of γ2-MSH on nitrite 
production in the K9 Leydig cell line 
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2 Expression of MC in the HPG systems of both 
male and female mice 
 
2.1  Introduction  
 
Melanocortin receptors are widely expressed throughout the body and can be 
found in the central nervous system as well as in the periphery. Since the 
discovery of the first melanocortin receptor (MC1) in skin in 1992 (Chhajlani and 
Wikberg, 1992), the main expression sites of another four receptors were 
determined. The primary cell type expressing MC1 are melanocytes (Chhajlani 
and Wikberg, 1992) but dendritic cells, neutrophils, B lymphocytes and 
macrophages (Star et al., 1995; Taherzadeh et al., 1999) also synthesize this 
protein. MC2 was found to be present in the zona glomerulosa and fasciculata 
of the adrenal cortex (Mountjoy et al., 1992) and adipocytes (Noon et al., 2006). 
The prime locations of MC3 and MC4 expression lie in the central nervous 
system and include the hypothalamus, hippocampus and thalamus (Gantz et 
al., 1993; Roselli-Rehfuss et al., 1993; Chhajlani, 1996). Peripheral expression 
of these two receptors has also been demonstrated: MC3 was found in gut, 
placenta, kidney, heart, immune cells, ovary and testis (Chhajlani, 1996), whilst 
MC4 is expressed in adipose tissue (Ellacott et al., 2007). MC5 is also present in 
the hypothalamus (Griffon et al., 1994) but it is primarily expressed in peripheral 
exocrine glands including the sebaceous, preputial, lacrimal and Harderian 
glands as well as adipocytes (Chen et al., 1997; Møllera et al., 2011) and the 
adrenal gland (Liakos et al., 2000).  
MC are activated with different affinities by melanocortin peptides, which are 
derivatives of the POMC protein. The main sites of POMC expression are the 
anterior and intermediate lobes of the pituitary but high expression can also be 
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found in the hypothalamus, particularly in the arcuate nucleus (as reviewed by 
Bicknell, 2008). In the periphery, POMC is detectable in organs such as the 
adrenal medulla, skin and neurones of the intestine, where it is thought to have 
paracrine action (as reviewed by Wikberg et al., 2000).     
The (co-)expression of MC3 and the other four receptor isoforms as well as 
POMC in the reproductive tissues, particularly gonads, has been reported, but 
not extensively studied. The factors that could influence (induce or inhibit) 
mRNA expression of MC and the melanocortin precursor molecule are 
unknown. Additionally, expression of MC3 is usually determined at the level of 
mRNA and it is not always clear whether it becomes translated into protein.   
The aim of this series of studies was to determine the expression of MC and 
POMC at the level of mRNA, and protein when possible, in tissues involved in 
the control of reproductive function in both male and female mice. The 
influences of age, gender and reproductive state, particularly in the female, 
were examined. Additionally, the expression of MC in two different mice strains 
namely Balb/c and C57BL/6, which are known to differ with regard to the 
steroidogenic activity and immune responses, were also determined.  
 
2.2  Materials and Methods 
 
2.2.1 Animals 
Tissues from 3-24 weeks old wild type C57BL/6 or Balb/c mice were provided 
by Dr Le Tissier (National Institute for Medical Research, London, UK). Tissues 
from MC3-/- mice (3-24 weeks) with C57BL/6 background were obtained from 
Professor Perretti (William Harvey Research Institute, London, UK). All animals 
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were collected from animal houses licensed by the Home Office and killed using 
a schedule 1 procedure (cervical dislocation) by licensed personnel. Following 
removal from an animal, tissues were either frozen on dry ice and stored at -80 
°C (until used for mRNA, protein extraction or radioimmunoassay) or fixed in 4 
% paraformaldehyde (PFA; PROL294474L, VWR, UK; for immunostaining).  
2.2.2 Expression of MC mRNA in the HPG system 
2.2.2.1 RNA extraction 
RNA was extracted using the Qiagen RNAeasy kit (74004, Qiagen, UK) 
following the manufacturer’s instructions. Frozen tissues (approximately 5 mg) 
from C57BL/6 or Balb/c mice (whole hypothalamus, whole pituitary, whole 
ovary, whole testis, pieces of the uterus removed from the junctions of both the 
oviduct and the cervix) were weighed and homogenized using a pestle and 
mortar in 350 µl of RLT lysis buffer. Tissues greater than 5 mg (testis and 
hypothalamus) were aliquoted and the RLT lysis buffer was added to the total 
volume of 350 µl. Solid material from tissue homogenate was separated by 
centrifugation for 5 min at full speed (13,000 rpm) in IEC Micromax 
microcentrifuge (DJB Labcare, UK). The supernatant was transferred to a new 
tube and one volume (approximately 350 µl) of 70 % ethanol added. Each 
sample was placed in a spin column in collection tube and spun for 15 sec at 
10,000 rpm. The flow-through was discarded and the spin column membrane 
washed (with 350 µl of wash buffer RW1 by centrifugation for 15 sec at 10,000 
rpm) in a microcentrifuge. To ensure removal of residual genomic DNA, the 
RNA preparations were treated with deoxyribonuclease. Briefly, 10 μl of DNase 
I stock solution (27 Kunitz units) were mixed with 70 μl resuspension buffer 
RDD and added directly to the membrane and incubated for 15 min (20 – 30 
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°C). The membrane was washed with 350 µl of wash buffer RW1 and 500 µl of 
wash buffer RPE (both by centrifugation for 15 sec at 10,000 rpm). In the final 
step 500 µl of 80 % ethanol were added and spun for 2 min at 10,000 rpm. The 
membrane was further dried by centrifuging an open spin column for 5 min at 
full speed (13,000 rpm). The RNA was eluted in 14 µl of RNase-free water (with 
centrifugation for 1 min at 13,000 rpm). The concentration and purity of each 
mRNA preparation were estimated spectrophotometrically at 260 nm and 280 
nm using the Nanodrop 1000 (Thermo Scientific, UK). A 260 nm/280 nm 
absorbance ratio higher than 2.0 was considered as pure mRNA.  
2.2.2.2 cDNA synthesis 
The first strand of cDNA was synthesized in a 20 µl reaction mixture containing: 
total RNA (<500 ng), 150 ng random hexamers and 40 µM 
deoxyribonucleotides (dNTPs), and incubated for 5 min at 65 °C. First strand 
cDNA synthesis buffer (4 µl) (250 mM Tris-HCl [pH 8.3 at room temperature], 
375 mM KCl, 15 mM MgCl2) and 7.5 mM dithiothreitol (DTT) were added and 
incubated for 2 min at 25 °C followed by the addition of 1 µl SuperScript II 
reverse transcriptase (RT; 200 U/µl). The mix was further incubated for 10 min 
at room temperature. Reactions were then incubated at 42 °C for 50 min and 
inactivated for 15 min at 70 °C with cDNA stored at -20 °C until required. All 
reagents used in the synthesis of cDNA were from a SuperScript II Reverse 
Transcriptase Kit (18064-014, Invitrogen, UK). A non-template negative control 
for each of the mRNA preparations contained no SuperScript II reverse 
transcriptase (no-RT control) and served as a control for the assessment of 
genomic DNA removal. Prepared cDNA served as a template for regular PCR 
and/or quantitative PCR.  
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2.2.2.3 RT- PCR 
Each PCR was carried out using 1 µl cDNA in a final volume of 20 µl using 0.5 
µM forward and reverse primers in a Taq PCR Master Mix containing 1 U Taq 
polymerase, 1.5 mM MgCl2 and 0.2 mM dNTP (201443, Qiagen, UK). The 
POMC, iNOS, 3β-HSD and β-actin (housekeeping gene) primer sequences are 
presented in Table 2.1 and PCR conditions in Table 2.2. Primer sequences 
were based on published literature. 
 
Table 2.1 Primer sequences used for RT-PCR. 
 
 
 
 
Name Sequence (5'–3') 
Amplicon 
size (bp) 
3β-HSD 
forward TATTCTCGGTTGTACGGGCAA 
348 
reverse GTGCTACCTGTCAGTGTGACC 
iNOS 
forward CAGATCGAGCCCTGGAAGAC 
249 
reverse CTGGTCCATGCAGACAACCT 
POMC 
forward 1 GCTGGTGCCTGGAGAGCAGCCAGTG 
F1&R-562;         
F2&R-509 
forward 2 TGCATCCGGGCCTGCAAACTCGACCTCT 
reverse TGGCTCTTCTCGGAGGTCATGAA 
β-actin 
forward AGCCATGTACGTAGCCATCC 
228 
reverse CTCTCAGCTGTGGTGGTGAA 
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primer 
name 
initial 
denatu-
ration 
denatu-
ration 
annealing extension 
final 
extension 
number 
of 
cycles 
iNOS, 
3β-HSD, 
β-Actin 
94 °C for         
5 min 
94 °C for 
45 s 
60 °C for 
30 s 
72 °C for 
1 min 
72 °C for 
10 min 
40 
POMC 
95 °C for         
5 min 
94 °C for 
1 min 
60 °C for 
1 min 
72 °C for 
1 min 
72 °C for 
10 min 
30 
Table 2.2 PCR conditions used for each set of primers. 
 
2.2.2.4 Gel Electrophoresis 
Amplification products were separated by electrophoresis on a 1.5 % - 2 % 
weight/volume (w/v) agarose gel at 100 V in Tris-Acetate-EDTA (TAE; 2 M Tris-
Acetate and 100 mM Na2EDTA in distilled/deionized water, pH 8.3) (EC-872; 
Geneflow, UK) buffer for 60 min and then stained with ethidium bromide (0.5 
µg/ml) (E1510; Sigma-Aldrich, UK) for 20 min. The PCR products were 
visualised under UV light using an UVIPRO Silver transilluminator (UVITEC, 
UK). The sizes of the DNA fragments were determined by comparison to a 
molecular weight marker (100 bp – 5000 bp; L3-0015; Geneflow, UK).  
2.2.2.5 Sequencing of PCR products 
The products of anticipated size were excised from the gels and puriﬁed using a 
Gel Extraction Kit (Geneclean® Turbo, 1102-200, MPBiomedicals, UK). The 
sequencing of puriﬁed products was performed as a service by the sequencing 
facility at the University College London (London, UK). The facility uses an AB 
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sequencer and the appropriate forward and reverse primers were supplied. 
Sequencing data were then further analysed using NCBI Blast. 
2.2.2.6 Quantitative RT-PCR (qRT-PCR)  
qRT-PCRs were performed on aliquots of cDNAs diluted to a working 
concentrations of 12.5 ng/µl of initial mRNA. The final reaction volume was 20 
µl and contained 25 ng of mRNA and either 1.6 µl of forward and reverse 
primers mix for MC1-MC5 or 2 µl of forward and reverse primers mix for 
GAPDH, ATP5B and ACTB in Rotor-Gene SYBR Green PCR Master Mix 
(HotStarTaq DNA Polymerase, PCR Buffer and dNTP mix; 204074, Qiagen, 
UK). The catalogue numbers for the primers used are listed in Table 2.3. Each 
mRNA was run in duplicate or triplicate using Rotor-Gene Q Light Cycler 
(Qiagen, UK). The cycling conditions using the Rotor-Gene SYBR Green PCR 
Master Mix are presented in Table 2.4.  
 
Company Primer name 
Catalogue 
number 
Amplicon size (bp) 
Qiagen MC1 QT00305011 110 
Qiagen MC2 QT00260967 67 
Qiagen MC3 QT00264404 108 
Qiagen MC4 QT00280861 106 
Qiagen MC5 QT01166494 90 
Qiagen GAPDH QT01658692 144 
PrimerDesign ATP5B ge-PP-12 112 
PrimerDesign ACTB ge-PP-12 84 
Table 2.3 A list of primers including their catalogue numbers and amplicon sizes 
used in qRT-PCR.  
60 
 
Step Time Temperature °C 
PCR initial activation 5 min 95 
Two-step cycling   
Denaturation 5 sec 95 
Combined 
annealing/extension 
10 sec 60 
   
Number of cycles 40  
Table 2.4 Cycling conditions for qRT-PCR. 
 
 
Melting curve analyses of the PCR products were performed to verify their 
specificity and identity. The melting curve began at a temperature of 60 °C and 
rose by one degree every 95 sec up to the final temperature of 95 °C. To 
ensure accurate estimation of the gene of interest (GOI) expression, the 
specificity of qRT-PCR was tested in reactions using ‘cDNA’ prepared without 
SuperScript reverse transcriptase (no-RT control). The Ct values for no-RT 
reactions were at least five cycles greater (32-fold less) than those for reactions 
with RT (Laurell et al., 2012). The specificities of the PCR products were 
additionally verified by agarose gel electrophoresis.  
The initial analyses were performed using Rotor-Gene Q Series Software 1.7. 
The threshold for all amplification plots was set within the exponential phase, 
equal to 0.03 of the fluorescence level, to determine the crossing point (Ct), a 
tool for the calculation of gene expression.   
 
61 
 
2.2.2.6.1 Primer amplification efficiency 
 
Standard curves were generated for every primer pair to determine amplification 
efficiencies for relative gene expression quantifications. Standard curves were 
prepared by two fold dilutions of testis and/or hypothalamus cDNAs, with an 
initial concentration of 100 ng/reaction mRNA. Each dilution series was then 
amplified in qRT-PCR and Ct values obtained were used to construct standard 
curves (Figure 2.1). The amplification efficiency, E value, for each target was 
calculated according to the following equation: E = 10(–1/S) – 1, where S is the 
slope of the standard curve (Table 2.5). 
 
 
 
Figure 2.1 Primer amplification efficiency. Standard curves were constructed by 
plotting the Ct values against the logarithm of RNA template amount for each primer 
pair. The amplification efficiencies were then calculated using the slope of the curve.  
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Primer Name Slope E Value 
Efficiencies 
(%) 
MC1 -3.4293 1.9160 93 
MC2 -2.7575 2.6265 93.85 
MC3 -2.9494 2.3905 130.49 
MC4 -3.5555 1.8125 118.3 
MC5 -3.2615 2.0661 91.1 
ATP5B -3.2512 2.0758 107.52 
ACTB -3.6802 1.6971 86.08 
GAPDH -3.4788 1.8746 86.95 
Table 2.5 Primer specific amplification efficiencies. 
 
 
2.2.2.6.2 Reference genes selection 
 
The most stable reference genes were selected from a panel of 12 genes 
(PerfectProbe geNorm 12 gene kit, ge-PP-12; PrimerDesign, UK). This was 
used to ensure accurate gene quantification by normalising the target genes’ Ct 
to genes with the least variance in gene expression between samples. The 
expression of 12 reference genes (Table 2.6) was measured in a representative 
set of 13 tissue samples (Table 2.7). The final qPCR reaction volume was equal 
to 20 µl containing 25 ng of mRNA, 300 nM of forward and reverse primers in 
PrimerDesign Precision qPCR Mastermix. The qPCR cycling conditions are 
presented in Table 2.8. 
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Species Primer name 
Accession 
number 
Product Tm 
(°C) 
Amplicon size 
(bp) 
Mouse 18S NR_003278.3 82.9 93 
Mouse ACTB NM_007393.3 90.2 84 
Mouse ATP5b NM_016774.3 89.8 112 
Mouse B2M NM_009735.3 84.7 120 
Mouse CANX NM_007597.3 86.3 105 
Mouse CYC1 NM_025567.2 92.1 141 
Mouse EIF4A2 NM_013506.2 84.4 152 
Mouse GAPDH NM_008084.2 90.8 127 
Mouse RPL13A NM_009438.5 91.0 130 
Mouse SDHA NM_023281.1 87.1 133 
Mouse UBC NM_019639.4 96.8 129 
Mouse YWHAZ NM_011740.3 87.8 141 
Table 2.6 List of primers used in the geNorm analysis. 
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Gender Strain Age Tissue 
Male Balb/c 8 weeks Hypothalamus 
Male Balb/c 8 weeks Pituitary 
Male Balb/c 8 weeks Testis 
Male C57BL/6 8 weeks Hypothalamus 
Male C57BL/6 8 weeks Pituitary 
Male C57BL/6 8 weeks Testis 
Male C57BL/6 14 weeks Hypothalamus 
Male C57BL/6 14 weeks Pituitary 
Male C57BL/6 14 weeks Testis 
Female C57BL/6 14 weeks Hypothalamus 
Female C57BL/6 14 weeks Pituitary 
Female C57BL/6 14 weeks Ovary 
Female C57BL/6 14 weeks Uterus 
Table 2.7 Samples included in the geNorm analysis. 
 
Step Time Temperature °C 
PCR initial activation 10 min 95 
Two-step cycling   
Denaturation 15 sec 95 
Combined 
annealing/extension 
60 sec 60 
   
Number of cycles 50  
Table 2.8 qPCR cycling conditions. 
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Melt curve analyses were performed following the cycles and the Cts for the 
samples were calculated at a threshold of 0.03 using Qiagen Rotor-Gene 
software as described before. 
The stability of each gene’s expression was analysed and ranked using geNorm 
incorporated in the qbaseplus software (Basic, Biogazelle, Belgium) provided 
with the kit (Figure 2.2). The two most stable genes in tissues from C57BL/6 
and Balb/c male and female mice were ACTB and ATP5B. 
 
 
Figure 2.2 The average expression stability value (M) of 12 reference genes for 
hypothalami, pituitaries and testes taken from C57BL/6 and Balb/c wild type male 
and female mice. The M value was calculated at each step during stepwise exclusion 
of the least stably expressed reference gene. The least stable genes are indicated to 
the left of the curve, whilst the most stable are to the right.  
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The optimal number of reference genes was determined by calculation of a 
pairwise variation, V(n/n+1), based on the variation in average stability of the 
reference genes (Figure 2.3). The geometric mean of the two most stable 
reference genes ATP5B and ACTB was sufficient to give a high quality 
normalization factor because the outcome of pairwise variation calculation is 
lower than the threshold value (V<0.15).  
 
 
 
Figure 2.3 Determination of the optimal number of reference genes. The figure 
shows sequential addition of each reference gene starting with the two most stably 
expressed genes on the left with the inclusion of a 3rd, 4th, 5th gene et cetera, moving 
to the right. The optimal number of reference genes n is found when V(n/n+1) drops 
below 0.15 and in this case an average of the two most stable genes would give a high 
quality normalising signal.  
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2.2.2.6.3 Relative gene expression analysis 
 
The analyses of the relative gene expression level were performed using 
qbaseplus software (Basic, Biogazelle, Belgium). This is based on the ∆∆Ct 
method but with a number of improvements (Hellemans et al., 2007; Hellemans 
and Vandesompele, 2011). First, qbaseplus calculates ∆Ct for each gene in each 
sample by comparing the Ct of a given sample (𝐶𝑡𝑠𝑎𝑚𝑝𝑙𝑒𝐴) with the average Ct 
across all samples for that gene (𝐶𝑡̅̅ ̅; equation 1).  The Relative Quantities (RQ) 
are calculated based on the primer specific PCR amplification efficiency (E; 
equation 2; Table 2.5). The RQ was then normalized by dividing it by the 
geometric mean Ct of a set of selected reference genes, in this case ACTB and 
ATP5B, which results in the Normalized Relative Quantity (NRQ; equation 3). 
All of the data for the presented experiments were scaled to the average 
expression level of a gene across all samples as a reference. The scaling only 
changes the scale of the data, but not the fold changes between the samples. 
The NRQ for each reference was calculated in the same manner as the NRQ 
for a target gene by dividing the RQ of a single reference gene by the geometric 
mean of two reference genes. The NRQ values for both reference genes 
approach 1 indicating similarity, hence stability.   
Equation 1  ∆𝐶𝑡 =  𝐶𝑡̅̅ ̅ − 𝐶𝑡𝑠𝑎𝑚𝑝𝑙𝑒𝐴 
Equation 2  𝑅𝑄𝐴 =  𝐸
∆𝐶𝑡 
Equation 3  𝑁𝑅𝑄 =  
𝐸
𝑔𝑜𝑖
∆𝐶𝑡𝑔𝑜𝑖
𝐸𝑟𝑒𝑓
∆𝐶𝑡𝑟𝑒𝑓
=  
𝑅𝑄𝑔𝑜𝑖
𝑅𝑄𝑟𝑒𝑓
                        
RQgoi = Relative Quantities for Gene Of Interest 
RQref = Relative Quantities for Reference Gene 
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 Multiple reference genes  𝑁𝑅𝑄 =  
𝑅𝑄𝑔𝑜𝑖
𝑔𝑒𝑜𝑚𝑒𝑡𝑟𝑖𝑐 𝑚𝑒𝑎𝑛 (𝑅𝑄𝑟𝑒𝑓𝑠)
 
      𝑁𝐹 =  
1
𝑔𝑒𝑜𝑚𝑒𝑡𝑟𝑖𝑐 𝑚𝑒𝑎𝑛 (𝑅𝑄𝑟𝑒𝑓𝑠)
 
 
2.2.3 Expression of MC3 protein in the HPG system  
2.2.3.1 Western blot 
Frozen tissue samples (whole hypothalami, whole pituitaries, whole ovaries, 
whole testes, pieces of the uterui removed from both the junctions of the oviduct 
and the cervix) from C57BL/6 mice were homogenised on ice in 1 ml of RIPA 
buffer (150 mM sodium chloride [S9888; Sigma-Aldrich, UK], 1 % 
volume/volume (v/v) Triton X-100 [T8787; Sigma-Aldrich, UK], 0.5 % w/v 
deoxycholic acid [D5670; Sigma-Aldrich, UK], 0.1 % w/v sodium dodecyl 
sulphate [SDS: BP166; Fisher, UK]) containing 1 % v/v of a cocktail of protease 
inhibitors (BPE 9707-1; Fisher Scientific, UK) using a mortar and pestle. 
Samples were then spun for 20 min at 4 °C at 14,000 rpm in a microcentrifuge 
and supernatants removed for further analysis. The protein contents were 
determined using the Bicinchoninic Acid Protein Assay Kit (BCA1 & B9643; 
Sigma-Aldrich, UK) in a 96 well plate. Protein standards 5 µg/ml – 1 000 µg/ml 
were prepared in duplicate using bovine serum albumin (BSA) (P0834-10X1ML; 
Sigma-Aldrich, UK) and their absorbance values were used to plot a standard 
curve (Figure 2.4). Absorbance was measured at 562 nm using a Versa Max 
microplate reader (Molecular Devices, UK) and analysed by SoftMaxPro 5.2 
software (Molecular Devices, UK). 
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Figure 2.4 Example of a standard curve generated to determine the protein 
content in samples of interest. Value R2 is displayed on the graph. 
 
Protein (20 - 40 µg) was mixed with SDS-PAGE loading buffer (S3401-10VL; 
Sigma-Aldrich, UK) followed by heating for 5 min at 99 °C, vortexing and 
loading (15 µl) onto 10 - 12 % sodium deodecyl sulphate-polyacrylamide gel 
(SDS-PAGE). Protein ladder (5 µl) was also loaded onto each gel (BPE3603-
500; Fisher, UK). The protein was separated by electrophoresis in a Bio-Rad 
Mini-PROTEAN® Tetra Cell electrophoresis system in Tris-Glycine-SDS 
Running Buffer pH 8.3 (250 mM Tris base [BP152; Fisher, UK], 1920 mM 
glycine [G8898; Sigma-Aldrich, UK], 1 % w/v SDS) for 35 min at 200 V.  
Following electrophoresis, the gel was incubated in ice-cold cathode buffer pH 
9.4 (25 mM Tris-base, 10 % v/v methanol [34860; Sigma-Aldrich, UK], 40 mM 
glycine) for 5 min in preparation for semi-dry protein transfer. The 
electrotransfer unit was organised in the following order starting from the anode 
electrode plate: two filter papers wetted in cold anode buffer I pH 10.4 (0.3 M 
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Tris base, 10 % v/v methanol), one filter paper wetted in cold anode buffer II (25 
mM Tris base, 10 % v/v methanol), Immun-BlotTM PVDF Membrane (0.2 µm) 
(162-0175; Bio-Rad, UK) (prepared by placing in methanol for 30 sec, rinsed in 
deionized H2O [dH2O] and then incubated in anode buffer II for 5 min), gel and 
three filter papers wetted in cathode buffer. The semi-dry protein transfer was 
done for 30 min at 100 A using a Geneflow (Fradley, UK) transfer system.   
The gel was stained for 30 min in Coomassie stain (0.25 % Coomassie brilliant 
blue [BP101-25, Fisher, UK] in Coomassie destain) followed by three washes in 
Coomassie destain (10 % v/v acetic acid [10001BT; VWR, UK] and 10 % v/v 
methanol). The membrane was then incubated in 5 % milk solution (5 % w/v 
milk powder [0.1 % fat skimmed milk powder, Sainsbury’s, UK] in TBS-T : pH 
7.4; 50 mM Tris base, 150 mM sodium chloride, 0.05 % v/v Tween® 20 
[233362500; Acros Organics, UK]) for 1 h at room temperature on a rocking 
platform in order to prevent non-specific antibody binding. Blocking solution was 
removed and the membrane incubated in the primary antibody diluted in 5 % 
milk solution (concentrations of each primary antibody are presented in Table 
2.9) at 4 °C overnight. Following incubation, the primary antibody solution was 
removed and membrane washed (3 x 5 min with TBS-T). The blot was placed in 
the corresponding secondary antibody conjugated to horseradish peroxidase 
(HRP, Table 2.9) for 1 h at room temperature and then washed as before (3 x 5 
min with TBS-T). 
To determine antibody specificity, a mix of particular antibody (0.5 µg) and 
recombinant MC3 protein (1 µg, H00004159-P01; Abnova, UK) or Enzo blocking 
peptide (for Enzo antibody only) was pre-incubated for 1 h at room temperature 
before applying the mixture onto the membrane and incubating overnight at 4 
°C.  
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Specific antibody binding was detected in the dark using a Chemiluminescence 
Detection Kit (K1-0170; Geneflow, UK) according to manufacturer’s instructions. 
Briefly, equal volumes of EZ-ECL Solution A and Solution B were mixed, 
applied onto the membrane and incubated for 5 min. Excess detection mix was 
drained off and the membrane was placed in a HypercassetteTM (Amersham 
Pharmacia Biotech, Buckinghamshire, UK) and exposed to CL-XPosureTM X-ray 
film (34090; Fisher Scientific, Loughborough, UK) for 5 min, 2 min or 30 sec. 
The films were developed by incubation for 5 min in Kodak® GBX 
developer/replenisher (P7042; Sigma-Aldrich, UK), washed in dH2O for 1 min 
and then fixed in Kodak® GBX fixer/replenisher (P7167; Sigma-Aldrich, UK). 
The size of detected protein bands were determined by comparison to a protein 
ladder (BPE3603-500; Fisher Scientific, Loughborough, UK).  
Following detection, bound antibodies were removed by incubating the 
membrane in acidic glycine solution (0.2 M glycine, 3.47 mM sodium dodecyl 
sulphate, 1 % v/v Tween 20, pH 2.2) twice for 10 min, and then washing with 
phosphate buffered saline (PBS, P4417; Sigma-Aldrich) (2 x 10 min) and TBS-T 
(2 x 5 min) at room temperature. This was followed by blocking in 5 % milk 
solution for 1 h at room temperature. The membranes were subsequently 
reprobed for the detection of other proteins, such as α-tubulin (housekeeping 
protein).  
To determine the efficiency of the transfer and protein separation on the gel the 
membrane was stained for 1 min with Coomassie solution, then destained with 
Coomassie destain three times for 5 min, dried in air and kept for future record.  
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primary 
antibody/ 
concentration 
primary 
antibody 
manufacturer/
catalogue 
number 
species reactivity 
Molecular 
weight 
(kDa) 
immunogen 
secondary 
antibody/ 
concentration 
secondary 
antibody 
manufacturer/
catalogue 
number 
MC3-rabbit 
polyclonal/ 
1:1000 
Sigma/M4937 
Rat, Mouse 
(predicted) 
40 
N-terminal region of rat 
MC3 (amino acids 15-33) 
(highly conserved in 
mouse MC3; 89% identity) 
goat anti-rabbit 
IgG-HRP/ 
1:5000 
BIO-RAD/170-
6515 
MC3-rabbit 
polyclonal/ 1:500 
Abcam/ab2123
1 
Human, Rat, 
Mouse 
55 
Unique C-terminal epitope, 
conserved in several 
species 
goat anti-rabbit 
IgG-HRP/ 
1:4000 
BIO-RAD/170-
6515 
MC3-rabbit 
polyclonal/ 
1:1000 
 
Enzo Life 
Sciences 
/BML-SA640 
Human, Rat, 
Mouse 
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Synthetic peptide 
corresponding to aa 102-
117 of rat MC3 
goat anti-rabbit 
IgG-HRP/ 
1:5000 
BIO-RAD/170-
6515 
α-tubulin-rat 
monoclonal/ 
1:3000 
Abcam/ab6160 
Human, Mouse, 
Caenorhabditis 
elegans, Fruit fly, 
Pig, 
Saccharomyces 
cerevisiae, 
53 
recognises short amino 
acid sequence Glu-Glu-
Phe(OH) which can be 
inserted into the C-
terminal domain of fusion 
proteins 
goat anti-rat 
IgG-HRP/ 
1:5000 
Santa Cruz 
Biotechnology/s
c-2032 
Table 2.9 List of primary and secondary antibodies used in Western blot. 
7
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2.2.3.2 Immunostaining 
2.2.3.2.1 Tissue preparation 
 
Testes of male mice were excised immediately following death and placed in 4 
% PFA for approximately 7 h at room temperature. Tissues were then 
transferred into PBS and stored at 4 °C.  Fixed testes were placed in plastic 
histology cassettes, dehydrated first in 30 % and then 50 % ethanol (32221, 
Sigma-Aldrich, UK) for 1 h each at 4 °C, followed by an overnight incubation in 
70 % ethanol at 4 °C. The tissues were further dehydrated in 90 %, 95 % and 
twice in 100 % ethanol for 1 h each at 4 °C before being cleared in 100 % 
xylene (4099-0025, Fisher Scientific, UK) once for 1 h and then 30 min at room 
temperature. Finally, tissues were incubated in infiltrating wax (1:1 paraffin 
wax/xylene) for 1 h at 56 °C and in 100 % paraffin wax (706043, VWR, UK) 
three times for 30 min at 56 °C. After wax infiltration, tissues were transferred to 
plastic moulds, embedded in paraffin wax and allowed to set before being 
stored at 4 °C overnight.   
Sections were cut from the wax blocks using a microtome (Anglia Scientific, UK) 
at a thickness of 6 µm but initially at 10 µm, placed briefly in water bath at 21 °C 
and then mounted onto gelatine coated glass slides. The sections were 
thoroughly dried on a heating plate at 45 to 50 °C and placed in an oven 
overnight at 37 °C. Prepared slides were stored at room temperature prior to 
being processed for haematoxylin and eosin staining or immunohistochemistry. 
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2.2.3.2.2 Immunohistochemistry (IHC) 
 
Unless otherwise indicated all washes were done by incubating the slides three 
times for 5 min in PBS on a rocking platform. Sections were first dewaxed with 
xylene and then rehydrated through an alcohol gradient followed by washes in 
PBS as described for haemotoxylin and eosin staining (section 3.2.2.1). If 
antigen retrieval was required (as for Abcam MC3 and WT-1 antibodies), the 
sections were kept in a Coplin jar containing citrate buffer (10mM citric acid, 
0.05 % Tween 20, pH 6.0) in boiling water for 5-20 min, then cooled down at 
room temperature for 20 min and washed. Sections were then treated with 3 % 
H2O2 (v/v) (UN2014; VWR, UK) in methanol (34860; Sigma-Aldrich, UK) for 10 
min at room temperature to block endogenous peroxidase activity. After 
washing, sections were incubated in 0.03 % Triton X-100 (TX-100: T8787; 
Sigma-Aldrich, UK) for 30 min at room temperature and rinsed before blocking 
in 10 % normal serum (serum was the same as the species that the secondary 
antibody was raised in, as opposed to the species of the primary antibody) in 
PBS for 30 min at room temperature. Slides were then placed in a humidified 
chamber, to prevent the sections from drying, and incubated in the specific 
primary antibody in 1 % serum in PBS (Table 2.10) for 1 h at room temperature 
followed by an overnight incubation at 4 °C. Sections were washed and 
incubated for 1 h at room temperature in the relevant biotinylated secondary 
antibody (Table 2.10). Following incubation sections were washed and left for 1 
h at room temperature in Vector A + B solution (SK-4100; Vector Laboratories, 
UK). Slides were then washed in PBS 2 x 5 min and Tris buffer (10 mM Tris 
base, pH 7.4) for 5 min, followed by incubation in 3,3-diaminobenzidine (DAB) 
solution (SK-4100; Vector Laboratories, UK) for 5 min to visualise the antigen–
antibody complex. Slides were further washed in Tris buffer (3 x 5 min) and 
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counterstained with Gill’s haematoxylin for 4 min. Following rinsing in tap water, 
incubation in acid rinse solution and bluing solution, sections were dehydrated 
through an alcohol gradient 30 to 100 % (as described in section 3.2.2.1 but 
eosin omitted). Finally, slides were incubated with xylene (2 x 5 min) and 
mounted with DPX mounting media. Sections immunostained in the absence of 
the relevant primary antibody (1 % normal serum in 0.1 % TX-100 in PBS) 
served as negative controls.  
2.2.3.2.3 Immunofluorescence (IF) 
 
As for immunohistochemistry (section 2.2.3.2.2), sections were deparaffinised 
and rehydrated through an ethanol gradient. Following three washes for 3 min 
in PBS (the same wash for all steps unless indicated) slides were incubated in 
0.03 % Triton X-100 for 30 min at room temperature. After rinsing, sections 
were placed in humidified chamber and blocked in 10 % normal serum 
containing 0.5 mg/ml of RNase A (19101; Qiagen, UK) in PBS for 30 min at 
room temperature to remove the cytoplasmic RNA and prevent background 
staining with nuclear stain. Slides were then incubated in first primary antibody 
(MC3; antibody concentrations for IF are presented in Table 2.11) in 1 % normal 
serum in PBS at 4 °C overnight. Following washing, sections were covered with 
the secondary antibody, usually conjugated to Texas Red, in PBS for 1 h at 
room temperature in the dark. For double immunostaining, slides were washed 
and incubated with a second primary antibody (3β-HSD) at an appropriate 
dilution (Table 2.11) in PBS for 3 h at room temperature in the dark. Sections 
were then washed and incubated with a fluorescein conjugated secondary 
antibody in PBS for 1 h at room temperature in the dark. To block intrinsic 
fluorescence present is some tissues, particularly the testis, sections were 
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rinsed and covered with 0.3 % Sudan Black B (w/v) (199664; Sigma, UK) in 70 
% ethanol at 37 °C for 5 or 10 min in the dark (Yang and Honaramooz, 2012). 
Finally, slides were washed and incubated with 1 µM TO-PRO-3 Iodide (T3605; 
Life Technologies, UK) in PBS for 30 min at room temperature in the dark to 
stain nuclei. After rinsing, slides were mounted and stored in the dark at 4 °C.  
 2.2.3.2.4 Staining visualisation 
Immunohistochemically stained sections were visualised using a Leica DM2000 
light microscope with a Leica DFC420 camera attachment. Images were 
acquired using Leica Application Suite software (Leica Microsystems, 
Version:V5.0 R222, Switzerland). Images for the slides with the fluorescent 
label were acquired by sequential scanning using a Leica TCS SP2 confocal 
system (Leica Microsystems, Milton Keynes, UK), with emission spectra set for 
green (max 515 nm), red (615 nm) and blue (661 nm).      
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primary 
antibody/ 
concentrations 
primary 
antibody 
manufacturer/
catalogue 
number 
secondary 
antibody/ 
concentration 
secondary 
antibody 
manufacturer/
catalogue 
number 
serum 
used 
serum 
manufacturer/
catalogue 
number 
MC3-rabbit 
polyclonal/ 
1:200, 1:400, 
1:800 
Sigma/ 
M4937 
goat 
biotinylated 
anti-rabbit 
IgG/1:300 
Vector 
Laboratories/B
A-100 
normal 
goat 
serum 
Vector 
Laboratories/ 
S-100 
MC3-rabbit 
polyclonal/ 
1:100, 1:200, 
1:400, 1:800 
Abcam/ 
ab21231 
goat 
biotinylated 
anti-rabbit 
IgG/1:300 
Vector 
Laboratories/B
A-100 
normal 
goat 
serum 
Vector 
Laboratories/ 
S-100 
MC3-rabbit 
polyclonal/ 
1:200, 1:400, 
1:800 
 
Enzo Life 
Sciences 
/BML-SA640R 
 
goat 
biotinylated 
anti-rabbit 
IgG/1:300 
Vector 
Laboratories/B
A-100 
normal 
goat 
serum 
Vector 
Laboratories/ 
S-100 
3β-HSD (P-18) 
goat 
polyclonal/1:200 
and 1:400 
Santa Cruz 
Biotechnology/
sc-30820 
horse 
biotinylated 
anti-goat 
IgG/1:300 
Vector 
Laboratories/B
A-9500 
normal 
horse 
serum 
Vector 
Laboratories/ 
S-200 
WT-1 rabbit 
polyclonal 
 (c-19)/ 1:50, 
1:100, 1:200 
Santa Cruz 
Biotechnology/
sc-192 
goat 
biotinylated 
anti-rabbit 
IgG/1:300 
Vector 
Laboratories/B
A-100 
normal 
goat 
serum 
Vector 
Laboratories/ 
S-100 
Table 2.10 Concentrations and manufacturers of primary and secondary 
antibodies used in IHC. 
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primary 
antibody/ 
concentrations 
primary 
antibody 
manufacturer/
catalogue 
number 
secondary 
antibody/ 
concentration 
secondary 
antibody 
manufacturer/
catalogue 
number 
serum 
used 
serum 
manufacturer
/catalogue 
number 
MC3-rabbit 
polyclonal/ 
1:200 and 1:400 
 
Enzo Life 
Sciences 
/BML-SA640R 
 
goat 
texas red 
conjugated 
anti-rabbit 
/1:300 
Vector 
Laboratories/ 
TI-1000 
normal 
horse 
serum 
Vector 
Laboratories/ 
S-200 
3β-HSD  
(P-18) goat 
polyclonal/ 
1:200 and 1:400 
Santa Cruz 
Biotechnology/ 
sc-30820 
rabbit 
fluorescein 
conjugated 
anti-goat 
/1:300 
Vector 
Laboratories/ 
FI-5000 
normal 
horse 
serum 
Vector 
Laboratories/ 
S-200 
Table 2.11 Concentrations and manufacturers of primary and secondary 
antibodies used in IF.  
 
2.2.4 Statistics 
Comparison between the relative mRNA expression of MC in C57BL/6 and 
Balb/c male mice tissues were performed using unpaired Student’s t-test (two-
tailed) (Excel, Microsoft Office 2010). For all statistical analyses P value is 
given. 
 
2.3 Results 
2.3.1 Expression of MC mRNA in the HPG systems of both male and 
female mice. 
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2.3.1.1 Relative mRNA expression of MC in the HPG systems of Balb/c 
and C57BL/6 male mice. 
Expressions of each of the five MC were detected in the male hypothalami, 
pituitaries and testes of both C57BL/6 and Balb/c mice. Each of the receptors 
appeared to be expressed at different level in each of these tissues, however 
comparisons of expression between each of the receptors will only be inferred 
from the number of cycles required for amplification as the exact receptor copy 
number per tissue was not determined. The size of each PCR product was 
confirmed by electrophoretic separation on an agarose gel (Figure 2.8, 2.12 and 
2.21). In general, the relative expressions of MC mRNAs were highest in the 
hypothalami, intermediate in the pituitaries and lowest in the testes of both 
C57BL/6 or Balb/c mice. MC3 and MC4 appeared to be the two dominant 
receptors in the hypothalami of both strains of mice (Figure 2.5). There were no 
significant differences in hypothalamic MC mRNA expression between the two 
strains but the relative expression of MC5 was 50 % lower in C57BL/6 
compared to Balb/c mice (t-test, p=0.11). MC3 was likely to be by far the most 
highly expressed receptor subtype in the pituitary of both strains (Figure 2.6). In 
contrast, the relative mRNA expression of MC2 in pituitaries was very low 
(Balb/c mice) or not detectable (C57BL/6 mice). Expression of MC3, MC5 and 
MC1 was 2-, 9- and 13-fold greater in pituitaries of C57BL/6 compared to Balb/c 
mice, respectively (t-test; MC3 p=0.17, MC5 p=0.09 and MC1 p=0.16; Figure 
2.6). MC2 appeared to have the highest mRNA expression level in testes of 
both strains and its expression was 50 % greater in Balb/c compared to 
C57BL/6 mice (t-test; p=0.12; Figure 2.7). Similarly, testicular expression of 
MC5 was 60 % higher in Balb/c than in C57BL/6 mice (t-test; p=0.12; Figure 
2.7).  
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Figure 2.5 Relative mRNA expression of MC in hypothalami of 8 weeks old Balb/c 
and C57BL/6 male mice. Relative expression was determined by qPCR and results 
were analysed using qBase plus software including target specific amplification 
efficiencies. Data normalisation was performed using geometric mean of two reference 
genes ACTB and ATP5B (first panel). To ensure accurate estimation of gene of interest 
(GOI) expression, the specificity of qRT-PCR was tested in reactions without reverse 
transcriptase (SuperScript; no-RT control). Data are presented as mean ± SEM of 
three independent samples. There are no significant differences between MC  
expression in Balb/c and C57BL/6 male mice (t-test). 
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Figure 2.6 Relative mRNA expression of MC in pituitaries of 8 weeks old Balb/c 
and C57BL/6 male mice. Relative expression was determined by qPCR and results 
were analysed using qBase plus software including target specific amplification 
efficiencies. Data normalisation was performed using geometric mean of two reference 
genes ACTB and ATP5B (first panel). To ensure accurate estimation of gene of interest 
(GOI) expression, the specificity of qRT-PCR was tested in reactions without reverse 
transcriptase (SuperScript; no-RT control). Data are presented as mean ± SEM of 
three independent samples. There are no significant differences between MC 
expression in Balb/c and C57BL/6 male mice (t-test). 
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Figure 2.7 Relative mRNA expression of MC in testes of 8 weeks old Balb/c and 
C57BL/6 male mice. Relative expression was determined by qPCR and results were 
analysed using qBase plus software including target specific amplification efficiencies. 
Data normalisation was performed using geometric mean of two reference genes 
ACTB and ATP5B (first panel). To ensure accurate estimation of gene of interest (GOI) 
expression, the specificity of qRT-PCR was tested in reactions without reverse 
transcriptase (SuperScript; no-RT control). Data are presented as mean ± SEM of 
three independent samples. There are no significant differences between MC 
expression in Balb/c and C57BL/6 male mice (t-test).  
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  A: C57BL/6        B: Balb/c 
 
Figure 2.8 MC mRNA expression in tissues from C57BL/6 and Balb/c 8 weeks old 
male mice. In both animal strains (panels A and B):  MC1 - 110 bp; MC2 - 67 bp; MC3 - 
108 bp; MC4 - 106 bp; MC5 - 90 bp; GAPDH - 144 bp. In all panels: H=hypothalamus, 
P=pituitary, T=testis, C=Control, no cDNA. Amplification products were separated on 2 
% agarose gel. Representative images of three independent qPCRs.  
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2.3.1.2 Relative mRNA expression of MC in the HPG systems of C57BL/6 
male mice at different ages. 
The relative expressions of mRNAs for each MC in 14 weeks old male C57BL/6 
mouse were based on a single mouse due to lack of animals supply, hence no 
statistical tests were performed but observed differences will be described. 
Expressions of all MC in the hypothalamus were 82-95 % greater in 14 weeks 
old compared to 8 weeks old male mice (Figure 2.9). In the pituitary, the mRNA 
levels of MC3 and MC4 were more than 2- and 3-fold, respectively, lower in the 
younger animals (Figure 2.10). MC2 mRNA expression was below detection 
level in 8 weeks old mice using this method. Conversely, the relative pituitary 
MC5 mRNA level was 60 % lower in 14 weeks old mouse (Figure 2.10). 
Testicular MC2 mRNA was two fold lower in the younger mice (Figure 2.11). 
The relative mRNA expressions of MC3 and MC4 were 35 % and 90 %, 
respectively, higher in testes of 8 weeks old mice compared to 14 weeks.  
    
 
 
 
 
 
 
 
 
85 
 
 
 
Figure 2.9 Relative mRNA expression of MC in hypothalami of 8 and 14 weeks 
old C57BL/6 male mice. Relative expression was determined by qPCR and results 
were analysed using qBase plus software including target specific amplification 
efficiencies. Data normalisation was performed using geometric mean of two reference 
genes ACTB and ATP5B. The average expression level for the two reference genes in 
all samples is shown in the first panel. To ensure accurate estimation of gene of 
interest (GOI) expression, the specificity of qRT-PCR was tested in reactions without 
reverse transcriptase (SuperScript; no-RT control). In 8 weeks old C57BL/6 male mice 
data are presented as mean ± SEM of three independent samples. In 14 weeks old 
C57BL/6 male mouse data are presented as mean of one sample only.     
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Figure 2.10 Relative mRNA expression of MC in pituitaries of 8 and 14 weeks old 
C57BL/6 male mice. Relative expression was determined by qPCR and results were 
analysed using qBase plus software including target specific amplification efficiencies. 
Data normalisation was performed using geometric mean of two reference genes 
ACTB and ATP5B. The average expression level for the two reference genes in all 
samples is shown in the first panel. To ensure accurate estimation of gene of interest 
(GOI) expression, the specificity of qRT-PCR was tested in reactions without reverse 
transcriptase (SuperScript; no-RT control). In 8 weeks old C57BL/6 male mice data are 
presented as mean ± SEM of three independent samples. In 14 weeks old C57BL/6 
male mouse data are presented as mean of one sample only.    
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Figure 2.11 Relative mRNA expression of MC in testes of 8 and 14 weeks old 
C57BL/6 male mice. Relative expression was determined by qPCR and results were 
analysed using qBase plus software including target specific amplification efficiencies. 
Data normalisation was performed using geometric mean of two reference genes 
ACTB and ATP5B. The average expression level for the two reference genes in all 
samples is shown in the first panel. To ensure accurate estimation of gene of interest 
(GOI) expression, the specificity of qRT-PCR was tested in reactions without reverse 
transcriptase (SuperScript; no-RT control). In 8 weeks old C57BL/6 male mice data are 
presented as mean ± SEM of three independent samples. In 14 weeks old C57BL/6 
male mouse data are presented as mean of one sample only.    
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2.3.1.3 Relative mRNA expression of MC in the HPG systems of male and 
female (14 weeks) C57BL/6 mice. 
There was approximately 2- to 3-fold higher mRNA expression of MC2, MC3 and 
MC5 as well as 10-fold greater for MC4 in male hypothalamus compared to that 
of female using this method (n=1 in both genders; Figure 2.13). Expression of 
MC2 was undetectable and MC4 was 80 % lower in the pituitary of female 
mouse (Figure 2.14).  Pituitary MC3 mRNA expression was nearly 2-fold higher 
in female than in male mouse (Figure 2.14). There were no gender differences 
in the expression of MC1 in both the hypothalamus and the pituitary (Figure 2.13 
and Figure 2.14).  
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Figure 2.12 MC mRNA expression in tissues from 14 weeks old male and female 
C57BL/6 mice. In both genders (panels A and B):  MC1 - 110 bp; MC2 - 67 bp; MC3 - 
108 bp; MC4 - 106 bp; MC5 - 90 bp; GAPDH - 144 bp. H=hypothalamus, P=pituitary, 
T=testis, O=ovary, U=uterus, C=Control, no cDNA. Amplification products were 
separated on 2 % agarose gel. Representative images of one qPCR.  
 
 
 
 
 
 
 
 
 
 
 
A: Male 
B: Female 
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Figure 2.13 Relative mRNA expression of MC in hypothalami from male and 
female (14 weeks) C57BL/6 mice. Relative expression was determined by qPCR and 
results were analysed using qBase plus software including target specific amplification 
efficiencies. Data normalisation was performed using geometric mean of two reference 
genes ACTB and ATP5B. The average expression level for the two reference genes in 
all samples is shown in the first panel. To ensure accurate estimation of gene of 
interest (GOI) expression, the specificity of qRT-PCR was tested in reactions without 
reverse transcriptase (SuperScript; no-RT control). Data are presented as mean ± SD 
(for technical replicates) of one sample.  
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Figure 2.14 Relative mRNA expression of MC in pituitaries from male and female 
(14 weeks) C57BL/6 mice. Relative expression was determined by qPCR and results 
were analysed using qBase plus software including target specific amplification 
efficiencies. Data normalisation was performed using geometric mean of two reference 
genes ACTB and ATP5B. The average expression level for the two reference genes in 
all samples is shown in the first panel. To ensure accurate estimation of gene of 
interest (GOI) expression, the specificity of qRT-PCR was tested in reactions without 
reverse transcriptase (SuperScript; no-RT control). Data are presented as mean ± SD 
(for technical replicates) of one sample.  
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2.3.1.4 Relative mRNA expression of MC in the HPG systems of C57BL/6 
female mice (14 weeks) at different stages of pregnancy. 
To determine whether reproductive state affects MC expressions as it did for 
POMC mRNA (Chen et al., 1986), female mice at different stages of pregnancy 
(one in each group) were obtained and their tissues were analysed for the 
relative expressions of MC mRNAs.  
Expressions of mRNAs for MC4 and MC5 were more than 2-fold and that for 
MC1 was approximately 10-fold greater in hypothalami of females at days 7 or 
14 of pregnancy compared to non-pregnant animals (n=1 for each group; Figure 
2.16). In contrast, hypothalamic MC3 mRNA expression was approximately 70 
% lower in pregnant animals compared to non-pregnant ones.  
The relative mRNAs expressions of MC1 and MC5 in pituitaries of pregnant 
animals were more than 1,000-fold higher compared to non-pregnant animals 
(Figure 2.17). Similarly, pituitary MC4 mRNA was 300-fold greater at days 7 or 
14 of pregnancy. Expression of MC3 mRNA was 70 % higher in the pituitary of a 
14 days pregnant female compared to mice at earlier stages of pregnancy or 
non-pregnant.  
The pattern of MC expressions in ovary and uterus seemed almost identical. 
Relative expressions of mRNAs for MC1 and MC5 were more than 300-fold 
greater in ovaries of 7 days pregnant and more than 1,500-fold higher in ovaries 
of 14 days pregnant female compared to non-pregnant animals (Figure 2.18). 
Ovarian MC4 mRNA was 90- and 300-fold greater in 7 and 14 days pregnant 
mice, respectively. Uterine mRNA expressions of both MC1 and MC5 were more 
than 100- or 1,000-fold greater in 7 or 14 days pregnant females compared to 
non-pregnant, respectively (Figure 2.19). The relative mRNA level of MC4 in the 
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uterus was 29-fold higher in 7 days and 140-fold greater in 14 days pregnant 
female than in non-pregnant mice. The relative mRNA for MC3 was very low in 
the ovary and undetectable in the uterus using this procedure. Due to 
insufficient sample volume, MC2 expression was not studied in tissues from all 
14 weeks old female mice. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.15 Average mRNA expression level of 
reference genes (ACTB and ATP5B) in all 
female samples. Relative expression was 
determined by qPCR and results were analysed 
using qBase plus software including target specific 
amplification efficiencies. The two reference genes 
were used to determine the normalised expression 
level of genes of interest (GOI). Data are 
presented as mean ± SEM. 
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Figure 2.16 Relative mRNA expression of MC in hypothalami of 14 weeks old 
C57BL/6 female mice at different stages of pregnancy. Relative expression was 
determined by qPCR and results were analysed using qBase plus software including 
target specific amplification efficiencies. Data normalisation was performed using 
geometric mean of two reference genes (ACTB and ATP5B). To ensure accurate 
estimation of gene of interest (GOI) expression, the specificity of qRT-PCR was tested 
in reactions without reverse transcriptase (SuperScript; no-RT control). Data are 
presented as mean ± SD (for technical replicates) of one sample for each physiological 
state.  
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Figure 2.17 Relative mRNA expression of MC in pituitaries of 14 weeks old 
C57BL/6 female mice at different stages of pregnancy. Relative expression was 
determined by qPCR and results were analysed using qBase plus software including 
target specific amplification efficiencies. Data normalisation was performed using 
geometric mean of two reference genes (ACTB and ATP5B). To ensure accurate 
estimation of gene of interest (GOI) expression, the specificity of qRT-PCR was tested 
in reactions without reverse transcriptase (SuperScript; no-RT control). Data are 
presented as mean ± SD (for technical replicates) of one sample for each physiological 
state.  
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Figure 2.18 Relative mRNA expression of MC in ovaries of 14 weeks old C57BL/6 
female mice at different stages of pregnancy. Relative expression was determined 
by qPCR and results were analysed using qBase plus software including target specific 
amplification efficiencies. Data normalisation was performed using geometric mean of 
two reference genes (ACTB and ATP5B). To ensure accurate estimation of gene of 
interest (GOI) expression, the specificity of qRT-PCR was tested in reactions without 
reverse transcriptase (SuperScript; no-RT control). Data are presented as mean ± SD 
(for technical replicates) of one sample for each physiological state.  
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Figure 2.19 Relative mRNA expression of MC in uteri of 14 weeks old C57BL/6 
female mice at different stages of pregnancy. Relative expression was determined 
by qPCR and results were analysed using qBase plus software including target specific 
amplification efficiencies. Data normalisation was performed using geometric mean of 
two reference genes (ACTB and ATP5B). To ensure accurate estimation of gene of 
interest (GOI) expression, the specificity of qRT-PCR was tested in reactions without 
reverse transcriptase (SuperScript; no-RT control). Data are presented as mean ± SD 
(for technical replicates) of one sample for each physiological state.  
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2.3.1.5 Relative mRNA expression of MC in the HPG system of a MC3 null 
male mouse.  
qPCR was also performed on cDNA from a hypothalamus, pituitary and testis of 
a 14 weeks old MC3-/- mouse in order to confirm ablation of MC3 gene and 
ensure that data obtained using this animal model are valid. There was a 
complete ablation of MC3 mRNA in all tissues tested compared to a wild type 
mouse. Some differences in the relative expression levels of the other four 
melanocortin receptors seem to exist, however, due to small sample size no 
statistical comparisons were made (Figure 2.20). Marked decreases in the 
relative expressions of the majority of MC were observed in the hypothalamus 
and pituitary of a MC3-/- mouse. In the testis, there was at least a 10 % increase 
in the expression of MC1, MC4 and MC5 in the absence of MC3. 
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Figure 2.20 Relative mRNA expression of MC in tissues from 14 weeks old wild 
type and MC3 null male mice. Relative expression was determined by qPCR and 
results were analysed using qBase plus software including target specific amplification 
efficiencies. Data normalisation was performed using geometric mean of two reference 
genes, ACTB and ATP5B. The average expression level for the two reference genes in 
all male samples is shown in panel A. To ensure accurate estimation of gene of interest 
(GOI) expression, the specificity of qRT-PCR was tested in reactions without reverse 
transcriptase (SuperScript; no-RT control). The inset in the top right corner of panels B-
D shows the ablation of MC3 mRNA expression in tissues of MC3-/- compared to WT 
mouse, differences in the scales should be noted. Data are presented as mean ± SD 
(for technical replicates) of one sample.   
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Figure 2.21 MC mRNA expression in tissues from 14 weeks old MC3 null male 
mouse. qPCR products separated on 2 % agarose gel. In all panels: 
H=hypothalamus, P=pituitary, T=testis, C=Control, no cDNA and +C= positive control. 
MC1 - 110 bp; MC2 - 67 bp; MC3 - 108 bp; MC4 - 106 bp; MC5 - 90 bp; GAPDH - 144 
bp. Image of one qPCR.  
 
2.3.2 Expression of POMC mRNA in C57BL/6 male and female mice. 
Distribution of POMC mRNA, a precursor of melanocortin peptides, has also 
been determined. The results indicate presence of a full length POMC mRNA in 
male and female hypothalami and pituitaries as well as in the ovary, which also 
had a second, smaller weight band (Figure 2.22 a, b). There was no detectable 
product in the testis. However, using a different set of primers amplifying the 
region specific for all exon 3-containing POMC transcripts, a truncated product 
was identified in male gonads but not in the ovary or uterus (Figure 2.22 c, d). 
The identities of the full length POMC PCR products were confirmed by 
sequencing (98 % homology with mouse sequences). 
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Figure 2.22 POMC mRNA expression in mice tissues. PCR for full-length (top 
panel) and truncated (bottom panel) POMC mRNA in male (A, C) and female (B, 
D) as well as approximate primers binding sites (E). Expected product length is 562 
bp. Bottom panel - RT-PCR for truncated POMC mRNA in male (C) and female (D). 
Expected product length is 509 bp. In both panels: MW= molecular weight marker, 
H=hypothalamus, P=pituitary, T=testis, O=ovary, U=uterus, C=no cDNA. No PCR 
products were detected in parallel control samples using mRNA preparations without 
SuperScript - reverse transcriptase. Amplification products were separated on 1.5 % 
agarose gel. Representative images of three independent PCRs.  
 
 
E 
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2.3.3 Expression of MC3 protein in the HPG system  
2.3.3.1 MC3 protein characterization  
Mouse MC3 is a 35,800-Da protein containing a number of glycosylation sides, 
which impair its migration during SDS-PAGE separation leading to the detection 
of a band of higher molecular weight. This may explain why the lowest 
detectable band for immunoreactive MC3-like protein was approximately 70 
kDa, which is 30 kDa higher than the expected size (Figures 2.23-2.26). 
Surprisingly, other bands, of even greater molecular weights were also 
detected. It is known that MC3 may form aggregates hence it was of interest to 
determine the exact form of MC3 protein in tissue homogenates. Exposure of 
hypothalamus homogenate to various denaturing conditions led to differential 
protein(s) bond breakdown, which were visualised in a form of different 
molecular weight bands (Figure 2.23).  Under no or mild denaturing conditions 
bands between 95 and 130 kDa were mostly detectectable (Figure 2.23, lane 1 
and 2). Exposure of tissue samples to additional denaturation by boiling for 5 or 
15 min resulted in breakdown of additional covalent bonds (disulphide bonds for 
dimers) and immunoreactive MC3-like protein detection at lower molecular 
weight, approximately 70 kDa (Figure 2.23, lanes 3-6). This suggests that the 
native MC3 protein may be present as a homo- or heterodimer in these tissues.   
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Figure 2.23 The effects of different dentauring conditions on detection of 
immunoreactive MC3-like protein in tissue homogenates. Male mouse 
hypothalamus homogenate was exposed to different denaturing conditions: Lane 1 – 
hypothalamus sample loading buffer with no β-mercaptoethanol; Lane 2 -  
hypothalamus sample loading buffer with β-mercaptoethanol; Lane 3 - loading buffer 
with β-mercaptoethanol, hypothalamus sample boiled (99 °C) for 5 min; Lane 4 -  
loading buffer with β-mercaptoethanol, hypothalamus sample boiled (99 °C) for 15 min; 
Lane 5 - loading buffer with β-mercaptoethanol, pituitary sample boiled (99 °C) for 5 
min; Lane 6 - loading buffer with β-mercaptoethanol, testis sample boiled (99 °C) for 5 
min. Samples were separated on 10 % SDS-PAGE, immunoreactive MC3-like protein 
was detected using anti-MC3 antibody from Enzo.  
 
 
2.3.3.2 Antibody characterization using recombinant MC3 
MC3 detection was attempted using three anti-MC3 antibodies from Enzo Life 
Sciences, Abcam and Sigma. First, the specificities of the antibodies were 
tested by preincubating them with either blocking peptides (immunogenic 
sequence against which the antibody was raised), if available, as in case of 
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Enzo or with human recombinant MC3 (H00004159-P01, Abnova, UK). The 
preincubation with blocking peptide completely blocked immunoreactive MC3-
like protein detection by the Enzo antibody (Figure 2.24 c). Recombiant MC3 
decreased but did not block completely immunoreactive MC3-like protein 
detection by the Enzo (Figure 2.24 b) and Abcam antibodies (Figure 2.25 b). 
The two antibodies from Enzo and Abcam detected recombinant MC3 by 
Western Blot (data not shown). The Sigma antibodies do not bind to human 
MC3 hence none of the experiments using recombinant MC3 were succesful.  
 
 
Figure 2.24 The effects of Enzo antibody preincubation with recombinant MC3  
protein or blocking peptide on immunoreactive MC3-like protein detection in 
tissue homogenate by Western blot. The Enzo antibody was pre-incubated for 1h at 
room temperature with either recombinant MC3 protein (Abnova, UK; panel B) or with 
peptide blocking solution (panel C) before applying it onto a membrane. The 
concentration of the antibody was 50 % lower than that of the recombinant MC3 protein 
or blocking peptide. The experiment was performed in parallel for a membrane 
incubated with the Enzo antibody only (panel A). In all panels: H=hypothalamus, 
P=pituitary, O=ovary, U=uterus. Samples were separated on 10 % SDS-PAGE.  
 
A B C 
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Figure 2.25 The effects of Abcam antibody preincubation with recombinant MC3  
protein on immunoreactive MC3-like protein detection in tissue homogenate by 
Western blot. The Abcam antibody was pre-incubated for 1 h at room temperature 
with recombinant MC3 protein (Abnova, UK; panel B) before applying it onto a 
membrane. The concentration of the antibody was 50 % lower than that of the 
recombinant MC3 protein. There was no blocking peptide available for this antibody. 
The experiment was performed in parallel for a membrane incubated with the Abcam 
antibody only (panel A). In both panels: H=hypothalamus, P=pituitary, T=testis. 
Samples were separated on 10 % SDS-PAGE.  
 
 
2.3.3.3 Immunoreactive MC3-like protein expression 
Immunoreactive MC3-like protein was detected with varying band intensities and 
molecular weights in all tissues tested using three anti-MC3 antibodies. The 
Enzo antibody detected a band of 70 kDa and one or two higher molecular 
weight band(s) of approximately 110 kDa in tissues from both male and female 
mice (Figure 2.26). Similarily, Abcam antibody identified immunoreactive MC3-
like protein at a weight of 75 kDa, although according to Abcam the expected 
MW is 55 kDa, and less intense bands between 95 -130 kDa in tissues from 
both genders (Figure 2.26). The Sigma antibody detected a band of 40 kDa, 
which is the expected molecular weight, in addition to many other bands of 
varying weights, indicating a lack of specificity (Figure 2.26). Additionally, 
A B 
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immunoreactive MC3-like protein was detected using all three antibodies in 
samples of MC3-/- mice, which were incorporated in Western blot following IHC 
experiments.   
 
 
         
Figure 2.26 Immunoreactive MC3-like protein expression in male and female mice 
tissues. In both Male and Female: Panel A- Western blot using anti-MC3 antibodies 
produced by Enzo Life Sciences (70 kDa); Panel B -Western blot using anti-MC3 
antibodies produced by Abcam (expected - 55 kDa, detected - 75 kDa); Panel C - anti-
MC3 antibodies from Sigma-Aldrich (40 kDa). Anti-α-tubulin (housekeeping protein) (53 
kDa) present in all panels. The amount of protein loaded for each tissue was 20 µg. 
Abbreviations: H=hypothalamus, P=pituitary, T (number)=testis (number), B=brain, 
WT=wild type, MC3-/-=MC3 null mouse, O=ovary, U=uterus. Proteins separated on 10 % 
SDS-PAGE. Representative images of five independent Western blots.  
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2.3.3.4 Expression pattern of immunoreactive MC3-like protein in testis of 
sexually mature (14 weeks) C57BL/6 mice. 
IHC was performed following the initial WB experiments using the Enzo 
antibody since it had appeared to detect immunoreactive MC3-like protein in the 
homogenate of a mouse hypothalamus with a certain degree of specificity 
(Figure 2.23). The aim of IHC experiments was to specifically detect the exact 
cell type expressing immunoreactive MC3-like protein in mouse tissues involved 
in reproductive function. The testis was the first tissue examined and it was 
chosen to further inform the in vitro testicular tissue steroidogenesis studies 
(Chapter 4). To aid in identification of the different cell types in the testis, two 
different cell markers were applied: namely Wilm’s Tumour, which binds to 
Sertoli cells, and 3β-HSD, a marker of Leydig cells (testosterone secreting cells) 
(Figure 2.27). The Enzo antibody detected immunoreactive MC3-like protein in 
the interstial islets and seminiferous tubules of testis from sexually mature 
mouse (Figure 2.28). To determine whether immunoreactive MC3-like protein is 
expressed in the Leydig cells of interstial islets, triple IF was performed (Figure 
2.29 A-C). Due to high autofluorescence in the testis, which was not fully 
blocked by the use of Sudan Black B, the results are not a true representation 
of the immunoreactive MC3-like protein and 3β-HSD expression pattern. Instead 
the IHC using the two antibodies separately provided a more accurate 
representation (Figure 2.29 D-F).  
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The pattern of immunoreactive MC3-like protein in the testis detected by the 
Enzo antibody was then compared to that detected by the Sigma and Abcam 
antibodies. Testes from MC3-/- were used as a negative control tissue. All 
antibodies detected immunoreactive MC3-like protein, although at different 
intensity, in the testis of WT and, most importantly, in MC3-/- regardless of the 
antibodies concentrations (Figure 2.30 and 2.31). 
 
 
Figure 2.27 Immunohistochemical staining for Sertoli (Wilm’s Tumour 1, WT-1) 
and Leydig cells (3β-HSD) in mice testes of 14 weeks old C57BL/6 mice. Images A 
and B show staining for WT-1 (1 in 100 antibody dilution), a marker of Sertoli cells, 
whilst images C and D present staining for 3β-HSD (1 in 200 antibody dilution), a 
marker of Leydig cells. Positive staining of cells is indicated by a brown precipitate (see 
arrows). There was no positive immunostaining in tissue sections incubated with 
secondary antibody only (negative controls, images B and D). Images are 
representative of the results of three independent experiments.  
109 
 
The Sigma antibody had the highest intensity of staining and, at the same time, 
it was least specific compared to the other two antibodies in both animal types. 
In contrast, Abcam antibody detected very little, if any, immunoreactive MC3-like 
protein in testis, even following the antigen retrieval step. The Enzo antibody 
appeared slightly more specifc, although the fact that it gave positive staining in 
the MC3-/-, discouraged its further use. Presented results confirm that the three 
anti-MC3 antibodies lack specificity, hence all further protein work was 
terminated at this stage.   
 
 
 
Figure 2.28 Expression of immunoreactive MC3-like protein (Enzo) in mice testes. 
Results of immunohistochemical staining in the testes of 14 weeks old wild type 
C57BL/6 mice for MC
3
 using anti-MC
3
 antibodies from Enzo (1 in 200 antibody 
dilution). Positive staining of cells is indicated by a brown precipitate (see arrows). 
There was no positive immunostaining in tissue sections incubated with secondary 
antibody only (negative control, image B). Images are representative of the results of 
four independent experiments. 
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Figure 2.29 Expression of immunoreactive MC3-like protein and 3β-HSD in mice testes. Results of immunofluorescent (IF, top panel) 
immunohistochemical (IHC, bottom panel) staining in testes of 14 weeks old wild type C57BL/6 mice for 3β-HSD (column 1) and MC3 
using anti-MC3 antibodies from Enzo (column 2). Positive staining of cells is indicated by a fluorescent signal (IF) or brown precipitate 
(IHC). Nuclear staining (ToPro3) for IF (image C) and control staining (secondary antibody only) for IHC (image F) are present in column 
3. Images are from adjacent sections and represent the results of three independent experiments.  
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Figure 2.30 Expression of immunoreactive MC3-like protein and 3β-HSD in testes of wild type and MC3 null mice. Results of 
immunohistochemical staining in the testes of 14 weeks old wild type C57BL/6 and MC3 null mice for 3β-HSD (top panel) and MC3 using anti-MC3 
antibodies from Abcam (bottom panel). Positive staining of cells is indicated by a brown precipitate. Antibody dilution factor is indicated at the top of 
each image. There was no positive immunostaining in testes from tissue sections incubated with either PBS alone or normal goat serum diluted in PBS, 
control (first image, top panel). Images are from adjacent sections and represent the results of three independent experiments.. Scale bar is present in 
the top right corner of each image.  
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Figure 2.31 Expression of immunoreactive MC3-like protein in testes of wild type and MC3 null mice. Results of IHC staining in the testes of 14 
weeks old wild type C57BL/6 and MC3 null mice for MC3 using anti-MC3 antibodies from Enzo (top panel) and Sigma (bottom panel). Positive staining of 
cells is indicated by a brown precipitate. Antibody dilution factor is indicated at the top of each image. There was no positive immunostaining in testes 
from tissue sections incubated with either PBS alone or normal goat serum diluted in PBS, control (see previous page). Images are from adjacent 
sections and represent the results of four independent experiments. Scale bar is present in the top right corner of each image.  
1
1
2
 
 
113 
 
2.4  Discussion 
 
The mRNAs for the majority of MC are expressed at each level of the 
hypothalamo-pituitary-gonadal system. Preliminary data indicate that MC  
expression may be regulated by both age and the reproductive state in the 
examined tissues. POMC mRNA is co-expressed with MC suggesting autocrine 
and/or paracrine action of melanocortins. Localization of MC3-expressing cells 
in the testis is still questionable as commercially available anti-MC3 antibodies 
lack specificity. 
Expression of mRNAs for all five receptors were detected in the hypothalamus. 
The mRNA levels of MC3, MC4 and MC5 appeared to be relatively higher than 
that for MC1 and MC2 in both C57BL/6 and Balb/c mice (Figure 2.5). These 
findings are in agreement with published literature as mRNAs for both MC3 and 
MC4 were identified primarily in the brain (Gantz et al., 1993 a, b). Hypothalamic 
MC3 was mainly localized in the arcuate nucleus, dorsomedial part of the 
ventromedial nucleus and medial preoptic nucleus (Gantz et al., 1993a; Roselli-
Rehfuss et al., 1993). MC4 mRNA was detected in the paraventricular nucleus 
(PVN), including both parvicellular and magnocellular neurones of the 
hypothalamus in the adult rat brain (as reviewed by Tao, 2009). Hypothalamic 
expression of MC5 was previously detected (Griffon et al., 1994), and localized 
to the rostral and medial parts of the medial preoptic area (Murray et al., 2002). 
Both MC1 and MC2 seemed to be expressed at very low levels in the male 
hypothalamus (Figure 2.5). Previously, MC1 was detected in the whole brain 
extract of Balb/c mice by RT-PCR (Rajora et al., 1997) but the hypothalamic 
expression of MC1 has only been determined in fish (Klovins et al., 2004). 
Similarly, the presence of MC2 in the hypothalamus has been observed in 
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rainbow trout (Aluru and Vijayan, 2008), whilst in the mammalian brain MC2 
expression was reported only during fetal life (Nimura et al., 2006). There were 
no statistically significant differences in MC expression between Balb/c and 
C57BL/6 mice but mRNA level of MC5 was lower in C57BL/6 mice.  
It appeared that the most highly expressed MC gene in the pituitary was MC3 
(Figure 2.6). This supports the results of Morooka and others (1998), who 
reported that MC3 may be the predominant MC receptor present in this gland in 
mice. MC3 mRNA was previously detected in the anterior and intermediate 
lobes of rat (Lorsignol et al., 1999) and mouse (Morooka et al., 1998; 
Roudbaraki et al., 1999) pituitaries. Expression of MC3 mRNA in the anterior 
pituitary was localized mainly to lactotrophs and some somatotrophs 
(Matsumura et al., 2003).  Low levels of expression were measured for MC1, 
MC4 and MC5, and even lower or no detectable signal for MC2 using this qPCR 
methodology (Figure 2.6). Expression of MC1 and MC4 were previously only 
detected in human pituitary (Chhajlani, 1996), whereas MC5 has been detected 
in both human (Chhajlani, 1996) and rat (Lorsingol et al., 1999) pituitaries. The 
mRNA levels of MC3, MC1 and MC5 seemed to be relatively higher in C57BL/6 
compared to Balb/c mice (Figure 2.6). 
In contrast to the pituitary, MC2 is likely to be the dominant receptor in the testis, 
followed by MC1 (Figure 2.7). Expression of the other isoforms, MC3, MC4 and 
MC5 seemed to be considerably lower (Figure 2.7). All MC except for MC4 were 
reported in human testes with expression intensity being the highest for MC5> 
MC1> MC3> MC2 (Chhajlani, 1996). Other groups have detected MC2, MC3, 
MC4 and MC5 in fetal mice testes (O’Shaughnessy et al., 2003; Nimura et al., 
2006; Johnson et al., 2007).  
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In general, there appeared to be noticeable, although non-significant, 
differences between C57BL/6 and Balb/c in all tissues examined, particularly in 
pituitary and testis (Figures 2.5–2.7). Physiologically, the two mouse strains are 
different. Bartke (1974) performed a detailed comparison of C57BL/6 mice to 
other strains, in which he described them as hypoandrogenic. The in vitro 
steroidogenic activity in these mice is 40 % less than in Balb/c (Chapter 4, 
section 4.3.1). Interestingly, C57BL/6 mice breed significantly more efficiently 
than Balb/c mice possibly due to increased copulatory behaviour (Batty, 1978; 
Silver, 1995). 
Age and gender are another two factors influencing MC expression. 
Hypothalamic mRNAs for all MC were more than five fold greater in 14 
compared to 8 weeks old male mice (Figure 2.9). Kistler-Heer and colleagues 
(1998) reported an increase in centrally expressed MC3 mRNA in the postnatal 
life of the rat. It also appeared that the dominant MC in the pituitary (MC3) and 
the testis (MC2) were two fold lower in 8 compared to 14 weeks old mice (Figure 
2.10 and 2.11). Additionally, O’Shaughnessy and others (2003) reported that 
MC2 expression in fetal mice testes was 100-fold higher than in the adult mice. 
Although the changing pattern of MC expressions during life span is still 
unclear, it seems that it may be related to the reproductive development of an 
animal. The preliminary results also suggest that some differences may exist 
between MC mRNAs in male and female mice. It appeared that the expressions 
of four MC (MC2, MC3, MC4 and MC5) were at least two fold greater in male 
compared to female hypothalami (Figure 2.13). In the pituitary, however, the 
relative mRNA expression of MC3 seemed to be 50 % higher in female 
compared to male mice (Figure 2.14), which is in agreement with previous 
116 
 
reports and may be due to a higher proportion of lactotorophs, known to 
express MC3, in female mice (Matsumura et al., 2003).  
Theoretically, loss of one receptor isoform should lead to overexpression of the 
other members from this receptor family to maintain normal physiology. This 
scenario was expected in MC3-/- mice, and indeed preliminary data indicate that 
absence of testicular MC3 may result in a slight increase in the relative mRNAs 
expressions of the other MC subtypes (Figure 2.20 D). Conversely, MC3 
ablation in the hypothalamus and pituitary led to an apparent reduction in the 
majority of MC (Figure 2.20 B, C). This preliminiary data suggest that 
expression of MC may be (co)-dependent and that it is tissue specific. As far as 
we are aware, this is the first study investigating the relative expression pattern 
of all the MC in the MC3-/- mice model but it still has to be reexamined.  
The second aim of this series of studies was to determine the expression of the 
melanocortin precursor molecule, POMC, in the reproductive axis in order to 
establish whether these peptides can act on MC in a paracrine manner.  To 
address this question, the expression of POMC mRNA was examined using two 
different primer pairs by RT-PCR. The POMC gene is expressed from 3 exons 
with approximate mRNA length equal to 1100 bp (Drouin et al., 1985). The first 
combination of primers used results in a product that should span across the 
exon 2/exon 3 boundary and thus detect full length POMC transcripts 
composed of three exons. The second primer pair combination corresponds to 
the exon 3 region and is specific for all exon 3-containing POMC transcripts. 
Both forms, full and truncated POMC mRNA, were identified in hypothalami and 
pituitaries of male and female mice and thus confirm local production of ligands 
for MC (Figure 2.22). 
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Expression of testicular POMC mRNA in this study was found using the primer 
pair specific for all exon 3-containing POMC transcripts, but not using the 
primers for the full length functional transcript, suggesting that the major form of 
POMC mRNA is truncated (Figure 2.22 A, C). These aberrant transcripts are 
products of gonadal specific alternative transcription initiation in the intron 2-
exon 3 boundary and thus lack the regions corresponding to exons 1 and 2 
(Ivell et al., 1988). Exon 1 includes a 5’ non-coding region, whilst exon 2 
encodes the signal peptide essential for entering the intracellular secretory 
pathway (Ivell, 1994). Theoretically, the truncated POMC gene transcripts may 
be functionally defective. However, the previously reported presence of POMC 
peptides in the gonads (Morris et al., 1987) suggests that either the full-length 
version of POMC mRNA, although expressed at much lower concentration, 
significantly contributes to the synthesis of POMC peptides, or they are derived 
from the systemic circulation.  
Two amplification products were detected for the ovarian tissue using POMC 
primers spanning across the exon 2/exon 3 boundary, one of 562 bp and the 
other one of approximately 500 bp (Figure 2.22 B). Interestingly, there was no 
detectable product using primers amplifying the truncated POMC transcript 
(Figure 2.22 D). Chen and colleagues (1986) reported that POMC mRNA is 
absent in ovaries from immature rats but increases markedly during pregnancy 
or in response to stimulation with gonadotropins. Similarly, POMC derivatives 
such as γ3-MSH were identified in large antral follicles and corpora lutea of 
cycling or pregnant mice but no immunostaining was reported in immature 
animals (Shaha et al., 1984). Based on the fact that the expression of POMC 
derivatives is determined by the state of the reproductive maturity and 
pregnancy of the female (Shaha et al., 1984; Chen et al., 1986), it could be 
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possible that the expression of MC is regulated in a similar fashion. Surprisingly, 
preliminary data indicated that the mRNA expressions of most MC appeared to 
progressively increase at all levels of the HPG axis during pregnancy (Figure 
2.16–2.19). In many cases there was a more than 1000-fold increase at day 14 
of pregnancy compared to the non-pregnant female, particularly in the ovary 
and uterus. It is worth highlighting that the mRNA level of MC3 was 
undetectable, regardless of the physiological state of female, in the uterus and 
very low in the ovary using this qPCR method (Figure 2.18 and 2.19). This is in 
contrast to Amweg and co-workers (2010) who localized the expression of MC3 
as well as MC1 and MC2 in various ovarian structures of adult cattle by RT-PCR. 
Further work is still required to determine the exact effect of the physiological 
state of the female on the pattern of MC expression.    
The initial investigation of MC3 protein distribution pattern was performed by 
Western blot using anti-MC3 antibodies from three different companies. The 
three antibodies have different immunogenic sequences and bind to different 
sites of the MC3 protein (Figure 2.32 A, B). A band of approximately 70 kDa was 
detected in all tissues tested using antibodies from Enzo and Abcam, although 
the actual protein size is equal to 35.5 kDa (Figure 2.26). The apparent increase 
in the molecular mass may be due to abnormal protein mobility in SDS-PAGE 
as a result of post-translational modifications such as glycosylation at the N-
terminus and/or phosphorylation in the intercellular loop or at the C-terminus of 
the protein (Desarnaud et al., 1994). Furthermore, an additional band(s) of even 
higher molecular weight, ranging from 95-130 kDa, was (were) identified (Figure 
2.26). It is known that MC3 and other MC may form homo- or hetero-dimers or 
higher order complexes of oligomers (Mandrika et al., 2005). This process is 
very common for all receptors belonging to the GPCRs family (Milligan, 2009). 
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MC3 contains a cysteine bridge in the extracellular loop 3 (Rediger et al., 2012), 
which may mediate the process of dimerisation. MC3 heterodimer formation with 
the growth hormone secretagogue receptor (GHSR)-1a (ghrelin receptor) in the 
arcuate nucleus has been previously reported (Rediger et al., 2011). The Sigma 
antibody detected a faint band at 40 kDa and a number of other bands of 
various molecular weights (Figure 2.26). The lack of specificity may be related 
either to a very close homology between the MC (42-67%) or to the fact that the 
immunogenic sequence of the Sigma antibody correlates with a highly 
glycosylated region of the MC3 protein (Wikberg, 1999; Figure 2.32 A). This 
may mask the amino acid sequence and prevent the formation of antigen-
antibody complex (Lisowska, 2002).   
Following the initial identification of what was thought to be the MC3 protein by 
Western blot in tissues of the HPG axis, the antibodies were used to establish 
the exact cell types expressing MC3. In the testis, the expression was detected 
in some cells of the seminiferous tubule and in the interstitial tissues (Figure 
2.28). Further experiments localized MC3 to Leydig cells of the interstitial islets 
(Figure 2.29). The exact size, molecular form and distribution of MC3 protein in 
the HPG system is questionable since all of the anti-MC3 antibodies gave 
positive signal when tested in tissues from MC3-/- mice by both Western blot and 
immunohistochemistry (Figure 2.26, 2.30 and 2.31). Kathpala and colleagues 
(2011) were the first to draw the attention to the fact that anti-MC3 antibodies 
appear to lack specificity. The group used antibodies from different companies 
to those presented above but still obtained comparable data with 
immunoreactive MC3-like protein being detected in both WT and MC3-/- mice.    
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Figure 2.32 Anti-MC3 antibodies – amino acid sequences and recognition sites. 
Panel A - relative amino acid sequences of MC3 protein used to generate anti-MC3 
antibodies. Panel B – approximate binding sites of antibodies from Sigma (red) and 
Enzo (blue). Please note that information regarding the exact immunogenic sequence 
for the Abcam antibody is unavailable.   
A 
B 
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In this series of experiments the presence of MC3 mRNA, and the other four 
MC, were determined in each tissue of the reproductive axes of both male and 
female mice. There are a number of factors including mouse strain, age and 
gender, which can affect MC mRNA levels but further investigation is required. 
Additionally, the full and truncated versions of POMC mRNA were detected in 
tissues of the HPG systems of both genders thus suggesting paracrine actions 
at MC. Interestingly, the reproductive (physiological) state of the animal may 
affect the mRNA expression levels of both MC and POMC but a larger sample 
size is needed before firm conclusions can be made. Although, immunoreactive 
MC3-like protein was detected in the reproductive tissues of both genders by 
Western blot and its testicular expression was identified in cells of the 
seminiferous tubules and Leydig cells of the interstitial islets by 
immunohistochemistry, the lack of antibody specificity, tested using tissues from 
MC3-/- mice, means that all protein results should be regarded as unreliable. 
Further work using in situ hybridization is necessary to accurately determine the 
exact pattern of MC3 expression as well as those for the other four MC. The 
development of specific antibodies or ligands for MC3 and/or proteomic analysis 
are required to confirm MC3 translation into protein and tissue distribution.    
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3 Comparison of Wild Type and MC3 null mice 
3.1  Introduction 
 
Genetically modified animals are an invaluable tool to establish the role of 
ablated genes in normal physiology. MC3 null mice (MC3-/-) were first generated 
in 2000 by two independent research groups (Butler et al., 2000; Chen et al., 
2000). A neomycin-resistance cassette replaced the entire MC3 coding region in 
C57BL/6 mice (Butler et al., 2000; Chen et al., 2000). It quickly became 
apparent that these animals develop a complex obesity phenotype. Despite 
being hypophagic, their fat mass and feed efficiency increased whilst lean mass 
decreased compared to wild type (WT) mice at 4-6 months of age (Chen et al., 
2000). Both male and female MC3-/- mice developed hyperleptinaemia, whilst 
males only were hyperinsulinaemic (Chen et al., 2000). 
Although, the two research groups (Butler et al., 2000; Chen et al., 2000) 
suggested that MC3-/- mice are able to reproduce, our experience (Stephen 
Getting, and some of his former colleagues at the William Harvey Research 
Institute, personal communications) indicated that these mice are difficult to 
breed. Long intervals between pregnancies and small litter sizes had been 
noted: unfortunately, full breeding records are not available. These anecdotal 
observations prompted us to investigate the effects of MC3 ablation on 
reproductive physiology, since for a long time the use of MC3-/- mice was mainly 
devoted to study the role of MC3 in obesity (Renquist et al., 2012) and 
inflammation (as reviewed by Getting, 2006a). Increased or reduced intake of 
nutrients can directly affect reproductive functions. Hypothalamic MC3 may have 
an indirect role in the control of reproductive system by regulating energy 
balance and it remains to be determined if there is a direct role of MC3 in the 
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regulation of GnRH secretion. Watanobe and colleagues (2002) suggested that 
hypothalamic MC3 could mediate the downstream effects of leptin, which is 
known to play a key role in weight homeostasis, on the release of LH and 
prolactin. The exact pathway is still unclear but some proposals exist (Chapter 
1, section 1.3.1). 
In contrast to the hypothalamus, the potential role(s) of MC3 and hence its 
contritubution to normal reproductive function at the other levels of the HPG 
system, particularly the gonads, has(have) not been established. The aim of this 
series of studies was to compare the different aspects of reproductive 
physiology of MC3-/- mice to WT C57BL/6 mice, which are the genetic 
background of the colony of MC3-/- mice. To determine the potential function(s) 
of MC3 in the pituitary, the contents of all the pituitary hormones were measured 
in both male and female MC3-/- mice and compared to WT control mice. In 
gonads, the possible consequences of MC3 ablation on normal tissue 
functioning were established by comparing the testicular morphology of MC3-/- to 
WT mice at different ages.    
 
 
3.2  Materials and Methods  
 
3.2.1 Comparison of pituitary hormone content in WT and MC3-/- mice 
3.2.1.1 Animals  
Animals and the collection of tissues were described in Chapter 2, section 2.2.1.  
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3.2.1.2 Radioimmunoassays (RIAs) for pituitary hormones (performed at 
the National Institute for Medical Research [NIMR])  
Pituitaries from WT and MC3-/- male and female mice were thawed and 
homogenised on ice in 1 ml cold PBS (pH 7.4; 50 mM sodium dihydrogen 
orthophosphate dihydrate, 100 mM sodium chloride, 0.6 mM thimerosal 
[antiseptic/antifungal] [all from Sigma-Aldrich, UK]). The pituitary content of 
adrenocorticotropic hormone (ACTH), thyroid stimulating hormone (TSH), 
luteinizing hormone (LH), follicle stimulating hormone (FSH), prolactin and 
growth hormone (GH) were measured by relevant RIA. Antibodies and hormone 
standards were kindly provided by Professor Parlow and the National Hormone 
and Pituitary Program (NHPP, Torrance, California). All hormones were 
iodinated at the NIMR. Each sample was initially diluted to the hormone 
concentrations detectable by the assay as presented in Table 3.1 and then 
further serially diluted 2-, 4- and 8- fold in PBS/BSA solution (3 mg/ml PBS, 0.3 
% w/v BSA [Sigma-Aldrich, UK]) or in ACTH buffer (2 % v/v aprotinin [Sigma-
Aldrich, UK], 0.1 % v/v Triton X-100 [Sigma-Aldrich, UK], 0.1 % w/v BSA, 0.1 % 
v/v β-mercaptoethanol [Sigma-Aldrich, UK], in PBS pH 7.4). Standards were 
prepared by serial dilution of known concentrations of each hormone in 
PBS/BSA solution and ranged from 0.01 ng/100 µl – 10.00 ng/100 µl. All 
components of the standard curve were prepared in triplicate including total 
counts (TC), non-specific binding (NSB) and total binding (B0), whilst samples 
were prepared in duplicate. Each tube contained 100 µl of PBS/BSA buffer and 
100 µl of either standard or sample, except for NSB which contained 200 µl of 
PBS/BSA buffer, B0 with 100 µl of PBS/BSA buffer and TC which only contained 
100 µl of tracer (hormone of interest labelled with I125 [Perkin Elmer, UK]). 
Antibody (100 µl) (the antibody dilution used for each of the hormones are 
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provided in Table 3.2) was then added to all assay tubes (except TC). Each 
tube was vortexed and then 100 µl of appropriate tracer (approximately 10,000 
cpm) were added. All tubes were incubated for 18-24 h at room temperature. 
PEG solution (600 µl) (18 % PEG prepared by mixing: 10 % Triton v/v, 0.15 % 
w/v bovine gamma globulin [Sigma-Aldrich, UK], 30 % w/v Tris base [Fisher 
Scientific, UK], 66.7 % of 27 % polyethylene glycol 6000 [Fisher Scientific, UK]) 
was added to all tubes (except TC) to precipitate the primary antibody-protein 
complexes, and incubated for 30 min at room temperature. All tubes (except 
TC) were then spun for 12 min at 3,000 rpm at 4 °C in a large capacity 
centrifuge. The supernatants were aspirated and the radioactivity of the pellet 
measured using a gamma counter (Wallac Wizard 1277, PerkinElmer Inc, 
USA). Standard curves were plotted using in-house software incorporated into 
the gamma counter. A summary of the RIA protocols for each of the pituitary 
hormones can be found in Table 3.3. 
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hormone analysed initial sample dilution 
ACTH male & female 1:50 
TSH male & female 1:50 
LH male & female 1:50 
FSH male -1:20; female-1:5 
prolactin male & female 1:500 
GH male & female 1:5000 
 
Table 3.1 Sample preparation for pituitary hormones RIAs. Initial dilutions in 100 µl that each 
sample was prepared as for assaying of each of different pituitary hormones.  
 
 
antibody concentrations used 
Anti-ACTH 1:300 
Anti-TSH 1:100 
Anti-LH 1:100 
Anti-FSH 1:100 
Anti-prolactin 1:100 
Anti-GH 1:100 
 
Table 3.2 Initial antibody concentrations used in each of the pituitary hormones RIAs (all 
antibodies provided by Professor Parlow, NHPP).  
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Table 3.3 Summary of pituitary hormones RIA protocol. TC total count, NSB- non-specific binding, B0- total binding.  
tube
volume of 
standard/sample (µl)
PBS/BSA 
buffer (µl)
antibody (µl)
tracer (antigen 
tagged with I125) 
(µl) 
PEG solution (µl)
Tc
NSB 200
Bo
standards         
(0.01  - 10.0 
ng/100 µl)
uknowns
incubate for 30 
mins at room 
temperature; 
centrifuge for 12 
minutes at 3 000 
rpm at 4°C
600
aspirate 
and 
count
vortex
100
100 100
100 incubate at 
room 
temperature 
for 18-24 
hours
1
2
7
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3.2.2 Histological comparisons of testes from WT and MC3-/- mice. 
Tissue collection, tissue processing, tissue sectioning and slide preparation 
were described in section 2.2.3.2.1. 
3.2.2.1 Haemotoxylin and Eosin (H&E) staining 
Selected sections were first cleared of wax by placing slides twice for 5 min in 
100 % xylene followed by rehydration through decreasing concentrations of 
ethanol, starting at 100 % ethanol twice for 5 min, then 95 %, 90 %, 70 %, 50 
%, and 35 % once for 5 min each. Slides were then washed twice in PBS each 
for 3 min and stained with Gill’s haematoxylin (H-3401, Vector Laboratories, 
UK) for 5 min. After rinsing with running tap water (until the run-off was 
colourless), the slides were incubated in acid rinse solution (2 % v/v acetic acid) 
for 1 min, rinsed with tap water and then placed in bluing solution (1.5 % 
ammonium hydroxide [35614, Alfa-Aesar, UK] in 70 % ethanol) for 1 min, 
followed by another rinse. The slides were then stained with eosin (1 % w/v 
eosin in dH2O) for 5 min and after rinsing with tap water, dehydrated with 
increasing concentrations of ethanol (30 %, 50 %, 70 %, 90 %, 95 %, 100 % x 
2: 5 min for each concentration). Finally the slides were immersed in 100 % 
xylene for 5 min twice before mounting each section using DPX mounting media 
(HX945813, Merck, UK) with glass coverslips (631-1574, VWR, UK). 
3.2.2.2 Staining Visualisation 
As described in Chapter 2, section 2.2.3.2.4  
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3.2.2.3 Histological comparisons  
Histological comparisons were made between MC3-/- and WT mice at four 
different ages: 3-4 weeks, 9-10 weeks, 16-17 weeks and 23-24 weeks. There 
were three animals per genotype (MC3-/- or WT) in each age group, and for each 
animal, four sections, approximately every 100 µm apart, were selected for 
imaging. For each section imaged, four separate frames, at distant areas within 
the section, were acquired.   
3.2.2.4 ImageJ analyses  
Acquired images were analysed using ImageJ software (ImageJ 1.47; NIH, 
USA). Selected quantitative measurements included: diameter and thickness of 
the seminiferous tubules, area of intertubular tissue and tubules as well as the 
total area occupied by the tissue. Tubules that appeared rounded and thus were 
cut at an approximately 90° angle to the length of the tubule were selected for 
making diameter measurements. However, if only oblique tubules were 
encountered in a frame, then the short axis of the tubular profile was measured. 
The areas of testicular structures were calculated based on the measurement 
for whole tubules and whole intertubular islets. Measurements obtained for a 
part of the structures (a part of a tubule visible on the microscopic image) were 
used to estimate the total area occupied by the tissue. Germinal layer (tubule) 
thickness was estimated by taking two measurements of the distance between 
basement membrane and lumen border. 
For quantification verification, some of the images were remeasured by 
independent observers. Detailed step-by-step instructions for measurements 
using ImageJ can be found in Appendix 1.  
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3.2.2.5 Quality Controls 
In order to estimate the variability in measurements between the operators the 
coefficient of variations (CV) for each parameter were determined. For each of 
the parameters the CV between operators was lower than 5 % except for the 
mean of tubule thickness (MC3-/-: 10.669% and WT: 9.572%) and the area of 
intertubular tissues (WT: 7.362% ; Table 3.4).  
 
 
 animal 
type 
mean of 
diameters 
(µm) 
mean of 
tubule 
thickness 
(µm) 
area of 
intertubular 
tissues (µm2) 
area of 
tubules 
(µm2) 
CV (%) 
MC3-/- 1.406 10.669 3.873 1.657 
WT 0.402 9.572 7.362 2.390 
Table 3.4 Coefficients of variations (CVs) calculated to determine the variability 
between operators’ measurements for each parameter.  
 
 
3.2.3 Statistics 
Comparisons between two groups were performed using unpaired Student’s t-
test (two-tailed) (Excel, Microsoft Office 2010). Statistical differences between 
all age groups were calculated using one-way ANOVA procedures followed by 
Tukey post-hoc tests (SPSS 18, IBM). For all statistical analyses P value is 
given. Data are expressed as mean ± SEM.  
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3.3  Results 
3.3.1 The effects of MC3 gene ablation on total pituitary hormone content   
 
Pituitaries from WT and MC3-/- mice were homogenised and their hormone 
content measured by RIAs. Total pituitary content of ACTH and TSH measured 
by RIA were similar in the two male genotypes. However, there were reductions 
in the amounts of LH (WT: 1062 ± 109 ng vs. MC3-/-: 427 ± 42 ng), FSH (WT: 
554 ± 21 ng vs. MC3-/- 346 ± 13 ng), prolactin (WT: 2.12 ± 0.22  µg vs. MC3-/-: 
1.30 ± 0.13 µg) and GH (WT: 64 ± 6 µg vs. MC3-/-: 35 ± 6 µg) in MC3-/- 
compared to WT male mice (t-test, p<0.05) (Figure 3.1). In female mice, the 
total pituitary contents of ACTH, TSH, LH, FSH and prolactin were unaffected 
by MC3 genotype, however there was approximately 40 % decrease in the 
amount of GH (WT: 61 ± 8 µg vs. MC3-/-: 37 ± 5 µg) in MC3-/- compared to WT 
female mice (t-test, p<0.05) (Figure 3.2).    
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Male 
 
Figure 3.1 Total pituitary hormone content in wild type (blue bars) and MC3 null 
(black bars) male mice. Pituitaries of sexually mature (14-16 weeks) wild type (WT; 
C57BL/6, n=5) and MC3-/- (n=6) male mice were removed, frozen, thawed and 
homogenised on ice in 1 ml cold PBS. Pituitary content of adrenocorticotrophic 
hormone (ACTH), thyroid-stimulating hormone (TSH), luteinizing hormone (LH), follicle 
stimulating hormone (FSH), prolactin and growth hormone (GH) were measured by 
relevant RIA. Data shown are expressed per pituitary, mean ± SEM. * p<0.05 vs. WT 
(t-test). Note the differences in scales between the hormones.  
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Female 
 
Figure 3.2 Total pituitary hormone content in wild type (pink bars) and MC3 null 
(black bars) female mice. Pituitaries of sexually mature (14-16 weeks) wild type (WT; 
C57BL/6, n=6) and MC3-/- (n=5) female mice were removed, frozen, thawed and 
homogenised on ice in 1 ml cold PBS. Pituitary content of adrenocorticotrophic 
hormone (ACTH), thyroid-stimulating hormone (TSH), luteinizing hormone (LH), follicle 
stimulating hormone (FSH), prolactin and growth hormone (GH) were measured by 
relevant RIA. Data shown are expressed per pituitary, mean ± SEM. * p<0.05 vs. WT 
(t-test). Note the differences in scales between the hormones.  
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3.3.2  The effects of MC3 gene ablation on testicular histology. 
There were no gross abnormalities in the testes analysed but occasionally 
some histological abnormalities occurred in WT and MC3-/- mice (Figure 3.4). 
There were age-dependent changes in the average areas of the interstitial 
tissues and the seminiferous tubules in both genotypes (Figure 3.3).   
The total area occupied by testicular tissue is regarded as the total intracapsular 
area occupied by interstitial tissue and seminiferous tubules (Figure 3.5), this 
includes the areas of all seminiferous tubules and interstitial islets, either whole 
or only a part of them visible on the image. A greater percentage of the total 
tissue indicates less intertubular space (Table 3.5). The tubules occupied 
approximately 70-80 % of the total area whilst interstitial tissue comprised only 
2-4 % of the total area. The total area (%) occupied by the tissue markedly 
increased following puberty between 3-4 and 9-10 weeks in both genotypes 
(p<0.05; ANOVA, Tukey). There were no significant differences between the 
total tissue areas in MC3-/- and WT mice but testicular tissue occupied 
approximately 7-12 % less of the total area in MC3-/- mice at 3-4, 9-10 and 16-17 
weeks (Figure 3.5).   
The average area of interstitial islets was low at 3-4 weeks, peaked at 9-10 
weeks and decreased by approximately 50 % at 16-17 weeks in both genotypes 
(Figure 3.6). The interstitial tissue area remained constant thereafter, until the 
animals reached 23-24 weeks of age. There were no significant differences 
between the areas of the interstitial islets in the two animal types, except in the 
youngest group examined (Figure 3.6). The mean area of interstitial tissues was 
markedly reduced in MC3-/- compared to WT mice at 3-4 weeks (t-test, p=0.02; 
Figure 3.6).  
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The average diameters of the tubules increased significantly in all animals from 
weeks 3-4 to 9-10 (p<0.001; ANOVA, Tukey) corresponding to the development 
of reproductive maturity at week 5 (Figure 3.7). The mean diameters of the 
seminiferous tubules in MC3-/- mice were smaller than WT mice at 3-4 weeks 
(p=0.004; ANOVA, Tukey) and, although not statistically significant, were also 
smaller at both 9-10 and 23-24 weeks (9-10 weeks: p=0.16 and 23-24 weeks: 
p=0.14; ANOVA, Tukey; Figure 3.7).  
As expected, the data for the average areas of the seminiferous tubules are 
comparable to that of tubular diameter. There was a marked increase in the 
average area of tubules following puberty (p<0.05; ANOVA, Tukey; Figure 3.8). 
There was a reduction of approximately 19-35 % in the tubule area in MC3-/- 
mice compared to WT at 3-4, 9-10 and 23-24 weeks, with the former age group 
being statistically significant (p=0.01; ANOVA, Tukey). In contrast, at weeks 16-
17 the tubular area was markedly greater in MC3-/- mice (p=0.002; ANOVA, 
Tukey; Figure 3.8).  
Similar to other tubular parameters measured, the thickness of the seminiferous 
tubules was markedly higher in all age groups examined compared to animals 
at 3-4 weeks. There were significant reductions in the thickness of tubules in 
MC3-/- compared to WT mice at 9-10 and 23-24 weeks of age (9-10 weeks: 
p=0.02; 23-24 weeks: p=0.04; ANOVA, Tukey; Figure 3.9). Conversely, at 16-
17 weeks of age the WT animals had significantly smaller tubular thicknesses 
(p=0.00091; ANOVA, Tukey; Figure 3.9) than MC3-/- mice. 
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Figure 3.3 Microscopic images of testes from Wild Type (WT) and MC3 null  mice 
(MC3-/-) at different ages. Testes from WT (left) and MC3-/- (right) were divided into four 
age groups (3-4 weeks of age; 9-10 weeks of age, 16-17 weeks of age and 23-24 
weeks of age) as indicated at the top of each panel. Selected sections were stained 
with H&E. Representative images from each group (32-36 images per group). Scale 
bar is present in the top right corner of each image.  
 
 
 
Figure 3.4 Examples of seminiferous tubules depleted of germ cells (arrow) in  
both WT (left) and MC3-/- (right) mice at 3-4 weeks of age.  
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Figure 3.5 Area (%) occupied by the tissue. Testes from WT and MC3-/- mice were 
removed at different age (3-4 weeks of age; 9-10 weeks of age, 16-17 weeks of age 
and 23-24 weeks of age), fixed (4 % PFA), embedded and stained with H&E. 
Microscopic images were analysed using ImageJ. The total area (%) occupied by the 
tissue is presented for WT (non-pattern filled bars) and MC3-/- (pattern filed bars). It was 
subdivided into area occupied by the intertubular tissue (top, red part of the bar) and 
area of tubules (bottom, blue bars). Data shown are expressed as mean ± SEM of 
three animals (mean of 12 images per animal). #p<0.05 vs. other age groups (ANOVA, 
Tukey).   
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Age 
(weeks) 
Animal 
Type 
Intertubular 
space (%) (mean 
± SEM) 
 3-4  
WT 34.00 ± 2.11 
MC3-/- 41.59± 1.85 
9-10 
WT 20.03 ± 1.58 
MC3-/- 25.64 ± 1.30 
16-17  
WT 20.16 ± 2.05 
MC3-/- 27.28 ± 1.51 
23-24 
WT 29.33 ± 1.71 
MC3-/- 25.98 ± 1.65 
 
Table 3.5 Intertubular space (%) in testes from WT and MC3-/- mice at different 
ages. Data were calculated based on the area (%) occupied by the tissue and are 
presented as mean ± SEM of three animals (mean of 12 images per animal). There 
were no significant differences in the intertubular space (%) between the MC3-/- and WT 
mice (t-test).  
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Figure 3.6 Average area (µm2) of interstitial islets. Testes from WT and MC3-/- mice 
were removed at different age (3-4 weeks of age; 9-10 weeks of age, 16-17 weeks of 
age and 23-24 weeks of age), fixed (4 % PFA), embedded and stained with H&E. 
Microscopic images were analysed using ImageJ. The average size (µm2) of interstitial 
islets is presented for WT (non-pattern filled bars) and MC3-/- (pattern filled bars). Data 
shown are expressed as mean ± SEM of three animals (mean of 12 images per 
animal). *p<0.05 MC3-/- vs. WT (t-test); #p<0.05 vs. other age groups (ANOVA, Tukey).   
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Figure 3.7 Tubule diameter (µm). Testes from WT and MC3-/- mice were removed at 
different age (3-4 weeks of age; 9-10 weeks of age, 16-17 weeks of age and 23-24 
weeks of age), fixed (4 % PFA), embedded and stained with H&E. Microscopic images 
were analysed using ImageJ. The tubule diameter (µm) is presented for WT (non-
pattern filled bars) and MC3-/- (pattern filled bars). Data shown are expressed as mean 
± SEM of three animals (mean of 12 images per animal). *p<0.05 MC3-/- vs. WT (t-test); 
#p<0.05 vs. other age groups (ANOVA, Tukey).   
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Figure 3.8 Average area (µm2) of tubules. Testes from WT and MC3-/- mice were 
removed at different age (3-4 weeks of age; 9-10 weeks of age, 16-17 weeks of age 
and 23-24 weeks of age), fixed (4 % PFA), embedded and stained with H&E. 
Microscopic images were analysed using ImageJ. The average size (µm2) of tubules is 
presented for WT (non-pattern filled bars) and MC3-/- (pattern filed bars). Data shown 
are expressed as mean ± SEM of three animals (mean of 12 images per animal). 
*p<0.05 vs. WT (t-test); #p<0.05 vs. other age groups (ANOVA, Tukey).   
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Figure 3.9 Tubule thickness (µm). Testes from WT and MC3-/- mice were removed at 
different age (3-4 weeks of age; 9-10 weeks of age, 16-17 weeks of age and 23-24 
weeks of age), fixed (4 % PFA), embedded and stained with H&E. Microscopic images 
were analysed using ImageJ. The thickness (µm) of tubules is presented for WT (non-
pattern filled bars) and MC3-/- (pattern filed bars). Data shown are expressed as mean ± 
SEM of three animals (mean of 12 images per animal). *p<0.05 MC3-/- vs. WT (t-test); 
#p<0.05 vs. other age groups (ANOVA, Tukey).   
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3.4  Discussion 
 
Ablation of MC3 led to a reduction in the content of a number of pituitary 
hormones, which are directly and/or indirectly implicated in the control of the 
reproductive system, including gonadal function. Testes from MC3-/- mice were 
different from that of WT with regard to a number of morphometric parameters 
at different ages, hence implying possible translation into functional 
abnormalities.   
The total pituitary content of each of the anterior pituitary hormones in MC3-/- 
mice were determined and compared to those measured in WT animals. 
Overall, the absence of MC3 had more profound effects on the total anterior 
pituitary hormone content of male mice (Figure 3.1 and 3.2). There was a 
significant reduction in GH content in both male and female MC3-/- mice. 
However, this content could still result in sufficient GH in the circulation to 
enable normal bone development and hence animal growth (McGuinness et al., 
2003). Phenotypically, however, MC3-/- mice have shorter body lengths 
compared to WT (Chen et al., 2000) and this may possibly be due to a 
reduction in the growth plate proliferation: an effect mediated by γ2-MSH on 
MC3-expressing chondrocytes and chondrocyte precursors (Yeh et al., 2006 ). It 
is also possible that altered release of GH, either the amount or pattern, could 
result in reduced growth plate proliferation (Westwood et al., 2010) but in the 
absence of a system for frequent sampling of blood for GH measurement this 
could not be determined. The pituitary content of ACTH and TSH in both male 
and female MC3-/- mice remained largely unaltered compared to WT. These 
data are partially supported by normal plasma concentrations of corticosterone 
and thyroxine (T4) in MC3-/- male and female mice (Butler et al., 2000). A 
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marked decrease for the two pituitary gonadotropins, LH and FSH, was seen in 
MC3-/- of both genders but only the reduction in MC3-/- male mice was significant. 
Female mice were sampled with no knowledge of the stage of the oestrous 
cycle, which accounts for the greater variability of LH, FSH and prolactin 
pituitary contents compared to the males. The concentrations of the three 
pituitary hormones are known to vary with the time of the day, the stage or any 
alteration of the oestrous cycle, as well as the age of the female mice 
(Parkening et al., 1982). Additionally, in order to determine the exact effect of 
the MC3 deletion on the anterior pituitary, the circadian pattern of release of the 
other pituitary hormones should also be measured. Overall, total content of the 
pituitary hormones in WT mice was comparable to that reported in the literature 
(McGuinness et al., 2003; Waite et al., 2010). The exact role of MC3 signalling 
in the pituitary is not understood, but clearly, its absence in this gland or other 
tissues leads to a marked reduction in pituitary hormone contents, which can 
directly or indirectly impair functioning of the gonads. It can be hypothesized 
that lack of pituitary MC3 can be compensated by activation of the other three 
melanocortin receptors namely MC1, MC4 and MC5 by pituitary α-MSH and γ-
MSH. However, the qRT-PCR results described in Chapter 2 (Figure 2.20) 
showed a reduction of all MC, except for MC1, in pituitary of MC3-/- mice 
compared to WT. This could indicate a type of co-dependency in melanocortin 
receptor expressions. 
The significant reductions in the pituitary hormone contents in male MC3-/- mice, 
particularly in the gonadotropins can indirectly affect testicular function. 
Therefore, the second aim was to determine the direct or indirect effects of MC3 
ablation on male gonads and ascertain whether they are age dependent. The 
possible functions of melanocortin receptors in the testis are described in detail 
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in Chapter 4. Classic methodologies for assessment of reproductive functions in 
mice apart from investigation of biochemical markers, also include evaluation of 
testicular histology and use of natural mating for fertility tests (Amann, 1986; 
Chubb, 1987). The histological analyses of testes applied in this study, have 
been routinely used in many laboratories worldwide to determine the 
reproductive state of an animal. There are many qualitative and quantitative 
histological measurements described in the literature, some provide an 
inexpensive but time-consuming way of assessing testicular functions. The 
quantitative measurements provide much stronger evidence of testicular 
abnormalities than the qualitative methods (Russell et al., 1990).  Five 
parameters were chosen in this study (diameter and thickness of the 
seminiferous tubules, area of intertubular tissues and tubules as well as total 
area occupied by the tissue) to compare the histology of testes from MC3-/- to 
WT mice and thus indirectly assess their reproductive abilities. Due to a 
paracrine interrelationship between the seminiferous tubules and interstitial 
tissue, selected parameters reflect the possible changes in both structures of 
the testis.  
The major parameter measured in the study was the area (%) occupied by the 
tissue. This included the number and area of the seminiferous tubules and 
interstitial islets (Figure 3.5). The percentages of tubules and interstitial islets 
were comparable to previously published data on mice and equal to 70-80 % 
and 2-4 %, respectively (Hess and deFranca, 2001). The area (%) occupied by 
the tissue was significantly lower in the youngest animals analysed compared to 
all other age groups (Figure 3.5). The size of tubules and interstitial islets 
increased following achievement of reproductive maturity at week 5 and 
remained constant thereafter. There was no significant difference in the areas 
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(%) occupied by the tissues in MC3-/- compared to WT but a marginal decrease 
of approximately 7 % was measured at 3-4 weeks. An increase in the 
percentage of interstitial space at this age (Table 3.5) could, in some cases, 
indicate a rise in the volume of interstitial fluid, which may exhibit infiltration of 
leukocytes (Kerr and Sharpe, 1989). The changes in the volume of the 
interstitial fluid could also be related to the fixation method, however tissues 
from both genotypes were prepared using the same protocol.  
The average area of the intertubular islets was also compared. The interstitial 
tissue is mostly composed of Leydig cells but macrophages are commonly 
present. In rodents, Leydig cells are usually located in the central portion of the 
intertubular tissue, in close proximity to lymph nodes but at considerable 
distance to blood vessels (Setchell and Breed, 2006). All of these structures 
were included to determine the average area of the interstitial islets, if present 
within the islet boundary. Tissues from both animal types, MC3-/- and WT, 
followed the same process of fixation and embedding to reduce the possibility of 
technical errors as both factors can influence the protein content of the 
intertubular islets and hence their size. In detail qualitative examination of the 
interstitial tissue, such as determination of size and appearance of individual 
Leydig cells or infiltration of leukocytes, has not been performed. The size of 
intertubular islets was approximately seven times greater at 9-10 weeks (2,140 
± 409 µm2) compared to the youngest age group (299 ± 107 µm2; Figure 3.6). A 
gradual increase in the volume of testicular interstitial tissue until day 90 in 
rodents was reported by Ariyaratne and colleagues (2000). The changes in the 
sizes of the interstitial islets at different age correspond with the genetic and 
hormonal profile of Leydig cells during their maturation. The onset of 
testosterone biosynthetic capacity in mice testes occurs at 3 weeks, the 
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maximal testosterone production appears at 7 weeks, followed by a gradual 
decline during the transition of immature Leydig cells into adult population (Wu 
et al., 2010).  The steroid producing capacity of newly formed adult Leydig cells 
is low from week 8 to 12 but their number is significantly higher (Ariyaratne et 
al., 2000), this may explain the peak in the intertubular islet area at 9-10 weeks 
described herein (Figure 3.6). The increase in the area of interstitial tissues at 
9-10 weeks of age was followed by reductions of approximately 60 % at 16-17 
weeks and 50 % at 23-24 weeks in both genotypes (Figure 3.6). The decrease 
could be related to the acquisition of a full steroidogenic capacity by adult 
Leydig cells. Data from a study on 30 men aged between 20 and 76 years 
demonstrated a gradual decrease in the population of interstitial cells with 
increasing age (Neaves et al., 1985). Although the aging process in humans is 
different from that in the mouse the decrease in the areas of the interstitial islets 
was noted in both species. The exact mechanism governing the loss of Leydig 
cells is unclear but phagocytosis by residual macrophages provides a possible 
explanation (Neaves et al., 1985).  In general, the mean area of the interstitial 
islets in MC3-/- was comparable to that of WT, except in the younger groups. 
There were approximately 40 % and 20 % reductions in the areas of interstitial 
tissues at 3-4 and 9-10 weeks, respectively, compared to age matched controls.  
Tubule diameter was regarded as being more accurate than the testis weight to 
indicate varying levels of spermatogenic abnormalities (Russel et al., 1990). A 
positive relationship exists between the tubular diameter and the spermatogenic 
activity of the testis (Hikim et al., 1989). In order to confirm the accuracy of the 
data, the areas of tubules were also measured. There were significant 
increases in tubule diameters and areas in both MC3-/- and WT mice following 
puberty at week 5 (Figures 3.7 and 3.8). This is in agreement with previous 
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studies reporting a gradual but significant increase in the absolute volume of the 
seminiferous tubules until 13 weeks (Ariyaratne et al., 2000). This post pubertal 
increase in tubular parameters coincides with a rise in the steroidogenic 
capacity of Leydig cells. FSH and testosterone are the key regulators of 
spermatogenesis. Both tubular diameter and area did not change significantly 
between 9-10 to 23-24 weeks in MC3-/- mice and their age-matched controls 
(Figures 3.7 and 3.8). In contrast to C57BL/6 mice, the diameter of seminiferous 
tubules of Balb/c mice progressively increased until 17 weeks of age (Shukri 
and Shire, 1989). There was a significant reduction in both tubule diameter and 
area in MC3-/- mice compared to controls in the youngest age group (3-4 
weeks). Interestingly, tubule diameter was 10 % higher in 16-17 weeks old MC3-
/- mice compared to WT and this difference was more significant for tubular area 
(Figures 3.7 and 3.8). This is even more surprising considering the fact that no 
known major reproductive event is occurring at this age in mice.     
The thickness of the seminiferous tubules was measured to provide an indirect 
assessment of the state of spermatogenesis. Moreover, it also enabled 
identification of possible tubular abnormalities including presence of vacuoles or 
blockage in the tubules or duct system indicated by shorter tubular thicknesses 
(Russel et al., 1990). In this study, the thickness of tubules correlated with the 
changes in other tubular parameters. Not surprising, the thinnest germinal 
epithelium was estimated at 3-4 weeks, whilst the thickest at 23-24 weeks 
(Figure 3.9). There were approximately 15 % and 25 % reductions in MC3-/- 
mice compared to WT at 9-10 and 23-24 weeks, respectively. Conversely, there 
was a significant increase in tubular thickness in MC3-/- animals at 16-17 weeks 
in conjunction with a rise in tubular diameter and area (Figure 3.7, 3.8 and 3.9).  
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The length of tubular diameter and thickness vary depending on the stage of the 
cycle (Wing and Christensen, 1982). The latter is highest at stage V of the 
spermatogenic cycle followed by a gradual decrease until stage XIV, from which 
it increases again. The diameter of tubules significantly increases from stages I-
IV to VII–VIII, followed by a decrease from stages VIII–IX caused by the 
depletion of the luminal contents (Wing and Christensen, 1982). Neither tubular 
diameters nor thicknesses were categorized according to the stage of the cycle 
hence the large variability in data, particularly for the latter parameter. 
Nevertheless, there are other examples in the existing literature of randomized 
tubule selection for morphometric analyses, regardless of cycle stage, which stil 
provided insightful information (Amann, 1986; Mehraein and Negahdar, 2011; 
Ebadi Manas et al., 2013).  
There were a number of atrophic seminiferous tubules depleted of germ cells 
and lined mainly with Sertoli cells in both WT and MC3-/- mice, particularly in the 
youngest animal groups. They were regarded as sporadic, background 
variations of the tubules (Figure 3.4).  Described results only provide preliminary 
indication of the differences in the histology of testes: more detailed qualitative 
and morphometric analyses including determination of cell numbers and 
volumes of tubules are still required.    
Although, all tissues were fixed and embedded using the same procedure, the 
possibility of technical errors must be taken into consideration when interpreting 
the data. The paraformaldehyde fixation used in this study could lead to 
shrinkage of germ and Sertoli cells. This appears as separation of the cells in 
the germinal epithelium and further contributes to data variability for tubular 
thickness. This method, however, was chosen over other possible methods as it 
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does not affect tubule diameter or distances between them, as other fixatives 
like Bouins do (Scudamore, 2014). 
In this part of the study, the reproductive abilities of the MC3-/- mice were initially 
assessed at two levels of the reproductive axis. The contents of a number of 
anterior pituitary hormones were reduced in both male and female MC3-/- mice 
compared to WT. The MC3 ablation led to more than 50 % reduction in 
gonadotropins as well as prolactin and GH in male mice. In female, GH was the 
only hormone significantly affected. It is still unclear whether the reduction in the 
pituitary hormones is mediated by a direct loss of MC3 in this gland, or indirectly 
through the hypothalamus or other tissues which interact with the pituitary 
gland. Furthermore, MC3 ablation, in varying degree, affected testicular 
histology. The age dependent changes in testicular parameters in MC3-/- mice 
were comparable to that of WT. In young (3-4 and 9-10) MC3-/- mice, however, 
these measurements were significantly smaller suggesting a defect in 
spermatogenesis. The intratesticular, plasma or urine (Munro et al., 1991; Muir 
et al., 2001; deCatanzaro et al., 2006) concentrations of testosterone could not 
be established due to lack of animals but it would be a good indication of the 
steroidogenic capacity of these animals. At present, it cannot be clarified 
whether the changes in testicular histology at young age are caused by direct 
effects of MC3 absence in the testis, or upstream effects.  A tissue specific gene 
ablation model would aid in establishing the exact aetiology.  
C57BL/6 mice are considered good breeders (Batty, 1978; Silver, 1995) and yet 
MC3-/- mice with this background have reduced frequency of pregnancy and 
litter size as anecdotally reported from our in-house observations (Stephen 
Getting, and some of his former colleagues at the William Harvey Research 
Institute, personal communications). Clearly, MC3 ablation does not induce 
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complete infertility as these mice are still able to reproduce (Butler et al., 2000; 
Chen et al., 2000). It is of note, however, that the spermatozoa production in 
laboratory animals exceeds the number needed for fertility. Therefore, in 
rodents, spermatogenesis must be decreased by 90 % or even more to affect 
the number of offspring (Amann, 1986). In order to establish the reproductive 
functions of MC3-/- mice a full biochemical profile and investigation of their 
sexual behaviour including mount patency, frequency, intromission latency et 
cetera, is required. It is not yet clear whether MC3 ablation affects both genders 
to the same degree as this study concentrated primarily on the male. Similar 
approaches should be taken to determine the effects in female MC3-/- mice. This 
would include examination of oogenesis, steroidogenesis, conception or 
implantation as they all may be potentially defective. 
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4 The effects of MC3 activation in normal and 
LPS-stimulated mouse testicular tissue. 
 
4.1  Introduction 
 
The testis is described as an immune-privileged site, where immune responses 
are actively suppressed to extend survival of autoantigenic male germ cells 
(Meinhardt and Hedger, 2011). Failure of these protective mechanisms may 
result in infertility or autoimmunity. Sertoli cells are considered to be the key cell 
type maintaining this immune privilege (Mital et al., 2010). They express several 
cytokines, which may modulate immune functions. Two of the cytokines 
interleukin 1 (IL-1) and tumour necrosis factor alpha (TNF-α), were shown to 
stimulate Leydig cell activity, but in the presence of acute or chronic testicular 
inflammation they led to a decrease in androgen secretion and hence a 
reduction in fertility (Gnessi et al., 1997). Acute or chronic forms of infection or 
inflammation are often due to bacterial invasion and can be experimentally 
reproduced by administration of lipopolysaccharide (LPS), a component of the 
outer membrane of Gram-negative bacteria. Studies showed that high 
concentrations of LPS can inhibit testicular steroidogenesis and disrupt 
spermatogenesis in vivo by release of a number of pro-inflammatory molecules 
(O'Bryan et al., 2000a). Prolonged inflammation may lead to partial or complete 
loss of fertility (Introduction, section 1.1), hence restoration to a non-inflamed 
state is at the heart of potential therapeutic interventions.      
Among the many pleiotropic actions of MC3, strong anti-inflammatory and 
immunomodulatory effects of this receptor subtype were displayed in various 
organs including skin, lung, heart, kidney, liver and joints (Catania et al., 2004; 
Getting, 2006a). As determined by qRT-PCR, MC3 as well as other MC are 
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present in the testes of mice (Figure 2.7). Therefore, the aim of the series of 
studies presented in this chapter was to determine the effects of [D-Trp8]-γ2-
MSH, a synthetic compound with selectivity towards MC3, in normal testicular 
function and, most importantly, during a LPS-induced inflammatory-like state. 
The testicular tissues were removed from two different mice strains, namely 
Balb/c and C57BL/6, as they are known to differ with regard to the steroidogenic 
activity and immune responses. The effects of the selective MC3 agonist were 
assessed by measuring concentrations of testosterone as well as inflammatory 
markers including nitric oxide (NO), IL-1β and KC. Additionally, the K9 Leydig 
cell line was used to determine whether MC3 and/or other MC exert direct 
effects on Leydig cell function during inflammatory-like states or act indirectly 
through other cell types present in the testis such as macrophages or Sertoli 
cells. The summary of the aims and sequence of events in this project is 
presented below.   
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4.2 Materials and Methods 
 
4.2.1 In vitro incubation of testicular tissue 
4.2.1.1 Tissue collection and incubation  
Testes of sexually mature (8–12 weeks) C57BL/6 and BALB/c mice were 
removed at the National Institute for Medical Research (London, UK) and 
transported to the University of Westminster in a warm DMEM media. Testes 
were hemi-sected, weighed and randomly distributed to tubes containing DMEM 
in varying concentrations of [D-Trp8]-γ2-MSH (selective MC3 agonist; 0.3-30 
µg/ml) in the presence or absence of human Chorionic Gonadotropin (hCG; 50 
mIU/ml; C1063-10VL, Sigma-Aldrich, UK) and/or SHU9119 (MC3/MC4 
antagonist and MC1/MC5 partial agonist; 10 µg/ml) (Table 4.1). Tissues were 
hemi-sected as opposed to dispersed cells to preserve the close cell to cell 
communication present in vivo. Incubations at 35 °C lasted for 5 h (de la Torre 
et al., 1976; O'Shaughnessy et al., 2003) and were performed in a total volume 
of 400 µl of media in round bottomed, capped, test tubes (17x100 mm, 14 ml, 
PP, 734-0438, BD FALCON, VWR, UK) in a culture water bath. In order to 
induce a mild inflammatory-like response, lipopolysaccharide (LPS; 10 µg/ml; 
L6529, Sigma-Aldrich, UK) (Stephan et al., 1997; Aly et al., 2009) was added 2 
h following compound administration (Kang et al., 2006; Getting et al., 2008) 
and incubated for the remaining 3 h (O'Bryan et al., 2005).  
Doses of SHU9119 (Hruby et al., 1995; Getting et al., 1999) and hCG (de la 
Torre et al., 1977; Mayerhofer et al., 1993) were based on published reports 
and confirmed with dose-response experiments (Figures 4.1-4.4). The 
pharmacological concentrations of [D-Trp8]-γ2-MSH used in in vitro incubation of 
mice testes were also based on previous experiments (Getting et al., 2006b). 
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Doses of the endogenous MC3 ligand γ2-MSH applied in vitro on K9 Leydig cell 
line ranged from the lowest intratesticular (0.03 ng/ml) (DeBold et al., 1988) to 
low pharmacological concentrations (3 µg/ml).   
After incubation the media were removed, aliquoted and stored at -20 °C until 
assayed for testosterone by RIA, nitrite by Griess Assay or cytokines by ELISA. 
Testicular tissue pieces were washed three times in PBS and stored at -80 °C 
for possible further analyses. Treatments were done in triplicates (three different 
testicular tissue pieces) and each experiment was repeated a minimum of three 
times.   
 
 
 
 
Figure 4.1 Dose response effect of hCG (mIU/ml) on in vitro testosterone 
production in Balb/c (left) and C57BL/6 (right) mice testes. Testes of sexually 
mature (8-12 weeks) Balb/c (left) and C57BL/6 (right) mice were hemi-sected and 
incubated in DMEM in varying concentrations of hCG (10, 20 and 50 mIU/ml) for 5 h at 
35 °C in air, media were removed and assayed for testosterone by RIA. The amounts 
of testosterone released into the media were expressed relative to the mass of 
testicular tissue. Data are mean ± SD of one experiment (n=4).  
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Figure 4.2 Dose response effect of LPS (µg/ml) on in vitro testosterone 
production in Balb/c mice testes. Testes of sexually mature (8-12 weeks) Balb/c 
mice were hemi-sected and incubated in DMEM in varying concentrations of LPS (1, 
10 and 50 µg/ml) in the presence or absence of hCG (50 mIU/ml) for 5 h at 35 °C in air, 
media were removed and assayed for testosterone by RIA. The amounts of 
testosterone released into the media were expressed relative to the mass of testicular 
tissue. Data are mean ± SD of one experiment (n=4).   
 
 
 
Figure 4.3 Dose response effect of SHU9119 (µg/ml) on in vitro testosterone 
production in Balb/c mice testes. Testes of sexually mature (8-12 weeks) Balb/c 
mice were hemi-sected and incubated in DMEM in varying concentrations of SHU9119 
(5, 10 and 20 µg/ml) in the presence or absence of [D-Trp8]-γ2-MSH (3.3 or 10 µg/ml) 
for 5 h at 35 °C in air, media were removed and assayed for testosterone by RIA. The 
amounts of testosterone released into the media were expressed relative to the mass 
of testicular tissue. Data are mean ± SD of one experiment (n=4).  
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Figure 4.4 Dose response effect of SHU9119 (µg/ml) on in vitro testosterone 
production in C57BL/6 mice testes. Testis of sexually mature (8-12 weeks) C57BL/6 
mice were hemi-sected and incubated in DMEM in varying concentrations of SHU9119 
(5, 10 and 20 µg/ml) in the presence or absence of [D-Trp8]-γ2-MSH (3.3 or 10 µg/ml) 
for 5 h at 35 °C in air, media were removed and assayed for testosterone by RIA. The 
amounts of testosterone released into the media were expressed relative to the mass 
of testicular tissue. Data are mean ± SD of one experiment (n=4).  
 
4.2.1.2 Radioimmunoassay (RIA) for testosterone  
 
The RIA was performed according to manufacturer’s instructions (07189102, 
MPBiomedicals, UK) with minor modifications such as reducing the volume of 
all reagents by half. Standards were provided in the kit and ranged from 0.1 to 
10.0 ng/ml. Samples were diluted 1:2–1:4 in 0.1 M PBS. All components of the 
standard curve including non-specific binding (NSB) and total binding (B0) were 
prepared in triplicate whilst samples were assayed in duplicate. Each tube 
contained 25 µl of standard or sample, 50 µl of sex binding globulin inhibitor 
solution (SBGI) and 250 µl of testosterone 125I. Following addition of anti-
testosterone (250 µl), all tubes were vortexed, mixed and incubated at 37 °C for 
120 min. After incubation 50 µl of secondary antibody were added. All tubes 
were vortexed, mixed and incubated for another 60 min at 37 °C. Finally, all 
tubes were placed in a large capacity centrifuge (2,300 rpm for 15 min; 5804R, 
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Eppendorf, UK). The supernatant was aspirated and the radioactivity of the 
pellet measured using a gamma counter (Wallac Wizard 1470, PerkinElmer Inc, 
USA). A summary of the testosterone RIA protocol is presented in Table 4.2. 
The standard curves were plotted and calculations of unknown testosterone 
concentrations were performed using Assayzap software (Biosoft, UK).    
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ligand action 
other receptors 
targeted 
manufacturer 
concentrations 
(µg/ml) 
reference 
[D-Trp8]-γ2-MSH full agonist none 
kind gift from 
Professor Paolo 
Grieco, University of 
Naples, Italy 
0.3-30.0 Grieco et al., 2000 
SHU9119 
full antagonist MC4>MC3 
H-3952, Bachem, 
Germany 
10 Hruby et al., 1995 partial agonist MC1>MC5 
Table 4.1 Compounds used in in vitro studies. The rank order of affinity is based on Wikber et al., 2000 and the IUPHAR/BPS Guide to 
Pharmacology.  
 
 
Table 4.2 Summary of testosterone RIA protocol. TC- total count, NSB- non-specific binding, B0- total binding. 
tube diluent buffer
standards or 
unknowns
SBGI 
solution
testosterone 125I antiserum
secondary 
antibody 
Tc 25 µl 50 µl 250 µl 250 µl 50 µl
NSB 250 µl
Bo 250 µl
testosterone standards 
(0.1 - 10.0 ng/ml)
unknowns
vortex, 
incubate at 
37°C for 120 
minutes or at 
37°C for 90 
minutes and at 
4°C overnight
vortex, 
incubate 
at 37°C 
for 60 
minutes
aspirate 
and 
count
1
6
1
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4.2.1.3 Biochemical Assays  
4.2.1.3.1 Griess Assay 
 
Nitrite is the final product of nitric oxide (NO) oxidation pathways, hence its 
concentrations were used to assess NO production in the testis in response to 
various treatments in vitro. Standards were prepared by serial dilution of 100 
mM sodium nitrite (S2252, Sigma-Aldrich, UK) in DMEM media and ranged 
from 1.6–100.0 µM, with media only as a negative control. Fifty microliters of 
standards or samples were loaded into each well of a 96 well plate in duplicate. 
An equal volume of Griess reagent mix (1:1 Solution A [1% sulphanilamide 
(S925, Sigma-Aldrich, UK) in 5 % phosphopric acid (452289, Sigma-Aldrich, 
UK)] and Solution B [0.1 % N(-1-naphthyl)ethylenediamine dihydrochloride 
(N9125, Sigma-Aldrich, UK)] in distilled water) was added and left for 10 min at 
room temperature to equilibrate. The absorbance was measured at 540 nm 
using VersaMax microplate reader (Molecular Devices, UK). The concentrations 
of nitrite in each sample were established by comparison to a standard curve 
(Figure 4.5). 
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Figure 4.5 Example of a standard curve used for determination of nitrite 
concentrations. Value R2 is displayed on the graph.  
 
 
4.2.1.3.2 ELISA IL-1β  
 
Concentrations of mouse IL-1β were determined using the DuoSet ELISA 
Development kit (DY401, R&D Systems, UK). Each 96-well plate (DY990, R&D 
Systems, UK) was coated with 100 µl of 4 µg/ml rat anti-mouse IL-1β (capture 
antibody, supplied in the kit) diluted in PBS and incubated overnight at room 
temperature. The solution was removed by gentle blotting against clean paper 
towel and the plate was washed by filling each well (approximately 400 µl) with 
wash buffer (0.05 % Tween® 20 in PBS, pH 7.2-7.4) using a squirt bottle. The 
process was repeated three times. The plate was blocked for 1 h at room 
temperature with 300 µl of block buffer (1 % BSA [DY995, R&D Systems, UK] in 
PBS). Following blocking, the plate was washed three times as described 
before. Standards were prepared by serial dilution of recombinant mouse IL-1β 
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(supplied) in reagent diluent (0.1 % BSA, 0.05 % Tween® 20 in Tris-buffered 
saline [20 mM Tris base, 150 mM sodium chloride] pH 7.2-7.4) and ranged from 
0.98–1,000.00 pg/ml. The standards and samples (100 µl) were then added to 
each well in triplicate and duplicate, respectively, and incubated for 2 h at room 
temperature. After incubation the plate was washed, coated with 100 µl of 1 
µg/ml biotinylated goat anti-mouse IL-1β (detection antibody, supplied) in 
reagent diluent and incubated for another 2 h at room temperature.  The plate 
was then washed and 100 µl of streptavidin-HRP (1:200 dilution with reagent 
diluent; supplied) was added and left for 20 min at room temperature in the 
dark. The plate was washed again and colour developed using 100 µl of 
3,3′,5,5′ - tetramethylbenzidine (TMB substrate; T0440-100ML, Sigma-Aldrich, 
UK) for 20 min at room temperature in the dark. The reaction was stopped by 
adding 50 µl of stop solution (2N H2SO4 [10765663, Thermo Fisher Scientific, 
UK]) and mixing. The absorbance was measured at 450 nm using a VersaMax 
microplate reader. The concentrations of IL-1β were determined by comparison 
to the standard curve (Figure 4.6). The data were linearized by plotting the log 
of both the IL-1β standard concentrations and the absorbance values. 
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Figure 4.6 Example of a standard curve used for determination of IL-1β 
concentrations. Value R2 is displayed on the graph.  
 
 
4.2.1.3.3 ELISA KC (CXCL1) 
 
The determination of KC concentrations using the DuoSet ELISA kit (DY453, 
R&D Systems, UK) were performed according to the protocol described for the 
ELISA IL-1β but with minor modifications. Briefly, the concentrations of capture 
and detection antibodies were reduced to 2 µg/ml and 200 ng/ml, respectively. 
The Reagent Diluent also served as a Block Buffer and was composed of 1 % 
BSA in PBS (pH 7.2-7.4). 
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4.2.2 The K9 Leydig cell line 
4.2.2.1 Maintenance of the K9 Leydig cell line 
The K9 cell line is a hybrid of mouse Leydig tumor cell line (MA-10) and isolated 
mouse Leydig cells (Finaz et al., 1987). It was kindly given by Dr Finaz (Equipe 
Institut National de la Santé et de la Recherche Médicale, Lyon, France). The 
cells were maintained in DMEM/F-12 medium (31330 – 38, Life Technologies, 
UK) containing 15 mM HEPES, 1.2 g/L NaHCO3 and supplemented with 4 mM 
L-glutamine (G7513, Sigma-Aldrich, UK), 1 % penicillin/streptomycin (15140-
122, Life Technologies, UK) and 15 % foetal calf serum (FCS; 10135552, 
Thermo Fisher Scientific, UK). The K9 cells were plated in 75 cm2 flasks and 
maintained at 37 °C with 5 % CO2 and 95 % O2. Media were changed at least 
every two days due to rapid acidification. The K9 cells doubling time was 18 h in 
medium supplemented with 15 % FCS, hence they were passaged every three 
days at approximately 80 % confluency using trypsin-EDTA solution in media 
(10194522, Thermo Fisher Scientific, UK) to dissociate and disaggregate the 
cells.  
4.2.2.2  In vitro stimulation of the K9 Leydig cell line The direct effects of γ2-
MSH on nitrite release by Leydig cells were investigated in vitro. The K9 Leydig 
cells were plated onto a 96 well plate following trypsinization and left overnight 
in the incubator. Cells were then stimulated with various concentrations of γ2-
MSH (0.3 x 10-4–3.0 µg/ml; H-4400, Bachem, Germany) in the presence or 
absence of 1 µg/ml lipopolysaccharide (LPS; L6529, Sigma-Aldrich, UK) for 6 h 
at 37 °C with 5 % CO2 and 95 % O2. The timing and dose of LPS were 
determined in initial experiments. Media (100 µl) from each well were then 
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transferred to another 96 well plate for determination of nitrite concentrations by 
Griess assay. 
4.2.2.3   RT – PCR 
4.2.2.3.1 RNA extraction  
 
The K9 Leydig cells were plated onto a 6 well plate and incubated overnight at 
37 °C with 5 % CO2 and 95 % O2. Media were removed and 500 µl of 
TriReagent (T9424, Sigma-Aldrich, UK) were added into each well to lyse the 
cells. The content of each well was transferred to a clean 1.5 ml tube and stored 
at -80 °C for future use or the RNA extraction protocol was immediately done. 
Chloroform (100 µl; C7559, Sigma-Aldrich, UK) was added and the mix was 
vortexed and partitioned by centrifugation in an IEC Micromax microcentrifuge 
(DJB Labcare, UK) for 30 min at 13,000 rpm at 4 °C. The colourless upper 
aqueous containing RNA layer was transferred into a new tube and 250 µl of 
isopropanol (I-9516, Sigma-Aldrich, UK) added. The content of the tube was 
vortexed and separated as before for 30 min at 13,000 rpm at 4 °C. Finally, the 
supernatant was discarded and 500 µl of 75 % ethanol were added to wash the 
precipitate. Following vortexing, the sample was spun for 15 min at 13,000 rpm 
at 4 °C. The pellet was air dried on ice, resuspended in 12 µl of DEPC water 
(0.1 % diethylpyrocarbonate [32490, Sigma- Aldrich, UK] in water) and stored at 
-80 °C. The RNA concentration and purity were assessed using a 
spectrophotometer as described before (Chapter 2, section 2.2.2.1). 
4.2.2.3.2 cDNA synthesis  
 
Performed as described in Chapter 2, section 2.2.2.2 
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4.2.2.3.3 PCR and gel electrophoresis 
 
Performed as described in Chapter 2, section 2.2.2.3 and 2.2.2.4 
4.2.3 Statistics 
 
Normality distribution of each outcome (testosterone, nitrite, KC and IL-1) was 
checked with Kolmogorov-Smirnov test and a histogram before using the 
parametric tests (SPSS 18, IBM, USA). Statistical differences were calculated 
using one-way ANOVA procedures followed by Tukey or LSD post-hoc tests for 
inter- and intra-group comparisons (SPSS 18, IBM, USA). The Tukey post-hoc 
test is appropriate for testing large numbers of means as in the experiments 
presented, but it is known to be very conservative. It controls type I error 
(rejection of a true null hypothesis) very well but lacks statistical power, hence 
the probability of a type II error (acceptance of a false null hypothesis) is high 
(Field, 2004). There is a substantial risk of rejecting meaningful differences 
between the means due to small sample size using this test. Therefore, the 
least-significant difference (LSD) test, which is very liberal and does not control 
the type I error, was used in conjunction with Tukey test to reduce the risk of 
rejecting a drug effect that does actually exist (Field, 2004).  
The differences obtained using the LSD test, however, are not regarded as 
being significant but serve more to highlight the potential effect, which could 
become significant with larger sample size.   
Comparison between two groups was performed using unpaired Student’s t-test 
(two-tailed) (Excel, Microsoft Office 2010) or non-parametric Mann-Whitney test 
(Field, 2004). For all statistical analyses P value is given. Data are expressed 
as mean ± SEM.   
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4.3 Results 
 
4.3.1 Comparison of testosterone production by the testicular tissue of 
Balb/c and C57BL/6 mice. 
There are substantial differences in the testicular tissue steroidogenic activities 
of Balb/c and C57BL/6 mice (Figure 4.7). Balb/c mice produce 40 % more basal 
testosterone than C57BL/6 mice (p=0.065, t-test). This difference was more 
striking following hCG (50 mIU/ml) stimulation (p<0.01, t-test). hCG increased 
testosterone release from the testicular tissue of Balb/c (p=0.021, t-test) but not 
from C57BL/6 mice (p=0.314, t-test; Figure 4.7). The low response from the 
testicular tissue of C57BL/6 mice could be due to generally low steroidogenic 
activity of these animals.  
 
Figure 4.7 Effects of hCG (50 mIU/ml) on in vitro testosterone production in 
Balb/c and C57BL/6 mice testes. Testes of sexually mature (8-12 weeks) C57BL/6 
and Balb/c mice were hemi-sected and incubated in DMEM in the presence or absence 
of 50 mIU/ml hCG for 5 h at 35 °C in air. After incubation media were removed and 
assayed for testosterone by RIA. The amounts of testosterone released into the media 
were expressed relative to the mass of the testicular tissue. Data are mean ± SEM of 
four independent experiments, n=7-10; *p<0.01 for Balb/c +hCG vs. C57BL/6 +hCG (t-
test).  
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4.3.2 Effects of [D-Trp8]-γ2-MSH under various conditions on in vitro 
testosterone and inflammatory markers production from the 
testicular tissue of Balb/c and C57BL/6 mice 
4.3.2.1 Balb/c mice 
4.3.2.1.1 In vitro testosterone production by testicular tissue from Balb/c mice.  
 
[D-Trp8]-γ2-MSH alone or in the presence of hCG (50 mIU/ml) had no effect on 
testosterone release from the testicular tissue of Balb/c mice in vitro ([D-Trp8]-
γ2-MSH -hCG, p=0.193 and [D-Trp8]-γ2-MSH +hCG, p=0.168; ANOVA; Figure 
4.8 A-D). The hCG alone increased testosterone production compared to 
control (0 µg/ml) (p=0.021, t-test; Figure 4.7). In the presence of LPS alone or in 
combination with hCG, there were no significant differences in the amounts of 
testosterone released into the media from Balb/c testicular tissues in response 
to various concentrations of [D-Trp8]-γ2-MSH ([D-Trp8]-γ2-MSH +LPS, p=0.155 
and [D-Trp8]-γ2-MSH +LPS +hCG, p=0.684; ANOVA; Figure 4.8 B and D). 
Similarly to other groups, [D-Trp8]-γ2-MSH had no effect on the steroidogenic 
activities of the testicular tissue of Balb/c mice in the presence of SHU9119 
alone or in combination with hCG ([D-Trp8]-γ2-MSH +SHU9119, p=0.673 and 
[D-Trp8]-γ2-MSH +SHU9119 +hCG, p=0.456; ANOVA; Figure 4.8 C and D). 
SHU9119 alone or in the presence of hCG increased testosterone production 
three fold compared to basal levels independently of ligand dose (p<0.05, 
ANOVA, Tukey; Figure 4.8 C and D).  
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Figure 4.8 Effects of [D-Trp8]-γ2-MSH in the presence or absence of various 
compounds on in vitro testosterone production in Balb/c mice testes. Testes of 
sexually mature (8-12 weeks) Balb/c mice were hemi-sected and incubated in DMEM 
in varying concentrations of [D-Trp8]-γ2-MSH (0.3–30 µg/ml) in the presence or 
absence of LPS (10 µg/ml), SHU9119 (10 µg/ml) and hCG (50 mIU/ml) for 5 h at 35 °C 
in air. Media were assayed by RIA. Testosterone concentrations were expressed 
relative to the mass of testicular tissue. Data are mean ± SEM of two or three 
independent experiments, n=5-9, *p<0.05 between treatment groups indicated on the 
graph (ANOVA, Tukey).  
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4.3.2.1.2 In vitro nitrite production by testicular tissue from Balb/c mice.  
 
[D-TRP8]-γ2-MSH inhibited nitrite production under basal and LPS-stimulated 
conditions at 10 and 30 µg/ml, respectively, from the testicular tissues of Balb/c 
mice ([D-Trp8]-γ2-MSH only, p=0.031 and [D-Trp8]-γ2-MSH +LPS, p=0.049; 
ANOVA, Tukey; Figure 4.9 B and D). In the presence of hCG alone there were  
no significant differences in the amounts of nitrite released into the media from 
Balb/c testicular tissues in response to various concentrations of [D-Trp8]-γ2-
MSH (p=0.475, ANOVA; Figure 4.9 A and D). [D-Trp8]-γ2-MSH with SHU9119 in 
the absence of hCG decreased nitrite release at 0.3 (p=0.025) and 1.3 µg/ml 
(p=0.011; ANOVA, Tukey; Figure 4.9 C and D). LPS with hCG as well as 
SHU9119 with hCG decreased nitrite release from the testicular tissues by 50 
%, compared to control (0 µg/ml [D-Trp8]-γ2-MSH (Figure 4.9 D).     
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Figure 4.9 Effects of [D-Trp8]-γ2-MSH in the presence or absence of various 
compounds on in vitro nitrite production in Balb/c mice testes. Testes of sexually 
mature (8-12 weeks) Balb/c mice were hemi-sected and incubated in DMEM in varying 
concentrations of [D-Trp8]-γ2-MSH (0.3–30 µg/ml) in the presence or absence of LPS 
(10 µg/ml), SHU9119 (10 µg/ml) and hCG (50 mIU/ml) for 5 h at 35 °C in air. Media 
were assayed by Griess Assay. Nitrite concentrations were expressed relative to the 
mass of testicular tissue. Data are mean ± SEM of three independent experiments, 
n=4-8, *p<0.05 vs. control (0 µg/ml [D-Trp8]-γ2-MSH) for appropriate treatment group, 
#p<0.05 between treatment groups indicated on the graph (ANOVA, Tukey).  
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4.3.2.1.3 In vitro IL-1β production by testicular tissue from Balb/c mice.  
 
[D-Trp8]-γ2-MSH alone or in the presence of LPS and/or hCG had no effect on 
IL-1β release from the testicular tissue of Balb/c mice in vitro (p=0.391 for [D-
Trp8]-γ2-MSH alone; p=0.836 for [D-Trp8]-γ2-MSH +LPS; p=0.754 for [D-Trp8]-
γ2-MSH +LPS +hCG; Figure 4.10 B and D). Some differences in IL-1β 
concentrations for [D-Trp8]-γ2-MSH in the presence of hCG have been 
identified: an increase at 1.3 µg/ml (vs. 0.3 and 10 µg/ml [D-Trp8]-γ2-MSH 
+hCGl; p<0.05; ANOVA, LSD; Figure 4.10 A and D) and 30 µg/ml (vs. 0 µg/ml 
[D-Trp8]-γ2-MSH +hCG; p=0.027; ANOVA, LSD; Figure 4.10 A and D). In 
contrast, IL-1β production was reduced at 10 µg/ml (p=0.032) of [D-Trp8]-γ2-
MSH in the presence of SHU9119 and hCG (ANOVA, LSD; Figure 4.10 C and 
D).   
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Figure 4.10 Effects of [D-Trp8]-γ2-MSH in the presence or absence of SHU9119, 
LPS and hCG on in vitro IL-1β production in Balb/c mice testes.Testes of Balb/c 
mice were incubated in DMEM in varying concentrations of [D-Trp8]-γ2-MSH (0.3–30 
µg/ml) in the presence or absence of SHU9119 (10 µg/ml), LPS (10 µg/ml) and hCG 
(50 mIU/ml) for 5 h at 35 °C in air, media were assayed by ELISA. IL-1β concentrations 
were expressed relative to the mass of testicular tissue. Data are mean ± SEM of three 
independent experiments, n=5-8; *p<0.05 vs. 0.3 and 10 µg/ml [D-Trp8]-γ2-MSH +hCG 
(ANOVA, LSD); #p=0.027 vs. control (0 µg/ml) [D-Trp8]-γ2-MSH +hCG (ANOVA, LSD); 
ǂp=0.032 vs. control (0 µg/ml) [D-Trp8]-γ2-MSH +SHU9119 +hCG (ANOVA, LSD).  
179 
 
4.3.2.1.4 In vitro KC production by testicular tissue from Balb/c mice.  
 
Exposure of the testicular tissue of Balb/c mice to [D-Trp8]-γ2-MSH (0.3-30.0 
µg/ml) did not affect KC production regardless of the absence or presence of 
hCG and LPS alone or in combination ([D-Trp8]-γ2-MSH only, p=0.12; [D-Trp8]-
γ2-MSH +hCG, p=0.342; [D-Trp8]-γ2-MSH +LPS, p=0.219; [D-Trp8]-γ2-MSH 
+LPS +hCG, p=0.854; ANOVA; Figure 4.11 A, B, and D). There was a marked 
increase in KC release from the testicular tissue from Balb/c mice at 1.3 
(p=0.015) and 30 µg/ml (p=0.02) of [D-Trp8]-γ2-MSH in the presence of 
SHU9119 (ANOVA, LSD; Figure 4.11 C and D). SHU9119 with hCG had 
moderate stimulatory effects on KC production from the testicular tissue of 
Balb/c mice in the absence of [D-Trp8]-γ2-MSH (P<0.05; ANOVA, Tukey; Figure 
4.11 C and D).  
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Figure 4.10 Effects of [D-Trp8]-γ2-MSH in the presence or absence of SHU9119, 
LPS and hCG on in vitro KC production in Balb/c mice testes. Testes of sexually 
mature (8-12 weeks) Balb/c mice were hemi-sected and incubated in DMEM in varying 
concentrations of [D-Trp8]-γ2-MSH (0.3–30 µg/ml) in the presence or absence of 
SHU9119 (10 µg/ml), LPS (10 µg/ml) and hCG (50 mIU/ml) for 5 h at 35 °C in air, 
media were assayed by ELISA. KC concentrations were expressed relative to the mass 
of testicular tissues. Data are mean ± SEM of three independent experiments, n=4-8; 
*p<0.05 vs. control [D-Trp8]-γ2-MSH +SHU9119 (ANOVA, LSD); ǂp<0.05 between 
treatment groups indicated on the graph (ANOVA, Tukey).  
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4.3.2.1.5 Correlations 
 
There was a moderate but significant negative correlation between testosterone 
and nitrite production from the testicular tissue of Balb/c mice (Pearson 
correlation coefficients (two-tailed) r=-0.196, n=189, p<0.01; Figure 4.12 A). In 
contrast, testosterone was positively correlated with KC (Pearson correlation 
coefficients (two-tailed) r=0.268, n=257, p<0.001; Figure 4.12 B) and IL-1β 
(Pearson correlation coefficients (two-tailed) r=0.419, n=257, p<0.001; Figure 
4.12 C) in Balb/c mice. A strong positive correlation was established between 
the two cytokines, KC and IL- 1β (Pearson correlation coefficients (two-tailed) 
r=0.644, n=257, p<0.001; Figure 4.12 D). No correlations were observed 
between nitrite and IL-1β (Pearson correlation coefficients (two-tailed) r=-0.026, 
n=188, p=0.72; not shown) or nitrite and KC (Pearson correlation coefficients 
(two-tailed) r=-0.137, n=189, p=0.06; not shown).  
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Figure 4.11 Relationship between testosterone, nitrite, KC and IL-1β release from 
in vitro incubated testicular tissue of Balb/c mice. Testes of sexually mature (8-12 
weeks) Balb/c mice were hemi-sected and incubated in DMEM in varying 
concentrations of [D-Trp8]-γ2-MSH (0.3–30 µg/ml) in the presence or absence of 
SHU9119 (10 µg/ml), hCG (50 mIU/ml) and LPS (10 µg/ml) for 5 h at 35 °C in air. 
Panel A: Correlation between testosterone (ng/mg of tissue) and nitrite (µM/mg of 
tissue); Pearson correlation coefficients (two-tailed) r=-0.196, n=189, p<0.01. Panel B: 
Correlation between testosterone (ng/mg of tissue) and KC (pg/mg of tissue); Pearson 
correlation coefficients (two-tailed) r=0.268, n=257, p<0.001. Panel C: Correlation 
between testosterone (ng/mg of tissue) and IL-1β (pg/mg of tissue); Pearson 
correlation coefficients (two-tailed) r=0.419, n=257, p<0.001. Panel D: Correlation 
between IL-1β (pg/mg of tissue) and KC (pg/mg of tissue); Pearson correlation 
coefficients (two-tailed) r=0.644, n=257, p<0.001.  
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4.3.2.2 C57BL/6 mice 
4.3.2.2.1  In vitro testosterone production by testicular tissue from C57BL/6 
mice.  
 
[D-Trp8]-γ2-MSH alone had marked inhibitory effects on testosterone production 
from the testicular tissues of C57BL/6 mice at the highest dose (p=0.008 by 
ANOVA, LSD and p=0.082 by ANOVA, Tukey; Figure 4.13 A, B and C). [D-
Trp8]-γ2-MSH with hCG led to 50 % reduction in testosterone release at 10 
µg/ml (p=0.165, ANOVA, LSD; Figure 4.13 A, C). Exposure of testicular tissues 
to [D-Trp8]-γ2-MSH in the presence of LPS had no effect (p=454, ANOVA; 
Figure 4.13 B and C), whilst [D-Trp8]-γ2-MSH in the presence of both LPS and 
hCG had moderate stimulatory effects on testosterone release (p=0.042, 
ANOVA, LSD; Figure 4.13 B and C).   
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Figure 4.12 Effects of [D-Trp8]-γ2-MSH in the presence or absence of LPS and 
hCG on in vitro testosterone production in C57BL/6 mice testes. Testes of 
sexually mature (8-12 weeks) C57BL/6 mice were hemi-sected and incubated in 
DMEM in varying concentrations of [D-Trp8]-γ2-MSH (0.3–30 µg/ml) in the presence or 
absence of LPS (10 µg/ml) and hCG (50 mIU/ml) for 5 h at 35 °C in air, media were 
assayed by RIA. Testosterone concentrations were expressed relative to the mass of 
testicular tissue. Data are mean ± SEM of three independent experiments, n=7-15, 
*p=0.008 vs. control (0 µg/ml [D-Trp8]-γ2-MSH) for [D-Trp8]-γ2-MSH only (ANOVA, 
LSD); #p=0.042 vs. control (0 µg/ml [D-Trp8]-γ2-MSH) [D-Trp8]-γ2-MSH +hCG +LPS 
(ANOVA, LSD).  
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4.3.2.2.2 In vitro nitrite production by testicular tissue from C57BL/6 mice.  
 
[D-Trp8]-γ2-MSH increased nitrite production from the testicular tissues of 
C57BL/6 mice under basal conditions at 10 µg/ml (p=0.03, ANOVA, Tukey; 
Figure 4.14 A, B and C). In contrast, [D-Trp8]-γ2-MSH in the presence of LPS 
had moderate inhibitory effect on nitrite production at 10 µg/ml (p=0.027, 
ANOVA, LSD and p=0.21, ANOVA, Tukey; Figure 4.14 B and C). [D-Trp8]-γ2-
MSH with hCG and [D-Trp8]-γ2-MSH with hCG and LPS had no effect on nitrite 
release from the testicular tissues regardless of compound dose (p=0.838 for 
[D-TRP8]-γ2-MSH +hCG; p= 0.862 for [D-Trp8]-γ2-MSH +hCG +LPS, ANOVA). 
LPS markedly increased nitrite production from the testicular tissue of C57BL/6 
mice compared to control (0 µg/ml [D-Trp8]-γ2-MSH; p=0.018, ANOVA, LSD and 
p=0.08, ANOVA, Tukey; Figure 4.14 B and C).   
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Figure 4.13 Effects of [D-Trp8]-γ2-MSH in the presence or absence of hCG and 
LPS on in vitro nitrite production in C57BL/6 mice testes. Testes of sexually 
mature (8-12 weeks) C57BL/6 mice were hemi-sected and incubated in DMEM in 
varying concentrations of [D-Trp8]-γ2-MSH (0.3–30 µg/ml) in the presence or absence 
of hCG (50 mIU/ml) and LPS (10 µg/ml) for 5 h at 35 °C in air, media were assayed by 
Griess Assay. Nitrite concentrations were expressed relative to the mass of testicular 
tissue. Data are mean ± SEM of three independent experiments, n=4-8; *p=0.03 vs. 0 
and 0.3 µg/ml [D-Trp8]-γ2-MSH only (ANOVA, Tukey); #p=0.027 vs. 0 µg/ml [D-Trp8]-γ2-
MSH +LPS (ANOVA, LSD); ǂp=0.018 between treatment groups indicated on the 
graph (ANOVA, LSD).  
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4.3.2.2.3  In vitro IL-1β production by testicular tissue from C57BL/6 mice.  
 
Exposure of the testicular tissue from C57BL/6 mice to [D-Trp8]-γ2-MSH (0.3-
30.0 µg/ml) did not affect IL-1β production regardless of the absence or 
presence of LPS ([D-Trp8]-γ2-MSH only, p=0.685; [D-Trp8]-γ2-MSH +LPS, 
p=0.455; ANOVA; Figure 4.15 A, B, and C). There was an increase in IL-1β 
release from the testicular tissue of C57 BL/6 mice at 0.3 and 30 µg/ml of [D-
Trp8]-γ2-MSH in the presence hCG (p=0.013, ANOVA, LSD) and [D-Trp8]-γ2-
MSH in combination with hCG and LPS (p=0.024, ANOVA, LSD), respectively 
(Figure 4.15 A, B and C).  
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Figure 4.14 Effects of [D-Trp8]-γ2-MSH in the presence or absence of hCG and 
LPS on in vitro IL-1β production in C57BL/6 mice testes. Testes of sexually mature 
(8-12 weeks) C57BL/6 mice were hemi-sected and incubated in DMEM in varying 
concentrations of [D-Trp8]-γ2-MSH (0.3–30 µg/ml) in the presence or absence of hCG 
(50 mIU/ml) and LPS (10 µg/ml) 5 h at 35 °C in air, media were assayed by ELISA. IL-
1β concentrations were expressed relative to the mass of testicular tissue. Data are 
mean ± SEM of three independent experiments, n=4-12; *p=0.013 vs. 1.3 and 30 µg/ml 
[D-Trp8]-γ2-MSH +hCG (ANOVA, LSD); #p=0.024 vs. 0, 0.3, 1.3 and 10 µg/ml [D-Trp8]-
γ2-MSH +hCG +LPS (ANOVA, LSD).  
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4.3.2.2.4 In vitro KC production by testicular tissue from C57BL/6 mice.  
 
[D-Trp8]-γ2-MSH alone and in the presence of hCG markedly increased KC 
release from the testicular tissue of C57BL/6 mice at 0.3 µg/ml of compound 
(p<0.05, ANOVA, LSD; Figure 4.16 A, B and C). In the presence of LPS there 
was a decrease in KC production at 3.3 µg/ml of [D-Trp8]-γ2-MSH (p<0.05, 
ANOVA, LSD; Figure 4.16 A, B and C). [D-Trp8]-γ2-MSH in combination with 
LPS and hCG had no effect on KC release from the testicular tissue of C57BL/6 
mice ([D-Trp8]-γ2-MSH +LPS +hCG, p=0.951, ANOVA; Figure 4.16 A, B and C). 
LPS alone increased KC production compared to control (0 µg/ml [D-Trp8]-γ2-
MSH, media only) or hCG alone (0 µg/ml [D-Trp8]-γ2-MSH +hCG; p=0.007, 
ANOVA, LSD and p=0.069, ANOVA, Tukey; Figure 4.16 C).  
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Figure 4.15 Effects of [D-Trp8]-γ2-MSH in the presence or absence of LPS and 
hCG on in vitro KC production in C57BL/6 mice testes. Testes of sexually mature 
(8-12 weeks) C57BL/6 mice were hemi-sected and incubated in DMEM in varying 
concentrations of [D-Trp8]-γ2-MSH (0.3–30 µg/ml) in the presence or absence of hCG 
(50 mIU/ml) and LPS (10 µg/ml) for 5 h at 35 °C in air, media were assayed by ELISA. 
KC concentrations were expressed relative to the mass of testicular tissue. Data are 
mean ± SEM of three independent experiments, n=4-8; *p<0.03 vs. 0 µg/ml [D-Trp8]-γ2-
MSH only (ANOVA, LSD); # p<0.05 vs. 0, 1.3, 3.3 and 30 µg/ml [D-Trp8]-γ2-MSH +hCG 
(ANOVA, LSD); Δp<0.05 vs. 0 and 30 µg/ml [D-Trp8]-γ2-MSH +LPS (ANOVA, LSD); 
ǂp<0.05 between treatment groups indicated on the graph (ANOVA, LSD).  
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4.3.2.2.5 Correlations 
 
There was no correlation between testosterone and nitrite (Pearson correlation 
coefficients (two-tailed) r=-0.08, n=151, p=0.33; Figure 4.17 A) or testosterone 
and KC production from testicular tissue of C57BL/6 mice (Pearson correlation 
coefficients (two-tailed) r=-0.005, n=164, p=0.94; Figure 4.17 B). In contrast, 
testosterone was negatively correlated with IL-1β (Pearson correlation 
coefficients (two-tailed) r=-0.16, n=164, p=0.037; Figure 4.17 C). Similarly to 
Balb/c, a strong positive correlation was established between the two cytokines, 
KC and IL- 1β produced from the testicular tissue of C57BL/6 mice (Pearson 
correlation coefficients (two-tailed) r=0.4, n=164, p<0.001; Figure 4.17 D). 
There are no correlations between nitrite and IL-1β (Pearson correlation 
coefficients (two-tailed) r=0.048, n=132, p=0.58; not shown) nor nitrite and KC 
production (Pearson correlation coefficients (two-tailed) r=-0.132, n=151, 
p=0.11; not shown).  
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Figure 4.16 Relationship between testosterone, nitrite, KC and IL-1β release from 
in vitro incubated testes of C57BL/6 mice. Testes of sexually mature (8-12 weeks) 
C57BL/6 mice were hemi-sected and incubated in DMEM in varying concentrations of 
[D-Trp8]-γ2-MSH (0.3–30 µg/ml) in the presence or absence of SHU9119 (10 µg/ml), 
hCG (50 mIU/ml) and LPS (10 µg/ml) for 5 h at 35 °C in air. Panel A: Correlation 
between testosterone (ng/mg of tissue) and nitrite (µM/mg of tissue); Pearson 
correlation coefficients (two-tailed) r=-0.08, n=151, p=0.33. Panel B: Correlation 
between testosterone (ng/mg of tissue) and KC (pg/mg of tissue); Pearson correlation 
coefficients (two-tailed) r=-0.005, n=164, p=0.94. Panel C: Correlation between 
testosterone (ng/mg of tissue) and IL-1β (pg/mg of tissue); Pearson correlation 
coefficients (two-tailed) r=-0.16, n=164, p=0.037. Panel D: Correlation between IL-1β 
(pg/mg of tissue) and KC (pg/mg of tissue); Pearson correlation coefficients (two-tailed) 
r=0.4, n=164, p<0.001.  
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4.3.3 Comparison of nitrite and cytokine production by LPS-stimulated 
testicular tissues of Balb/c and C57BL/6 mice.  
 
Significant differences in basal nitrite, KC and IL-1β production as well as in 
response to a mild inflammatory stimulus in the form of LPS (10 µg/ml), from 
testicular tissues were measured between Balb/c and C57BL/6 mice. Balb/c 
mice had significantly greater basal production of nitrite, KC and IL-1β 
compared to C57BL/6 mice (p<0.05, t-test; Figure A, B and C). However, 
testicular tissue of Balb/c mice did not respond to treatment with LPS (p<0.05, t-
test; Figure A, B and C) In contrast, testicular tissue of C57BL/6 significantly 
increase production of both nitrite and KC in response to LPS (p<0.05, ANOVA, 
LSD; Figure 20 C and 22 C). A summary of all of the effects of [D-Trp8]-γ2-MSH 
on testosterone and inflammatory markers production by the testicular tissue of 
C57BL/6 and Balb/c mice under various treatment conditions is presented in 
Table 4.3 and 4.4. 
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Figure 4.17 Effects of LPS (10 µg/ml) on in vitro nitrite and cytokines production 
in testicular tissue of Balb/c and C57BL/6 mice. Testes of sexually mature (8-12 
weeks) C57BL/6 and Balb/c mice were hemi-sected and incubated in DMEM in the 
presence or absence of LPS (10 µg/ml) for 3 h at 35 °C in air. The concentration of 
nitrite and cytokines released into the media was expressed relative to the mass of 
testicular tissue. Data are mean ± SEM of 4-6 independent experiments. Panel A – 
nitrite, p<0.01 for Balb/c vs. C57BL/6 (–LPS), n=3-4 (t-test). Panel B – KC, p<0.01 for 
Balb/c vs. C57BL/6 (–LPS), n=8-14 (t-test). Panel C – IL-1β, p<0.02 for Balb/c vs. 
C57BL/6 (– LPS and +LPS), n=8-12 (t-test).  
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product measured 
Strain 
(treatment group) 
 [D-Trp8]-γ2-MSH Testosterone Nitrite IL-1β KC 
Balb/c 
 Figure 4.8 Figure 4.9 Figure 4.10 Figure 4.11 
(1) [D-Trp8]-γ2-MSH   alone − ↓↓ − − 
(2) +hCG − − ↑ − 
(3) +LPS − ↓↓ − − 
(4) +hCG +LPS − − − − 
(5) +SHU9119 − ↓↓ − ↑ 
(6) +SHU9119 +hCG − − ↓ − 
C57BL/6 
 Figure 4.13 Figure 4.14 Figure 4.15 Figure 4.16 
(1)  [D-Trp8]-γ2-MSH   
alone 
↓ ↑↑ − ↑↑ 
(2) +hCG ↓ − − ↑ 
(3) +LPS − ↓ − ↑/↓ 
(4) +hCG +LPS ↑ − ↑ − 
 
Table 4.3 Effects of [D-Trp8]-γ2-MSH on testosterone, nitrite, IL-1β and KC 
production by testicular tissue of Balb/c and C57BL/6 mice under various 
treatment conditions.  − =no effect; ↑=slight stimulatory effect (non-significant); 
↑↑=stimulatory effect; ↑↑↑= strong stimulatory effect; ↓=slight inhibitory effect (non-
significant); ↓↓=inhibitory effect; ↓↓↓=strong inhibitory effect; ↑/↓=effect depends on 
compound concentration.    
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product measured 
strain 
treatment 
type 
testosterone nitrite IL-1β KC 
Balb/c 
 Figure 4.8 Figure 4.9 Figure 4.10 Figure 4.11 
hCG ↑ − − − 
LPS ↑ − − − 
hCG & 
LPS 
↑↑ ↓↓↓ − − 
SHU9119 ↑↑↑ − − − 
SHU9119 
& hCG 
↑↑↑ ↓↓ ↑ ↑↑↑ 
C57BL/6 
 Figure 4.13 Figure 4.14 Figure 4.15 Figure 4.16 
hCG − ↑↑ − − 
LPS − ↑↑↑ − ↑↑↑ 
hCG & 
LPS 
− ↑↑ − ↑↑ 
 
Table 4.4 Effects of various treatments on testosterone, nitrite, IL-1β and KC 
production by testicular tissue of Balb/c and C57BL/6 mice. Treatments were 
compared against appropriate control, in the absence of compounds.− =no effect; 
↑=slight stimulatory effect (non-significant); ↑↑=stimulatory effect; ↑↑↑= strong 
stimulatory effect; ↓=slight inhibitory effect (non-significant); ↓↓=inhibitory effect; 
↓↓↓=strong inhibitory effect.    
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4.3.4 The K9 Leydig cell line 
4.3.4.1 Relative mRNA expressions of MC in the K9 Leydig cell line  
 
The mRNA expressions of all MC were identified in the K9 Leydig cell line. 
There appeared to be no significant differences in the mRNA expression levels 
between the receptors (Figure 4.19). The origin of the cell line was confirmed by 
detection of 3β-HSD mRNA, an enzyme involved in steroidogenesis and 
normally expressed by Leydig cells (Figure 4.20 A). The cell line also expressed 
iNOS (inducible nitric oxide synthase) enzyme in normal and LPS-treated cells, 
which indicates the ability of the K9 Leydig cells to produce nitric oxide (Figure 
4.20 B).  
 
 
 
 
 
 
 
 
 
 
206 
 
 
 
 
 
Figure 4.18 Relative mRNA expression of MC in the K9 Leydig cell line. Relative 
expression was determined by qPCR and results were analysed using qBase plus 
software including target specific amplification efficiencies. Data normalisation was 
performed using geometric mean of two most stable reference genes for this 
experimental setting, namely GAPDH and ACTB (inset in the top right corner). The 
average relative expression level of ACTB and GAPDH in all K9 cells samples is 
shown in the inset (explanation for calculation can be found on p. 67). To ensure 
accurate estimation of gene of interest (GOI) expression, the specificity of qRT-PCR 
was tested in reactions without reverse transcriptase (SuperScript; no-RT control). 
Data are presented as mean ± SEM of two independent qRT-PCRs; no statistical 
differences were determined between the groups (ANOVA, Tukey).    
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Figure 4.19 3β-HSD and iNOS mRNA expression in the K9 Leydig cell line. Panel 
A – RT-PCR for 3β-HSD (Leydig cells marker) mRNA. Expected product length is 348 
bp. Panel B - RT-PCR for iNOS (inflammatory marker). Expected product length is 249 
bp. In both panels: MW= molecular weight marker, 1=K9 cell line 1, 2=K9 cell line 2, 
L=LPS-treated K9 cells, T=testis, C=control, no cDNA. No PCR products were 
detected in parallel control samples using mRNA preparations without Super Script-
reverse transcriptase. Amplification products were separated on 2 % agarose gel. 
Representative images of two independent PCRs.  
 
 
 
 
 
 
 
208 
 
4.3.4.2 Effects of γ2-MSH on in vitro nitrite production of the LPS-
stimulated K9 Leydig cell line. 
The highest concentrations of nitrite released were induced by 1 µg/ml of LPS 
(Figure 4.21), hence this dose was applied in further experiments. LPS (1 
µg/ml) significantly increased nitrite release compared to the untreated cells 
(Figure 4.22). Since mRNA expressions of all MC were identified in the K9 
Leydig cell line, γ2-MSH, a high potency agonist at MC3, was used to determine 
the effects of MC3 activation. There were significant reductions in nitrite 
concentrations in response to all doses of γ2-MSH (p<0.05 for control vs. all 
other groups; ANOVA, Tukey; Figure 4.22).  
 
 
 
Figure 4.20 Dose response effect of LPS on nitrite release by the K9 Leydig cell 
line. K9 Leydig cells were stimulated with various concentrations of LPS (0.01–10 
µg/ml) for 6 h at 37 °C in 5 % CO2 and 95 % O2 incubator. After incubation, media were 
collected and assayed for nitrite by Griess assay. Data are mean ± SD of one 
experiment.  
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Figure 4.21 Effects of γ2-MSH on LPS-induced nitrite release by the K9 Leydig 
cell line. The K9 Leydig cells were treated with various concentrations of γ2-MSH in the 
presence of LPS (1 µg/ml) for 6 h at 37 °C in 5 % CO2 and 95 % O2 incubator. After 
incubation, media were collected and assayed for nitrite by Griess assay. Data are 
mean ± SD of three experiments, n=3; *p<0.05 vs. all other groups (ANOVA, Tukey); 
#p<0.05 between groups indicated (t-test).   
 
 
 
 
 
210 
 
4.4 Discussion 
 
Addition of [D-Trp8]-γ2-MSH to the incubation medium did not exert any discrete 
effects on steroidogenesis in Balb/c and C57BL/6 mice under normal and LPS-
treated conditions. Conversely, this compound was inhibitory on nitrite release 
from both strain types in inflammatory-like state but had no effects on cytokines 
production. The decrease in nitrite production induced by LPS was also evident 
in the K9 Leydig cell line suggesting the involvement of Leydig cells in 
mediating some of the MC effects.    
The two mouse strains, namely Balb/c and C57BL/6 exhibited marked 
differences in their levels of steroidogenic activities. C57BL/6 mice produced 40 
% less testosterone than Balb/c mice basally (Figure 4.7). Additionally, Balb/c 
mice had a significantly greater response to stimulation with hCG (an analogue 
of LH), which was added to resemble the normal testicular environment (Figure 
4.7). These results are in agreement with published literature investigating the 
testicular reproductive physiology of Balb/c and C57BL/6 mice. Shukri and Shire 
(1989) reported that testis of Balb/c were significantly heavier and the cross-
section of their seminiferous tubules was larger compared to C57BL/6 mice. In 
general, C57BL/6 mice were classified as hypoandrogenic with a lower number 
of germinal cells (Bartke and Krzanowska, 1972), lower plasma testosterone 
concentrations as well as being less aggressive (Bartke, 1974).   
Despite these facts, C57BL/6 mice are considered good breeders.  They have 
40 % higher rate of productive matings and their relative fecundity is 50 % 
higher than that of Balb/c mice (Silver, 1995). It appears that plasma 
testosterone concentrations are negatively correlated with mice copulatory 
behaviour, which includes its initiation (latency and frequency of mount), 
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execution and completion (latency and frequency of ejaculation) (Batty, 1978). 
Two explanations have been suggested for this phenomenon; high testosterone 
clearance rate and/or increased sensitivity to testosterone at the levels of the 
hypothalamus and the pituitary (Batty, 1978). The first explanation however, 
seems unlikely as intratesticular production of testosterone in vitro, unaffected 
by the clearance system, was decreased in C57BL/6 mice (Figure 4.7).  
Balb/c and C57BL/6 mice are also known to differ in their immune responses. 
C57BL/6 mice generate responses mediated by T helper 1 lymphocytes (Th1), 
releasing in particular interleukin-2 (IL-2) and interferon-γ (IFN-γ), which activate 
macrophages (Mosmann and Coffman, 1989). In contrast, Balb/c mice are 
regarded as having Th2-directed responses with predominant secretion of 
interleukins 4, 5 and 10 (IL-4, IL-5 and IL-10), which stimulate the release of 
antibodies and inhibit macrophage activation (Mosmann and Moore, 1991; Mills 
et al., 2000). The Th1-mediated responses confine protection against infections 
by intracellular viruses, protozoa and bacteria whilst Th2-mediated responses 
against extracellular pathogens (Mosmann and Coffman, 1989). This makes 
C57BL/6 mice display increased susceptibility to organ-specific autoimmune 
conditions including experimentally induced autoimmune myasthenia gravis (as 
reviewed by Chen et al., 2005). Balb/c mice, though, are more susceptible to 
tumour formation such as mammary or colon tumours (as reviewed by Chen et 
al., 2005). Upon infection with Leishmania major, an intracellular parasite, T 
lymphocytes of C57BL/6 mice release IFN-γ, which in turn stimulates production 
of NO by macrophages that kill the parasite (Heinzel et al., 1989; Mosmann and 
Coffman, 1989). C57BL/6 mice display resistance to this type of infection 
through the generation of Th1 response. This is in contrast to Balb/c mice, 
which are susceptible to infection with Leishmania major as their subset of T 
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lymphocytes produce more IL-4 instead of NO to suppress macrophages and 
hence show a Th2-response type (Heinzel et al., 1989; Mosmann and Coffman, 
1989). Not only lymphocytes but also macrophages respond to the same stimuli 
in a different manner in C57BL/6 and Balb/c mice and can be classified into M-1 
and M-2 phenotypes, respectively (Su et al., 2001). M-1 macrophages are more 
easily induced by LPS to release NO than M-2 (Mills et al., 2000). Taking into 
account the high number of residual macrophages present in the testis (Hedger, 
2002), the lack of response by Balb/c mice to LPS stimulation displayed in this 
series of studies could be due to their macrophage phenotype (Figure 4.18). 
Conversely, C57BL/6 mice produced a marked response to the stimuli in the 
form of NO and KC release but not IL-1β. Concentrations of IL-1β were higher 
under normal and LPS-stimulated conditions in Balb/c compared to C57BL/6 
mice (Figure 4.18 C). This is in agreement with Heinzel and colleagues (1989), 
who reported that mRNA expression of IL-1β was significantly greater in Balb/c 
than in C57BL/6 mice. This cytokine type serves as a co-stimulator for IL-4, 
which acts as an autocrine growth factor for Th2 cells (Kurt-Jones et al., 1987). 
In general, basal concentrations of all the inflammatory mediators measured 
were greater in Balb/c than in C57BL/6 mice (Figure 4.18). Watanobe and 
others (2004) reported that although Balb/c mice do not respond to LPS 
stimulation by release of NO, they do have elevated concentrations of 
inflammatory cytokines/chemokines leading to exaggerated local inflammation 
in response to polymicrobial infection. It now becomes clear that the effects of 
MC3 agonist/antagonist on testicular functioning should be analysed taking into 
account the interstrain differences in both the steroidogenesis and the immune 
responses.  
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Expressions of mRNA for both MC and POMC were previously determined in 
mice testes (Chapter 2, section 2.3.1 and 2.3.2). It remains to be established, 
however, which MC subtype is involved in mediating the paracrine and/or 
autocrine actions of testicular melanocortins on Sertoli and Leydig cells 
(Chapter 1, section 1.3.3.1). Since the reported effects in the adult animals were 
mediated mainly by α-MSH, MC2 can be excluded as it only binds ACTH 
(Bardin et al., 1987). It is very likely that the action of melanocortins in the testes 
results from interaction with one or more of the four receptors; namely, MC1, 
MC3, MC4 and MC5. The main interest of this PhD project lies in MC3 and since 
there is very low selectivity for endogenous melanocortin peptides between MC, 
a synthetic agonist for the MC3 subtype was applied. [D-Trp8]-γ2-MSH is a 
stabilized γ2-MSH analogue developed by Grieco and colleagues (2000) with 
more than a 200 fold higher potency at MC3 over MC4 and MC5.  
Testosterone is crucial for the maintenance of spermatogenesis and thus 
normal fertility. Considering the potential expression of MC3 in Leydig cells, as 
identified in the K9 Leydig cell line (Figure 4.19), it was of interest to determine 
the effects of its activation on steroidogenesis under normal physiological 
conditions. MC3 agonist, [D-Trp8]-γ2-MSH had no effect on testosterone release 
from the testicular tissue from Balb/c mice in the absence or presence of hCG. 
Incubation of testicular tissue from C57BL/6 mice with [D-Trp8]-γ2-MSH alone 
resulted in a dose dependent inhibition in testosterone release. The inhibitory 
effects of [D-Trp8]-γ2-MSH were also evident in the presence of hCG but at 10 
µg/ml only. O’Shaughnessy and colleagues (2003) demonstrated that γ-MSH 
alone, did not affect basal testosterone production in both adult and fetal mice 
testes (C3H/HeJ x 101/H strain). Instead, the group reported that MC2 activation 
by ACTH increased testosterone release but in the fetal testis only. 
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Interestingly, here MC2 expression appeared to be the greatest in testes of adult 
Balb/c and C57BL/6 mice compared to other MC (Chapter 2, section 2.3.1.1).     
To determine the effects of [D-Trp8]-γ2-MSH on the release of inflammatory 
markers in normal physiology, NO, IL-1β and KC were measured. A stable 
metabolite of NO, nitrite was measured to indicate the production of 
endogenous NO, which is generated through the oxidation of L-arginine to L-
citrulline by NO synthases (NOSs). The three major isoforms belonging to this 
family of enzymes are: endothelial NOS (eNOS), neuronal NOS (nNOS) and 
inducible NOS (iNOS). The presence of the two constitutively expressed 
isoforms, eNOS and nNOS, as well as the inducible form, iNOS, were identified 
in normal rat testes (Middendorff et al., 1997; O'Bryan et al., 2000b). 
Interestingly, a fourth testis-specific nNOS (TnNOS) was found in Leydig cells 
(as reviewed by Lee and Cheng, 2008). The mRNA for iNOS was detected in 
normal adult mice testes and in unstimulated K9 Leydig cells (Figure 4.20 B). 
The presence of NO synthases in these cells indicates a possible role in 
testicular functioning in normal physiology. 
Melanocortins are known to affect the release of NO in various tissues (Altavilla 
et al., 2000; Nocetto et al., 2004). Here, similarly to other studies, MC3 
activation by [D-Trp8]-γ2-MSH alone had inhibitory effects on nitrite release at 10 
µg/ml in Balb/c (Figure 4.9 A). Surprisingly, this compound was stimulatory at 
the same concentration in C57BL/6 mice (Figure 4.14 A). There were no effects 
of the agonist on nitrite release in the presence of hCG in both strains. The 
differences in response of Balb/c and C57BL/6 mice to [D-Trp8]-γ2-MSH in the 
absence of hCG may be due to differential activity of the target cell(s) – 
macrophages and/or Leydig cells (Mills et al., 2000; Bartke, 1974). Although, 
macrophages are thought to be the main NO producers in the testis (Weissman 
215 
 
et al., 2005), other cell types including Leydig, Sertoli and germ, also express 
the traditional NOS isoforms; iNOS, eNOS and nNOS. Leydig cells, however, 
exclusively express a truncated form of nNOS called TnNOS (as reviewed by 
Lee and Cheng, 2004). Since both, macrophages and Leydig cells express 
MC3, their nitrite releasing capacity could be directly affected by [D-Trp8]-γ2-
MSH under basal and hCG-stimulated conditions. The exact role of NO in 
normal physiology is still being unravelled but some contrasting reports exist. 
Welch and others (1995) suggest that intercellular and/or intracellular NO may 
regulate Leydig cell function as inhibitors of NO formation L-NMMA and L-
NAME increased testosterone production under basal and hCG-stimulated 
conditions. In contrast, O’Bryan et al., (2000b) reported stimulatory effects of 
NO in non-inflamed testes as inhibitors of NOS reduced testosterone release. 
Other functions of NO in normal testicular physiology include the relaxation of 
seminiferous tubules and dilation of blood vessels (Middendorff et al., 1997). 
Involvement of NO in regulation of spermatogenesis cannot be excluded as 
NOS isoforms were identified in both Sertoli and germ cells in the normal rat 
testes (as reviewed by Lee and Cheng, 2008; O’Bryan et al., 2000b). 
Furthermore, NO may control the release of cytokines and other inflammatory 
mediators, which take part in normal functioning of testicular interstitial cells 
including differentiation of the Leydig cells (Hales et al., 1999).   
The role of MC3 activation on the release of cytokines in normal testicular 
function was also investigated. There were no effects of [D-Trp8]-γ2-MSH 
stimulation under basal conditions on either IL-1β or KC production in Balb/c 
mice (Figure 4.10 A and 4.11 A). However, in the presence of hCG, [D-Trp8]-γ2-
MSH had weak stimulatory effects on IL-1β (1.3 and 30 µg/ml) and KC (1.3 
µg/ml) in the same mouse strain (Figure 4.10 A and 4.11 A). MC3 agonist had 
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no effect on basal IL-1β but increased KC release at 0.3 µg/ml in C57BL/6 mice 
(Figure 4.15 A and 4.16 A). In hCG stimulated tissue, [D-Trp8]-γ2-MSH 
increased production of both cytokines at the lowest concentrations in C57BL/6 
mice (Figure 4.15 A and 4.16 A). In general, MC3 activation exerted stimulatory 
effects at low concentrations of the agonist in the presence of hCG. Not only are 
immune cells, like macrophages residing in the testis, a source of inflammatory 
mediators. Both Sertoli and Leydig cells were shown to express mRNA for and 
release inflammatory mediators; including IL-1β, which exerts paracrine or 
autocrine effects (Hales et al., 1999). Leydig cell steroidogenic activity is also 
known to be affected by cytokines present in the interstitial fluid of the testis. IL-
1β was reported to stimulate testosterone release under basal and low LH-
stimulated conditions (Verhoeven et al., 1988). In the presence of high 
concentrations of LH or hCG, however, IL-1β exerts inhibitory effect on 
steroidogenensis at the level of the 17α-hydroxylase enzyme (Hales et al., 
1999). KC, also named CXCL1, was also detected in the media. It belongs to a 
small subset of cytokines known as chemokines, which display chemotactic 
activity for a variety of leukocytes; including, neutrophils, monocytes and 
lymphocytes (Borish and Steinke, 2003). There are still no reports 
characterising the role of this chemokine under basal conditions in the testis  
thus the effects of [D-Trp8]-γ2-MSH on the release of KC will be later described 
under inflammatory-like conditions.   
To conclude, in C57BL/6 mice, MC3 activation had inhibitory actions on basal 
testosterone release but had moderate stimulatory effects on nitrite release in 
normal testicular physiology. Conversely, in Balb/c mice, [D-Trp8]-γ2-MSH had 
no effect on testosterone but decreased nitrite production under basal 
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conditions. Both strains exhibited a weak stimulatory pattern of cytokine release 
at some doses of MC3 agonist.   
In general, testicular inflammation exerts inhibitory effects on steroidogenesis 
and spermatogenesis (Del Punta et al., 1996; O'Bryan et al., 2000b). In order to 
create an inflammatory-like environment in this study, an endotoxin was added 
to the incubation media. Interestingly, LPS alone increased testosterone release 
in the testicular tissue of Balb/c mice but not in that of C57BL/6 mice, which is in 
contrast to previous reports. In vivo studies investigating the effects of LPS 
indicate that inhibition in testosterone release was seen after 6 hours following 
endotoxin administration and that it reduced testosterone concentrations by 30 
% (O’Bryan et al., 2000a). Therefore, discrepancies between the results 
obtained in this study and the work of others could be related to the in vitro 
model, low concentrations of LPS used or the short incubation period. In the 
presence of hCG, [D-Trp8]-γ2-MSH did not affect testosterone production under 
mild inflammatory-like conditions in Balb/c mice. In C57BL/6 mice, [D-Trp8]-γ2-
MSH in the presence of LPS had no effect on testosterone release but was 
stimulatory at the highest agonist dose (30 µg/ml) in the presence of both LPS 
and hCG.  
Although MC3 activation did not exhibit a clear effect on testosterone release, it 
was inhibitory on nitrite production. The effects of LPS on steroidogenesis are 
known to be mediated mainly by inflammatory mediators; primarily, NO, IL-1β 
and TNF-α (Del Punta et al., 1996; O'Bryan et al., 2000a; Shang et al., 2011). A 
moderate but significant negative correlation between testosterone and nitrite 
production was found in Balb/c mice, with lower amounts of nitrite associated 
with higher amounts of testosterone released(Figure 4.12 A). The LPS-induced 
NO release was significantly higher compared to basal concentrations in 
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C57BL/6 mice (Figure 4.18 A). It could be related to increased expression of 
inducible isoform of NOS in response to LPS stimulation in Leydig cells, Sertoli 
cells or germ cells (O’Bryan et al., 2000b) and most importantly in macrophages 
(Holan et al., 2001). An increase in the expression of iNOS following LPS 
stimulation was determined in the K9 Leydig cells (Figure 4.20 B) and has been 
reported by others in a mouse Leydig tumour cell line MA-10 (Del Punta et al., 
1996), from which the K9 Leydig cells partially originate (Finaz et al., 1987). 
High concentrations of NO released in response to inflammation inhibit 
steroidogenesis possibly at the level of cholesterol side-chain cleavage enzyme 
(cytochrome P450scc) (Del Punta et al., 1996). [D-Trp8]-γ2-MSH markedly 
reduced nitrite release at 10 and 30 µg/ml in response to LPS stimulation in 
C57BL/6 and Balb/c mice, respectively, but it had no effect in the presence of 
both LPS and hCG in either mouse strain (Figure 4.9 B and 4.14 B). Activation 
of MC3 by γ2-MSH also exerted inhibitory effects on nitrite release from the K9 
Leydig cell line exposed to low concentration of LPS (Figure 4.22). A 
remarkable reduction in NO production was also observed in an in vivo model of 
LPS-induced neuroinflammation, but not under basal conditions, following the 
administration of different melanocortins (with an order of effectiveness of β-
MSH ≥ γ1-MSH = γ2-MSH > α-MSH) (Muceniece et al., 2004).  
LPS stimulation also led to increased production of cytokines possibly through 
macrophage and/or Leydig cell activities. Interestingly, the latter cell type 
expresses high levels of Toll-like receptors 3 and 4 (TLR3 and TLR4), which 
bind LPS. Upon stimulation with this endotoxin, Leydig cells are known to 
release IL-1β, IL-6, TNF-α and type 1 interferons (Shang et al., 2011). In 
contrast to nitrite, however, the effects of MC3 activation on cytokines IL-1β and 
KC were not very distinct. [D-Trp8]-γ2-MSH did not attenuate IL-1β or KC 
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release in Balb/c mice in the presence of LPS in either basal or hCG-stimulated 
conditions (Figure 4.10 B and 4.11 B). In C57BL/6 mice, the MC3 agonist had 
no effect on IL-1β release but led to a 30 % reduction in KC production (at 0.3 - 
3.3 µg/ml) from LPS-treated testicular tissues (Figure 4.15 B and 4.16 B). 
Conversely, [D-Trp8]-γ2-MSH in the presence of both LPS and hCG, increased 
IL-1β release at the highest concentration from the testicular tissue of C57BL/6 
mice (Figure 4.15 B and 4.16 B). These results are in contrast to previous 
reports describing clear inhibitory actions of MC3 on the production of both IL-1β 
and KC in other models of murine and human inflammation (Getting et al., 
2001; Getting et al., 2006b; Montero-Melendez et al., 2011; Kaneva et al., 2012) 
potentially indicating that different reponses occur in other models and under 
different physiological conditions. 
Previous in vivo experiments demonstrated that administration of LPS in mice 
leads to inhibition of steroidogenesis through reduction in the synthesis of  
steroidogenic acute regulatory protein (StAR) and steroidogenic enzymes 
including  3β-hydroxysteroid dehydrogenase (3β-HSD), cholesterol side-chain 
cleavage enzyme (cytochrome P450scc) and 17α-hydroxylase enzyme (as 
reviewed by Hales, 2002). A number of mediators are considered to be involved 
in this inhibition including NO, oxygen free radicals (Del Punta et al., 1996), IL-
1β, TNF-α and IL-6 (O’Bryan et al., 2005). This reduction in testosterone 
release during times of inflammation may allow for the generation of a full 
immune response, as androgens are immunosuppressive and testicular 
macrophages have reduced inflammatory response compared to peritoneal 
macrophages (Hales et al., 1999). Mild inflammation appears to mainly affect 
the activity of the Leydig cells, as spermatogenic damage is seen only during 
severe inflammatory responses. The forms of the studies presented herein on 
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the effects of MC3 on the functioning of the Leydig cells were for a number of 
reasons. Firstly, this cell type resides in close proximity to macrophages, known 
to affect Leydig cell function during normal and diseased states (Hedger, 2002). 
It was determined that macrophages release 25-hydroxycholesterol to 
neighbouring Leydig cells for conversion to testosterone (Hutson, 2006). Most 
importantly, macrophages are potential targets of melanocortins as they have 
previously been shown to respond to stimulation by endogenous or synthetic 
melanocortin compounds by reducing the release of inflammatory mediators in 
various models of experimental inflammation (Getting et al., 2001; Getting et al., 
2006b). Secondly, Leydig cells contain POMC mRNA and were shown to 
release melanocortins (Bardin et al., 1987b). Finally, expression of MC3 and 
other MC were detected in the K9 Leydig cells suggesting the possibility of 
direct effects of melanocortins on this cell type. From the series of experiments 
using [D-Trp8]-γ2-MSH, it can be concluded that MC3 may have modulatory, but 
not significant, effects on testosterone release in normal and LPS-stimulated 
testicular tissue. This modulation may be exerted directly on some of the 
enzymes involved in steroidogenesis and/or, most probably, indirectly through 
regulation of the release of inflammatory mediators. The effects of MC3 
activation on nitrite release, possibly derived from macrophages or Leydig cells, 
were clearly inhibitory in mild LPS-induced inflammatory-like state in both strain 
types and the K9 Leydig cells. Surprisingly, however, MC3 activation had no 
distinct effects on the production of inflammatory mediators.   
Nevertheless, there are still some doubts regarding the exact receptors 
mediating the described effects on the release of testosterone and inflammatory 
mediators. During the course of this series of studies, it was reported that [D-
Trp8]-γ2-MSH may not be fully selective for MC3 and can act as a potent agonist 
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at both MC4 and MC5 (Renquist et al., 2011). Furthermore, SHU9119 
(antagonist at MC3/MC4) with or without hCG, increased testosterone production 
more than three fold compared to unstimulated tissue regardless of [D-Trp8]-γ2-
MSH dose in Balb/c mice (Figure 4.8 C, D). The stimulatory effects of SHU9119 
in the presence or absence of hCG on testosterone release, could be mediated 
by either MC1 or MC5 as it also acts as an agonist at these receptors and 
expressions of both subtypes were determined in the testis (Chapter 2, section 
2.3.1.1) and specifically in Leydig cells (Figure 4.19). Furthermore, it was 
determined that both MC1 and MC5 may also exert anti-inflammatory and 
immunoregulatory functions, respectively (Chapter 1, section 1.2.3).     
In summary, the effects of MC3, or other MC activation in the testis are complex 
and may differ with regard to mouse strain. MC3 may be involved in discrete 
paracrine and/or autocrine modulatory actions on Leydig or other cell types 
present in the testis. Its importance, however, is more apparent during the 
induction of a mild inflammatory-like response, as it inhibits the release of NO 
and hence may contribute to the restoration of testicular homeostasis. 
Nevertheless, there is still a lot to be determined; including the type of cells 
directly responding to melanocortins as well as the exact MC mediating these 
effects. Furthermore, the in vitro model applied in this series of studies could be 
substituted for an in vivo one. This would aid in determination of the exact 
effects of MC agonists during mild as well as severe testicular inflammation, 
characterised by an influx of leukocytes from the systemic circulation. 
Additionally, this model would also help establish the effects of testicular MC 
activation on the rest of the reproductive system.  
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5 General discussion 
 
The overarching aim of the three studies was to characterise the involvement of 
the melanocortin system in the hypothalamo-pituitary-gonadal system. The first 
study demonstrated the mRNA distribution pattern of MC at each level of the 
reproductive axis and possible factors, which can influence, stimulate or inhibit, 
this expression. The second study described abnormalities in pituitary 
physiology and testicular morphology of MC3-/- mice, which can directly and 
indirectly translate into functional deficiencies in reproduction.  The third study 
focused on the least researched topic in this area, the role of MC activation in 
normal testicular function. This series of experiments also investigated whether 
synthetic agonists for specific members of the MC family, may be used to 
reduce immune responses in testicular tissue during a period of inflammation, 
an effect reported previously in other systems.   
In order to gain a holistic view of the role of the melanocortin system in the 
hypothalamo-pituitary-gonadal system, the effects reported here and that in the 
literature will be summarised and discussed below. In the hypothalamus, 
expressions of both MC3 and MC4 were confirmed in male and female mice, as 
extensively described before (Gantz et al., 1993 a, b; Introduction, section 
1.3.1). Additionally, mRNA for MC5 was also detected in the hypothalamus. This 
receptor subtype was previously underestimated in the hypothalamus and only 
one research group has described its possible involvement in the control of 
GnRH release (Murray et al., 2002; Murray et al., 2006). Low expression of the 
mRNAs for MC1 and MC2 were also demonstrated. The hypothalamic MC 
mRNA expression may be influenced by age (Figure 2.9), gender (Figure 2.13) 
or reproductive state (Figure 2.16) of an animal. Age- and oestrous cycle-
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related changes in mRNA expression were previously reported for GnRH and 
neighbouring neurones, and are associated with different concentrations of 
oestrogen and progesterone (Herbison, 2006; Gore et al., 2002). As described 
before (Introduction; section 1.3.1), POMC neurones send inputs to GnRH 
neurones (Leshin et al., 1988; Naftolin et al., 1996) and contain oestrogen 
receptors (Simonian et al., 1999). Evidence suggests that the hypothalamic 
expression of POMC (Kelly et al., 2003) and possibly MC may change in 
response to gonadal steroids and hence contribute to the modulation of GnRH 
biosynthesis under different reproductive states. 
Similarly to previous reports on pituitary MC, this study suggested that the most 
highly expressed subtype in this tissue is MC3 (Morooka et al., 1998; 
Roudbaraki et al., 1999). All other isoforms were also identified but at 
considerably lower levels of expression. Therefore, it is not surprising that 
ablation of MC3 led to a significant reduction in the content of a number of the 
pituitary hormones in both male and female mice. Although, the expression of 
MC3 appears to be greater in female than in male mice as shown here (Figure 
2.14) and by others (Matsumura et al., 2003), lack of MC3 had more profound 
effects on the total pituitary hormone content of male pituitaries. In males there 
was a significant reduction in all but two (ACTH and TSH) of the pituitary 
hormones. Theoretically, the decrease in gonadotropins should lead to a direct, 
whereas that in prolactin and GH to an indirect, impairment in testicular function 
(Chandrashekar et al., 1999). It is intriguing that prolactin, the main target of 
pituitary MC3 (Matsumura et al., 2003), was unaffected in female MC3-/- mice 
and the only reduction observed was for GH. However, pituitaries for these 
experiments were collected from females at an unknown stage of the oestrous 
cycle, and there is evidence that MC3 expression in this tissue is affected by 
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gonadal steroids (Matsumura et al., 2004). The idea of a direct regulation of 
melanocortin system activity in the pituitary by the reproductive state of the 
female is further supported through data showing: an increase in the relative 
expression of pituitary MC3 in pregnant mice (Figure 2.17) as well as a rise in  
pituitary (Visser and Swaab, 1979) and plasma α-MSH in pregnant women 
(Clark et al., 1978). Additionally, an increase in circulating α-MSH 
concentrations, most probably of pituitary origin, was also demonstrated in the 
late follicular phase of women (Mauri et al., 1990). These reports lead to the 
hypothesis that pituitary MC and POMC can directly respond to gonadotropin 
and/or gonadal steroids.  
In comparison to the 1179 articles on the melanocortin system in the 
hypothalamus (822) and pituitary (357), to date only 58 research papers 
investigated this system in the ovary (34) and testis (24) (PubMed; accessed 26 
April 2014). This area has clearly received little attention. It is surprising since 
some of the early studies following the cloning of the five MC subtypes 
demonstrated the expression of most of the receptors in the human testes, 
which consequently suggests a role in this tissue (Chhajlani, 1996). As 
described herein, all five isoforms were identified in mice testes, with MC2 being 
the most highly expressed using this method (Figure 2.7 and 2.11).  
In contrast, there was relatively low expression of MC in the ovary or uterus of 
normally cycling female mice. During pregnancy, however, expression of most 
of the MC significantly increased, which resembles the changes in POMC 
expression in this tissue (Shaha et al., 1984; Chen et al., 1986). These findings 
indicate that the ovarian melanocortin system, similarly to the hypothalamo-
pituitary axis, indirectly and/or directly responds to the changing concentrations 
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of pituitary gonadotropins as well as prolactin and/or gonadal steroids, 
respectively.  
Testicular MC3 expression at the level of protein is still unclear as the antibodies 
used lack specificity, which could be due to high homology between the MC or 
inappropriate antigen site (section 2.4). However, the fact that they primarily 
bound to the interstitial tissue of the testis suggests at least some expression of 
MC3 protein in the population of Leydig cells. This observation is further 
supported by: MC3 mRNA expression in the K9 Leydig cell line (Figure 4.19) 
and reports showing expression of MC1 (Thornwall et al., 1997) and MC2 
(Johnston et al., 2007) proteins in Leydig cells. The apparent agreement with 
regard to the localization of MC in the testis proposes a role for this family of 
receptors in Leydig cell function. However, in vitro incubation of testicular tissue 
in the presence of MC3 agonist [D-Trp8]-γ2-MSH did not exert any discrete 
effects on steroidogenesis in Balb/c and C57BL/6 mice under normal and LPS-
treated conditions. Conversely, this compound was inhibitory on nitrite release 
from both strain types under inflammatory-like state but had no significant effect 
on other inflammatory markers. The decrease in LPS-induced nitrite production 
following γ-MSH administration was also evident in the K9 Leydig cell line 
supporting the idea of a direct involvement of Leydig cells in mediating some of 
the MC effects. These data suggest that MC3 may be involved in the 
maintenance of immune homeostasis, through immune (most probably 
macrophages) and Leydig cells, and not directly in steroidogenesis. It cannot be 
excluded that other MC are  involved in different activities in the testis. MC2, for 
example, may have a role in the regulation of testosterone release at different 
time points in an animal’s life (O’Shaughnessy et al., 2003), whilst MC5 may 
affect spermatogenesis (Nimura et al., 2006). 
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An ablation of MC3 in mice led to indirect (through a decrease in pituitary 
function) and/or direct effects on a number of testicular parameters, which could 
translate into reproductive deficiencies. The magnitude of the observed 
testicular changes seems to be age dependent. Mice at 3-4 weeks and 
following puberty (9-10 weeks) were more affected by the loss in MC3 than at 
older ages (16-17 and 23-24 weeks). They had significantly smaller interstitial 
islets, which are thought to be the prime site of MC expression in this tissue 
(Thörnwall et al., 1997; Johnston et al., 2007). These observations may be 
explained by the pattern of testicular POMC expression, which is considerably 
greater during periods of high gonadotropin release in fetal and pubertal 
development (Bardin et al., 1987b). 
Summarising all of the presented evidence, a question arises about the 
apparent conserved ability of the MC3-/- mice to reproduce. To date, none of the 
studies using this mouse model have reported on their fertility. Difficulties in 
breeding were noted by Stephen Getting and colleagues (personal 
communications) but no breeding records are available to verify their 
observations. There is the possibility that the absence of MC3 is compensated 
for by increased expression or responsiveness of the other four receptors from 
this or other members of the GPCR family. In contrast to this theory are 
preliminary data for MC mRNA in MC3-/- mice showing a marked reduction in the 
expression level of the majority of MC in the hypothalamus and pituitary. This 
would suggest that expression of MC in these tissues may be co-dependent, 
and ablation of one MC leads to reduction in expression or functionality of 
another. Formation of heterodimers between MC and other GPCRs have been 
reported in the hypothalamus (Rediger et al., 2012). In the testis however there 
was no change in the pattern of expression of the other MC, except perhaps for 
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a slight increase in both MC4 and MC5 expression, implying that a 
compensatory mechanism could be in place there.  
To conclude, the melanocortin system is present at each level of the HPG axis, 
and hence can affect various aspects of reproductive physiology. In the 
hypothalamus, MC (MC3, MC4 and/or MC5) and POMC neurones comprise a 
part of GnRH neuronal network modulating GnRH biosynthesis in response to 
neuronal and hormonal cues such as oestrogen or leptin. In the pituitary, MC3 
influences the release of a number of hormones, which can directly and/or 
indirectly affect reproductive function. In male gonads, MC may play various 
functions including control of immune responses, steroidogenesis or 
spermatogenesis. MC may be co-localized in the same cell type and possible 
redundancy in functions may hence prevent a completely infertile phenotype in 
specific MC knockout models. The anti-inflammatory properties exerted by the 
synthetic and endogenous γ-MSH peptides may become a target for therapeutic 
applications in testicular immune imbalances. Interestingly, although still 
requiring confirmation, is the possibility of a direct control of MC and POMC 
expression by gonadotropins or gonadal steroids at each level of the 
reproductive axis. This implies a role for the melanocortin system in regulation 
of some major reproductive events, and hopefully opens new avenues that 
would lead to diagnosis and hence treatment of some cases of idiopathic 
infertility.  
 
 
 
228 
 
5.1 Recommendations for future work 
 
Further work is still required to gain greater insight into the potential 
neuroendocrine, endocrine and paracrine interactions of the melanocortin 
system within and between tissues of the hypothalamo-pituitary-gonadal axis. 
In the hypothalamus, it is still to be determined which of the three ‘neural’ 
receptors, MC3, MC4 and MC5 mediate the effects of the POMC peptides on 
GnRH release. The localization of mRNA and protein for the above receptors 
with that of GnRH by in situ hybridization and immunohistochemistry, 
respectively, should provide the answer. Furthermore, determination of the 
exact stimuli (for example, oestrogen, progesterone, leptin, MCH, 
gonadotropins or prolactin), affecting the expression of MC and POMC is also of 
interest.  
A direct effect of the MC and their ligands in gonadotroph function is unclear. In 
addition to the localization of MC-expressing trophs, there is a need to establish 
the exact source, regulation and role(s) of melanocortins, particularly α-MSH, 
highly detectable during pregnancy and at different stages of the 
oestrous/menstrual cycle in females. 
Considering the expression of all five isoforms in the testis of mice and their 
possible co-localization, it is of interest to establish the exact, receptor-specific 
role in this tissue, whether it is steroidogenesis, spermatogenesis or other. In 
order to further explore the anti-inflammatory properties of MC3 or other MC, a 
model of chronic testicular inflammation induced by higher LPS concentration or 
other agents should be applied. In order to conduct the functional work selective 
agonists and antagonists at MC are required and the possibility of homo- or 
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hetero-dimerisation, which can modulate ligand signalling, should be taken into 
account. 
As mentioned, in situ hybridization should be used initially to localize the MC 
expression, however, immuno- or fluorescent staining is required to confirm that 
the MC mRNA is translated into protein. Nevertheless, there is a great need for 
the development of highly specific anti-MC3 antibodies to undertake the protein 
work.  
To characterise the role of MC3 at different ages, transgenic mice with tissue 
specific MC3 gene manipulation should be used. This would allow inactivation of 
the receptor in particular tissues at specific stages of the life cycle and thus 
subsequent assessment of reproductive functions of the animals.  
Furthermore, it would also be interesting to determine whether changes in α-
MSH expression seen in circulating females are correlated with MC and POMC 
expression in tissues of the reproductive axis. This would help determine the 
effects of gonadotropins and/or gonadal steroids on the melanocortin system.  
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7 Appendices 
 
7.1  Appendix 1: Image J instructions 
 
 
1. Open ImageJ software.  The ImageJ window will appear on the desktop; 
do not enlarge this window. 
Note that this window has a Menu Bar, a Tool Bar and a Status Bar. 
  
 
 
2. Select  File – Open – to select folder with images from Disk E 
(removable disk) 
3. Set Measurement Scale. Select straight line drawing option on the Image 
J tool bar. Draw a line between two points of the scale (black bar in the 
top left corner) on the photograph. Go to Analyze - Set Scale. In the Set 
Scale window the length of the line, in pixels, will be displayed. Type the 
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known distance (100) and units of measure (um) in the appropriate 
boxes and click OK. Measurements will now be shown using these 
settings. Check 'global' to apply this scale to other image frames. 
4. Choose tubules that appear rounded and thus are cross-sectioned for 
making diameter measurements. If slightly oblique tubules are 
encountered, then the short axis of the tubular profile should be 
measured.  
5. Measure tubule diameter. Draw a line between two points. The status 
bar will show the length.  To transfer the values to a data window simply 
type M on the keyboard. Perform two measurements for each tubule. 
Transfer the measurements to the excel spreadsheet. 
6. Measure thickness of the tubule. Select the points between the base of 
the tubule and lumen. Perform two measurements for each tubule. 
Transfer the measurements to the excel spreadsheet.  
7. Measure total area of the image by typing M. Transfer the measurement 
to the excel spreadsheet. 
8. Measure the area of each intertubular tissue. Surround an area with a 
perimeter. This can be done with an area selection tool, the freehand. 
Type in M to transfer the area measurement to a data window. Transfer 
the measurement to the excel spreadsheet. Highlight the measurements 
for whole intertubular islets.  
9. Repeat the measurement for all intertubular tissues. Transfer the 
measurements to the excel spreadsheet.  
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10. Measure the area of each tubule. Surround an area with a perimeter. 
This can be done with an area selection tool, the freehand. Type in M to 
transfer the area measurement to a data window then type in the 
measurement to the excel spreadsheet. Highlight the measurements for 
whole tubules.  
11. Remember to clearly indicate the slide number on the spreadsheet.  
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7.2  Appendix 2: Ethics forms 
 
OFFICE USE:        /   /   
University of Westminster 
Research Ethics sub-Committee  
 
Application for Research Ethics Consideration 
 
COVER SHEET 
 (To be completed by all applicants) 
 
 
Section 1 – PROJECT AND APPLICANT DETAILS  
 
To be completed by all applicants 
 
 
 
1.1 Project Title:  
The effect of age on fertility:  melanocortin signalling in the male and female 
reproductive axes. 
 
 
 
1.2 Applicant Details  
 
 
Name: Monika Dowejko 
 
 
 
Email Address: 
monika.horanin@my.westminster.ac.uk 
 
Contact Address: 
 
1 Farrant House, 
Winstanley Road 
London, SW11 2EJ  
 
 
 
 
Telephone Number: 
07885990906 
Please check the relevant box: 
 
Undergraduate Postgraduate  x MPhil/PhD Student   Staff  
 
    
 
1.3 Supervisor/Dean of School/ School Research Director details 
 
Please note that all applicants with a supervisor(s) must ensure that the supervisor signs the 
declaration at the bottom of this page if completing Part A only or in Section 10.3 if 
completing Part B 
 
All staff must ensure that their Dean of School, or School Research Director (or nominee), as 
appropriate, signs the declaration at the bottom of this page if completing Part A only or in 
Section 10.3 if completing Part B 
 
 
Name: Dr Joanne Murray 
 
 
 
Email Address: 
j.f.murray@westminster.ac.uk 
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School/Centre/Unit: 
School of Life Sciences 
 
 
Telephone Number:  
020 7911 5000 ext 3566 
NOW COMPLETE PART A 
PART A 
 
Section 2 – Project Details 
 
2.1 Please provide a description of the background to your study including a literature review 
(250 words maximum):  
 
Melanocortins are the products of posttranslational modification of proopiomelanocortin 
(POMC) prohormone. This family of POMC peptides includes adrenocorticotropic hormone 
(ACTH), as well as α-, β-, and γ- Melanocyte Stimulating Hormones (MSH) (Gantz and Fong, 
2003). Melanocortins exert their effects by binding and activating one of five melanocortin 
receptors (MC1 through to MC5), which belong to the family of G-protein-coupled receptors, 
and are widely distributed throughout the body (Getting, 2006). The melanocortins are 
involved in a number of physiological roles, including regulation of food intake, memory, 
behaviour and inflammation. MC3, to be investigated in this study, is predominantly expressed 
in the CNS but has also been found in periphery (including placenta, gastrointestinal tract, 
heart, and immune cells) (Gantz et al., 1993). Furthermore, MC3 has been detected in the 
pituitary and testis of adult mice, but its exact function in reproductive physiology is still not 
clear. Some evidence, however, suggests that MC3 may play serve as a potential link between 
energy metabolism and reproductive function (Watanobe, 2002).  
 
 
2.2. Please provide a brief description of your study (250 words maximum):  
 
The overarching aim of the project is to characterize the expression and role of MC3 in the 
reproductive systems of both the male and the female. 
The first part of the project will determine the expression of MC3 in the hypothalamus, pituitary, 
gonads and other reproductive organs of mice at different ages.  
The next part will evaluate the physiological effects and mode of action of MC3 in various 
tissues and/or cell lines by administration of agonists/antagonists of this melanocortin receptor 
subtype. 
 
 
2.3. What are the specific aims of the study? (250 words maximum):  
 
 To determine the distribution pattern of MC3 in mice tissue and/or cell line at the level 
of mRNA and protein. 
 To determine the functional role of MC3 in reproductive physiology. 
  
 
2.4. Please outline the design and methodology of your study [attach extra information as 
necessary] (250 words maximum in total):  
 
Reproductive organs of sexually mature wild type mice will be obtained from a range of animal 
houses licensed by the Home Office following a schedule 1 procedure and cell lines will be 
purchased. 
The presence or absence of melanocortin receptor 3 in mouse tissue and/or cell line will be 
determined: 
 at the level of mRNA by Reverse Transcriptase-PCR (RT-PCR) or qRT-PCR,  
 at the level of protein by Western Blot and immunohistochemistry. 
 
Radioimmunoassay or ELISA will be performed to measure hormone output following in vitro 
incubation of mouse tissue and/or cell line with MC3 agonist/antagonist.  
 
 
2.5 Timescales 
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Start Date (DD/MM/YY): 1/10/2010 
 
 
Estimated duration of work: 46 months 
 
 
Section 3 
RISK OF HARM  
  Yes No N/A 
1 Is pain or more than mild discomfort likely to result from the study  X  
2 Could the study induce psychological stress or anxiety or cause 
harm or negative consequences beyond the risks encountered in 
normal life? 
 X  
3 Will the study involve prolonged or repetitive testing?  X  
4 Will the study involve raising sensitive topics (e.g. sexual activity, 
drug use, revelation of medical history and/or illegal activities) 
 X  
5 Does your work involve any material containing human cells (e.g. 
blood, urine, saliva, body tissues) from living or deceased 
persons? (Such work must take account of the Human Tissue Act).  
 X  
6 Will DNA samples be taken from human participants? (Such work 
must take account of the Human Tissue Act).  
 X  
7 Does your study raise any issues of personal safety for you or 
other researchers involved in the project? (Especially relevant if 
taking place outside working hours or off University premises) 
 X  
8 Does your study involve deliberately misleading the participants 
(e.g. deception, covert observation)  
 X  
9 Does your work involve administration of a non-food substance in 
abnormally large amounts or one that is known to cause allergic 
reaction(s) in some people? 
 X  
PARTICIPANTSx 
Does your work involve any of the following:  
  Yes No N/A 
10 Human participants in health settings (e.g. private patients in 
private clinics) 
 X  
11 Human participants in health settings (e.g. NHS patients in NHS 
clinics/hospitals) 
 X  
12 Human participants who are in the care of a social worker  X  
13 Expectant or new mothers  X  
14 Refugees  X  
15 Minors (under the age of 18 years old)  X  
16 Participants in custody (e.g. prisoners or arrestees)   X  
17 Participants with impaired mental capacity (e.g. severe mental 
illness, brain damaged, sectioned under Mental Health Act, 
lowered or reduced sense of consciousness) 
 X  
INFORMATION TO PARTICIPANTS 
  Yes No N/A 
18 Will you provide participants with a Participant Information Sheet 
prior to obtaining consent which can be taken away by the 
participant? 
  X 
19 Will you describe the procedures to participants in advance, so that 
they are informed about what to expect? 
  X 
20 Will you obtain consent for participation? (normally written)   X 
21 Will you tell participants that they may withdraw from the research 
at any time and for any reason? 
  X 
22 With questionnaires, will you give participants the option of omitting 
questions they do not want to answer? 
  X 
23 Will you tell participants that their data will be treated with full 
confidentiality and that, if published, it will not be identifiable as 
theirs?  
  X 
24 Will you debrief participants at the end of their participation (e.g. 
give them a brief explanation of their study)? 
  X 
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If you have answered NO to questions 1-17 (inclusive) and YES to questions 18-24 
(inclusive), you do not need to complete the Full Research Ethics Approval Form (Part 
B). Please keep this form for your records.  
 
If you have answered YES to any of the questions 1-17 (inclusive) or NO to any of the 
questions 18-24 the Full Research Ethics Approval Form (Part B) MUST be completed.  
 
If you are applying for external Ethical Approval, please send an electronic copy of the 
Cover Sheet and Part A of the form to Huzma Kelly, Senior Research Officer (Policy and 
Governance), Academic Registrar's Department, Copland Building, New Cavendish 
Street. 
 
